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ABSTRACT 
 
Malaria and leishmaniasis are potentially lethal protozoan diseases affecting a huge number of 
people worldwide, especially in underdeveloped countries. The alarming spread of drug resistance 
concerning both Plasmodium and Leishmania parasites makes the search of novel antimalarial and 
antileishmanial agents an urgent need. Unfortunately, at the moment even the combination therapies 
are failing in many regions afflicted by the diseases and alternatives are scarcely found. In addition, 
the available antileishmanial drugs are quite toxic, expensive and very often need monitoring and 
hospitalization. In the light of this dramatic situation, the discovery of novel effective, safe and 
affordable molecules is vital. 
Thus far, several strategies have been developed to overcome resistance mechanisms; among them, 
of particular interest are the structural optimization of already known antiprotozoal molecules, the 
development of hybrid compounds and the search of new chemical scaffolds. Based on these 
considerations, the aim of the present thesis was the synthesis of different novel sets of molecules, 
potentially candidates for the treatment of malaria and/or leishmaniasis. On one hand I prepared 
derivatives of the antiprotozoal agents chloroquine and clofazimine, in order to improve the 
biological activity and to reduce resistance mechanisms. On the other hand, I explored the 
potenzialities of new chemical scaffolds, such as indeno[2,1-c]quinolines, to design new 
antimalarials. Moreover, I evaluated the possibility of creating hybrid molecules, combining 
moieties with different mechanism of action which could carry out a synergistic effect. In particular, 
the quinoline nucleus has been combined with different HDACs inhibiting structures to generate 
antiplasmodial hybrids, whereas aphidicolin (a fungal metabolite with antileishmanial activity) has 
been condensed with other molecules endowed with antileishmanial activity, such as ethyl 3-
chloroacetamidobenzoate and eflornithine.  
   
 
 
Biological assays were in general quite encouraging and suggested that these new classes of 
compounds could be considered as potential leads for the synthesis of new effective antiprotozoal 
drugs that, in some cases, could hopefully overcome resistance mechanisms. 
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1. INTRODUCTION 
 
 
1.1 Malaria 
 
 
1.1.1 Historical hints and epidemiological data 
 
Malaria is the most important parasitosis and the second infectious disease in the world in terms of 
clinical cases and mortality after tubercolosis, involving nearly 207 million cases and 627000 deaths 
every year, with the highest mortality occurring in Africa and in children under 5 years of age.
1
  
The disease is caused by intracellular protozoan parasites of the genus Plasmodium, which are 
transmitted to humans by the bites of female Anopheles mosquitoes. There are four main 
Plasmodium species that affect humans: P. falciparum, P. vivax, P. ovale and P. malariae. In 
addition, a simian parasite, P. knowlesi, occasionally infects humans.
2
 Among them, P. falciparum 
is the most deadly form whereas P. vivax is the most widespread, as it is able to develop at lower 
temperatures and to survive at higher altitudes and in cooler climates. It has also a dormant liver 
stage (known as hypnozoite) that enables it to survive during periods when Anopheles mosquitoes 
are not present to continue transmission, such as during winter months.
1
 
About 10000 years ago there was the development of the first focuses of Plasmodium in Central and 
Western Africa and, after the migration of people also for commercial purposes, malaria spread in 
Mesopotamia, South-east Asia and Indian peninsula. Afterwards, it reached also China and 
Mediterranean areas up to the American shores, becoming in the XIX century a globally widespread 
disease.
3
 Malaria was eliminated from North America, Europe and parts of Asia and South America 
during the 1950s and 1960s due to a global campaign that relied on the new synthetic insecticide 
dichlorodiphenyltrichloroethane (DDT) and on new powerful synthetic drugs, such as chloroquine 
(CQ) and the combination sulfadoxine-pyrimethamine. When the parasites became resistant to these 
drugs and DDT use was restricted because of environmental and health hazards, malaria returned to 
many areas and the number of deaths peaked at 1.8 million in 2004.
4
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Nowadays there are 97 countries and territories with ongoing malaria transmission and 7 countries 
in the prevention of reintroduction phase, making a total of 104 countries and territories in which 
malaria is presently considered endemic (Fig.1).
1
  
 
 
        Fig.1 Classification of countries by stage of malaria elimination.
1
 of 
 
Malaria is mostly present in tropical and sub-tropical regions, such as Sub-Saharan Africa and 
South-East Asia, as well as Western Pacific and South America. The disease has been eradicated in 
Europe, except in Azerbaijan, Georgia, Kyrgyzstan, Tajikistan and Turchia, which guess to defeat it 
within 2015 as reported in the Tashkent Declaration: “The move from malaria control to 
elimination” (2005).5  
However, every year thousands of people with malaria arrive in non-endemic countries: case 
fatality is around 1% overall but varies by age and previous exposure to malaria. This rate is similar 
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to that seen in endemic countries, but the age profile of deaths is very different. In Africa mortality 
is highest in young children, but in imported cases it is highest in older patients, especially those 
over 65 years. If malaria is treated early, with widely available drugs before it becomes severe, 
death is avoidable and a full recovery almost guaranteed. Late presentation carries a higher risk of 
death and the management of severe malaria is a medical emergency.
6
   
Malaria places a heavy economic burden on many endemic countries, contributing to the cycle of 
poverty and limiting economic development. For example, Africa alone is estimated to lose at least 
US$ 12 billion per year in direct losses (e.g. illness, treatment, premature death) and many times 
more than that in lost economic growth.
7
 International disbursements to malaria-endemic countries 
increased from less than US$ 100 million in 2000 to US$ 1.60 billion in 2011; they were estimated 
to be US$ 1.94 billion in 2012 and US$ 1.97 billion in 2013 (Fig.2). Increases in international 
funding have slowed in recent years, falling to an average of 4% per year between 2009 and 2013, 
compared to average increase of 43% per year between 2005 and 2009. A lower level of funding in 
2011 was mainly due to lower levels of disbursements from the Global Fund. The Global Fund is 
the largest source of funding for malaria control globally; it accounted for 40% of the estimated 
total disbursed funds in 2011 and 50% in 2013.
1
 
 
 
 
Fig.2 Past and projected international funding for malaria control, 2000-2016.
1 
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Global resource requirements for malaria control were estimated in the 2008 Roll Back Malaria 
(RBM) Global Malaria Action Plan (GMAP) to exceed US$ 5.1 billion per year between 2011 and 
2020. In Africa alone, the resource requirements estimated by GMAP were, on average, US$ 2.3 
billion per year during the same period. Combining both domestic and international funds, the 
resources available for malaria control globally were estimated to be US$ 2.5 billion in 2012, 
leaving a gap of US$ 2.6 billion. Available projections of both domestic and international resources 
indicate that total funding for malaria control will reach about $US 2.85 billion between 2014 and 
2016.
1 
 
1.1.2 Plasmodium life cycle 
P. falciparum has a complex lifecycle involving stages in humans and mosquitoes, with the blood 
stage of the infection responsible for much of the disease pathology. During this stage the parasite 
undergoes cycles of growth and division inside the red blood cells (RBCs) of its host.  
Female Anopheles mosquitoes become infected when they feed on the blood of a human who is 
carrying mature gametocytes (sexual stage parasites developing within RBCs) (Fig.3). The male 
and female gametes fuse in the stomach of the mosquito to produce a zygote that undergoes rapid 
meiosis, then transforms into a motile ookinete. The ookinete migrates through the mosquito midgut 
wall and matures into an oocyst. Sporozoites (infective stages) develop during a period of 10–22 
days, before budding and migrating to the mosquito’s salivary glands. When the infected Anopheles 
mosquito bites again a human, it injects the motile sporozoites into the victim’s blood stream. 
The sporozoites enter the liver and invade hepatocytes. Here they multiply and differentiate to 
generate many thousands of merozoites. These merozoites invade the host’s RBCs to initiate the 
blood stage of the infection. Each intraerythrocytic asexual cycle takes ∼48 h. The intraerythrocytic 
parasite progresses through the ring and mature trophozoite stages, then divides during the schizont 
stage, eventually rupturing the host cell to release ∼20 daughter merozoites. After a few weeks of 
asexual cycling in the blood stream some of the intraerythrocytic parasites develop into the highly 
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specialized gametocyte forms which, when taken up by a feeding mosquito, serve in disease 
transmission.
8
 
 
 
Fig.3 Schematic representation of the intraerythrocytic cycle of P. falciparum.
8
 
 
1.1.3 Hemozoin synthesis 
During its 48-hour residence within an infected red blood cell, an asexual Plasmodium parasite 
imports up to 80% of host hemoglobin into the acidic digestive vacuole, where the collaborative 
action of multiple aspartic, cysteine and metal-dependent proteases hydrolyzes the globin 
polypeptide into diverse small peptides and amino acids (Fig.4).
9
 Although during the ring stage 
some hemoglobin degradation is detectable, the major part of this process takes place during the 
trophozoite and schizont stages, which perform most of the metabolic activity of the parasite. 
Hemoglobin degradation was believed to play a vital role as an amino acids source for malaria 
parasites because it has been observed that they have a limited capacity to synthesize their own. 
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Fig.4 Schematic depiction of heme metabolism within blood-stage Plasmodium parasites.
9 
 
Most of the enzymes implicated in the hemoglobin degradation pathway have been elucidated. Two 
aspartic proteases (plasmepsins I and II) and a cysteine protease (falcipain) have been isolated and 
purified from the digestive vacuole of P. falciparum. Other enzymes involved are the histoaspartic 
protease (HAP) and the heme detoxification protein (HDP).
10 
Within the parasite digestive vacuole, the copious heme liberated during hemoglobin proteolysis is 
expected (and commonly assumed) to be cytotoxic based on its potential to destabilize the vacuolar 
membrane, to inhibit the function of proteases and other enzymes and to spontaneously generate 
reactive oxygen molecules, either within this compartment or upon protonation and passive 
diffusion into the reduced environment of the parasite cytoplasm. However, the cellular 
mechanisms of heme toxicity to parasites remain poorly defined, but the general ability of the 
parasite to tolerate and indeed proliferate despite generation of high, local concentrations of heme 
suggests the presence of protective mechanisms to attenuate heme toxicity.
9
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Rather than degrading heme, Plasmodium parasites sequester host heme into crystals of insoluble 
hemozoin in the digestive vacuole. These crystals, which feature repeating reciprocal dimers of 
ferric (Fe
3+
) protoporphyrin IX in which the carboxylate moiety of a propionate group on one 
monomer coordinates the iron atom in a second monomer and vice versa, are chemically inert. 
Their formation thus neutralizes the oxidative, cytotoxic properties of unassociated heme in situ 
without a requirement for further chemical processing.
 
Although the structure of hemozoin crystals 
has been characterized in detail, the specific mechanisms that nucleate and propagate hemozoin 
crystallization within the digestive vacuole remain unresolved. Distinct hypotheses have proposed 
that nucleation and growth occur (a) within the digestive vacuole itself or within hemoglobin-
containing vesicles en route to the digestive vacuole, (b) within lipid droplets suspended in vacuolar 
compartments or at the membrane lipid–aqueous interface, or (c) via a spontaneous or protein-
assisted process.
9 
 
 
Fig.5 Hemozoin formation. (a) Electron micrograph of an asexual parasite within host red blood cell; 
(b) Heme-heme reciprocal dimer that forms repeating subunit within hemozoin crystals.
9
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1.1.4 Clinical manifestations 
The first symptoms of malaria, common to all the different malaria species, are nonspecific and 
mimic a flu-like syndrome. The hallmark of malaria is fever. Up to two days before the onset of 
fever, prodromal symptoms, such as malaise, anorexia, lassitude, dizziness, with a desire to stretch 
limbs and yawn, headache, backache in the lumbar and sacroiliac region, myalgia, nausea, vomiting 
and a sense of chillness may be experienced. The fever is usually irregular at first but after some 
days it tends to become periodic, depending on the synchronized schizogony.
11
 The classic 
symptom of malaria is paroxysm, a cyclical occurrence of sudden coldness followed by shivering 
and then fever and sweating, occurring every two days (tertian fever) 
in P. vivax and P. ovale infections and every three days (quartan fever) 
for P. malariae. P. falciparum infection can cause recurrent fever every 36-48 hours or a less 
pronounced and almost continuous fever.
12
 Cyclic fever is the result of the release of protein 
material, pro-inflammatory cytokines (IL-6, IL-10, IL-12 and TNF-α) and nitric oxide, due to the 
infected red blood cells lysis.
13 
Most of the severe malaria complications occur in non immune subjects with P. falciparum malaria 
and involve central nervous system (cerebral malaria), pulmonary system (respiratory failure), renal 
system (acute renal failure) and/or hematopoietic system (severe anemia). These complications can 
evolve rapidly, indeed severe malaria can lead to death.
11
 
 
1.1.5 Antimalarial therapies 
The cure for malaria originated from Amerindian knowledge when the Spaniards learned to use the 
bark of the plant named quina (or china) in the 17th century. Quina are species of the Rubiaceae 
family, especially Cinchona succirubra and Cinchona calisaya which produce quinine (Table 1). 
The bark of these plants was introduced to Europe in 1640 by the Jesuits and, until the mid 1800s, 
the powder prepared from quina bark (Jesuit′s powder) was the most important remedy for the 
treatment of malaria.
14
 Quinine is an effective treatment, especially when given with other drugs for 
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certain types of malaria, but adverse effects (“cinchonism”) and a short duration of action make it a 
suboptimal prophylactic agent. During World War I, countries producing quinine were controlled 
by anti-German forces. Projected quinine shortages and the need for long-acting prophylactic drugs 
prompted an effort by German companies to synthesize antimalarial compounds. Consequently, in 
1934 the 4-aminoquinoline chloroquine and its derivatives sontoquine and mepacrine were prepared 
(Table 1). Chloroquine rapidly controlled clinical symptoms of susceptible malaria with minimal 
toxicity and was useful as a once-weekly prophylactic drug. It has been the first-line treatment of 
malaria for several years, till early 80s; then, the emergence of chloroquine-resistant strains of P. 
falciparum and P. vivax rendered this drug less useful.
15 
Other important antimalarial compounds 
were synthesized during World War I, such as the 8-aminoquinoline primaquine, the biguanide 
proguanil and mefloquine (Table 1).  
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Table 1 First antimalarial agents. 
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The search for new antiplasmodial agents continued along the whole century with the discovery of a 
lot of compounds such as atovaquone, amodiaquine, lumefantrine, piperaquine, pyrimethamine, 
sulfadoxine and tebuquine (Table 2). In early 90s some antibacterial compounds, such as 
doxycycline, erythromycin and azithromycin (Table 2) were found to have antimalarial effects with 
a good safety profile, especially for children and pregnant women. 
The discovery of artemisinin (Table 2) for malaria therapy by Chinese scientists in the 1970s was 
one of the greatest discoveries in medicine in the 20th century. The absolute configuration of 
artemisinin was obtained using anomalous diffraction x-ray crystal analysis in 1976 and it provided 
further foundation for improvement of the drug. Several derivatives were subsequently produced in 
China to treat malaria, including artemether and artesunate (Table 2) in 1987, and 
dihydroartemisinin (DHA) in 1992.
16
 The development of resistance to artemisinins by Plasmodium 
falciparum prompted the introduction of the Artemisinin Combination Therapies (ACTs), in which 
artemisinin is administered in combination with other antimalarial drugs with different mechanism 
of action. These ACTs are now recommended by WHO as the first-line treatment for uncomplicated 
malaria. The five ACTs currently recommended by WHO are: artemether-lumefantrine, artesunate-
amodiaquine, artesunate-mefloquine, artesunate-sulfadoxine-pyrimethamine and 
dihydroartemisinin-piperaquine. The choice of the ACT should be based on the therapeutic efficacy 
of the combination in the country or area of intended use.
1
 The most recently developed 
antiplasmodial compounds are bulaquine and tafenoquine, which are still under clinical trials.
17
 
Currently, no effective vaccine is available to fight human malaria; however, various antigen 
formulations are undergoing field trials. In particular, RTS,S/AS01E, a vaccine based on the P. 
falciparum circumsporozoite protein and blood stage parasite proteins, has demonstrated promising 
results.
17 
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Table 2 Most recent antimalarial drugs. *Compounds under clinical trials. 
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1.2 Leishmaniasis 
 
1.2.1 Historical hints and epidemiological data 
Leishmaniasis is a complex of mammalian diseases caused by parasitic protozoans classified as 
Leishmania species (Kinetoplastida, Trypanosomatidae). Natural transmission may be zoonotic or 
anthroponotic and it occurs usually by the bite of a phlebotomine sandfly species (order Diptera, 
family Psychodidae; subfamily Phlebotominae) of the genera Phlebotomus (Old World) and 
Lutzomyia (New World).
18
 The cutaneous afflictions of leishmaniasis have been known since 
antiquity. Descriptions of the cutaneous disease in the Old World are found from the first century 
AD. New World pottery from Peru and Ecuador dating from AD 400–900 illustrates faces afflicted 
with a process consistent with leishmaniasis. The first description in English of a lesion resembling 
leishmaniasis was made in 1756 by Russell, who described the "Aleppo evil" from Syria. In 1885, 
Cunningham observed organisms in macrophages from lesions of "Delhi boil" in India. A Russian 
army physician named Borovsky noted the protozoal nature of the organism in 1898 in biopsy 
specimens from skin lesions. In 1903 Leishman published his identification of the parasite in the 
spleen of an English private who had died of Dumdum fever in Dum-Dum, India in 1900. Few 
months later Donovan described identical organisms in a splenic puncture specimen from a living 
child.
19
  
There are three main forms of the disease: 
- Visceral leishmaniasis (VL also known as kala-azar) is fatal if left untreated. It is 
characterized by irregular bouts of fever, weight loss, enlargement of the spleen and liver 
and anemia. It is highly endemic in the Indian subcontinent and in East Africa. An estimated 
200000 to 400000 new cases of VL occur worldwide each year. Over 90% of new cases 
occur in six countries: Bangladesh, Brazil, Ethiopia, India, South Sudan and Sudan. 
- Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis and causes ulcers 
on exposed parts of the body, leaving life-long scars and serious disability. About 95% of 
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CL cases occur in the Americas, the Mediterranean basin and the Middle East and Central 
Asia. Over two-third of CL new cases occur in six countries: Afghanistan, Algeria, Brazil, 
Colombia, Iran (Islamic Republic of) and the Syrian Arab Republic. An estimated 0.7 
million to 1.3 million new cases occur worldwide annually. 
- Mucocutaneous leishmaniasis leads to partial or total destruction of mucous membranes of 
the nose, mouth and throat. Almost 90% of mucocutaneous leishmaniasis cases occurs in the 
Plurinational State of Bolivia, Brazil and Peru.
20
 
Anthroponotic cutaneous leishmaniasis (where humans are the major reservoir of the parasite) is 
predominantly urban and periurban and shows patterns of spatial clustering similar to those of 
anthroponotic visceral leishmaniasis in South Asia. The disease is usually characterized by large 
outbreaks in densely populated cities, especially in war and conflicts zones, refugee camps and in 
settings where there are large-scale migration of populations.
21
  
 
 
 
Fig.6 Worldwide distribution of leishmaniasis.
21
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The increased appearance of leishmaniasis in developed countries can be attributed to several 
factors: increased overseas travel, U.S. Gulf War veterans and the simultaneous encroachment of 
leishmaniasis into urban areas and of HIV infection into rural areas. In the Mediterranean, where L. 
infantum is endemic, the number of cases of VL in HIV-infected patients has increased dramatically 
since the mid-1980s. The World Health Organization estimates that 25%-70% of adult VL cases in 
Southern Europe are related to HIV, while between 2% and 9% of AIDS patients are at risk of 
experiencing newly acquired or reactivated VL. Preliminary data suggest that Leishmania may be a 
cofactor in the pathogenesis of HIV infection: the lipophosphoglycan (LPG) surface molecule of L. 
donovani has been shown to induce transcription of HIV in CD4
+
-T cells. The WHO estimates that 
AIDS increases the risk of VL by 100–1000 times in endemic region.19 
 
1.2.2 Leishmania life cycle 
The life cycle of Leishmania involves alternation between a mammalian host and a phlebotomine 
sand fly host. In the mammalian host the developmental biology of the parasite is relatively simple 
and consistent between species: metacyclic promastigotes (infective forms) are introduced into the 
skin by the bite of the sand fly. These are taken up by macrophages and transformed into 
intracellular amastigotes (small, immotile and rounded form of the parasite), remaining in this form 
for the duration of the life cycle in the mammalian host. In contrast, the developmental biology of 
the parasite in the sand fly host is more complex and less well understood.
22
 Outside the vertebrate 
host, the Leishmania life cycle is confined to the digestive tract of sand flies. The precise location 
differs between subgenera Leishmania and Viannia. Development in the vector is initiated when 
female sand flies ingest blood containing macrophages infected with amastigotes. The change in 
conditions moving from the mammalian host to the sand fly midgut (such as decrease in 
temperature and increase in pH) triggers morphological transformation and development of the 
parasite in the vector. The amastigotes transform into procyclic promastigotes (weakly motile forms 
with a short flagellum beating at the anterior end of the cell). These are the first replicative forms 
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that proliferate in the early blood meal. Around 48–72 hours later, parasites begin to slow their 
replication and differentiate into strongly motile long nectomonad promastigotes. They move 
towards the anterior midgut and later develop into short nectomonad promastigotes, also called 
leptomonads, which enter another proliferative cycle. Ultimately, Leishmania transform into 
infective metacyclic stages, which are delivered to the vertebrate host during the next blood 
feeding.
23 
 
  
 
Fig.7 Representation of Leishmania life cycle.
24
 
 
1.2.3 Pathogenesis 
To initially establish infection, promastigotes enter macrophages silently to evade triggering host 
responses; progressive intracellular (amastigote) infection depends on the maintenance of 
macrophages in an inert, deactivated state. At the same time, however, the immunocompetent host 
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is also equipped and responds with interdigitating non-specific (innate) and antigen-specific 
(acquired) mechanisms (cell-mediated immunity, delayed-type hypersensitivity). These 
inflammatory responses mediate disease expression and may (asymptomatic infection, self-healing 
disease) or may not (non-healing disease) produce the desired clinical end-result. Under optimum 
conditions, macrophages are eventually activated to a leishmanicidal state largely governed by an 
intact T-helper cell-type 1 (Th1) response. This complex response revolves around antigen-
presenting dendritic cells, responding CD4 T cells, and secretion of pro-inflammatory cytokines, 
including interleukin 12, interferon and tumor necrosis factor. This same Th1 response also 
prevents recrudescence of latent, chronic infection. In subclinical infections, host responses are by 
definition effective and presumably tightly regulated since signs of inflammation are not noticeable. 
By contrast, inflammation is prominent and underlies pathogenesis in nearly all forms of clinically 
apparent infection.
25
 
 
1.2.4 Clinical manifestations 
Clinical manifestations vary by Leishmania species, area of acquisition of infection and host 
factors. CL is the most common form of leishmaniasis, whereas VL is the most serious one. 
Typically the patient with VL develops fever, weakness, anorexia, weight loss, pallor, 
hepatosplenomegaly (usually splenomegaly predominates), lymphadenopathy, and progressive 
deterioration. Children may also present growth retardation. Late findings include epistaxis, 
gingival hemorrhage, abdominal distension, edema, and ascites. Occasionally VL may manifest as 
acute hepatitis, cholecystitis, hemophagocytic syndrome, and Guillain–Barré syndrome. If not 
treated, VL is almost always fatal. Death is caused by hemorrhage, severe anemia, or secondary 
infection. HIV-infected patients usually have higher parasite loads and atypical symptoms (e.g., 
gastrointestinal), especially with low CD4 cell counts. This group of HIV-infected patients responds 
poorly to treatment and rates of relapse are high, regardless of treatment used. 
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CL may manifest with one or more skin lesions on the exposed body within several weeks or 
months after the sand fly bite. New World CL has variable clinical manifestations, ranging from 
ulcerative skin lesions to destructive mucosal inflammation and is often accompanied with local 
lymphadenopathy, while Old World CL may present with multiple lesions. The initial lesion is 
usually a papule, which subsequently progresses to nodule and then to ulcer during the next 1–3 
months. Despite the fact that CL is not a lethal disease and many lesions (especially due to Old 
World species) heal spontaneously over months to years, it is frequently associated with significant 
morbidity and may affect daily activities and social life when located on the hands and face.  
ML occurs in 1–10% of CL cases 1–5 years after healing. Clinical manifestations include chronic 
nasal congestion and bleeding, ulceration and septal granulomas. ML is not self-cured and may 
progress and cause permanent or life-threatening complications such as ulcerative destruction of the 
nose, mouth, pharynx and larynx, nasal septum perforation and facial disfigurement, resulting in 
social stigma.
26
 
 
 
Fig.8 Typical ulcerative skin lesion.
27 
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1.2.5 Antileishmanial therapies 
The poor knowledge about the disease and the lack of effective health policies are the primary 
hurdles in the elimination of leishmaniasis.
28
 Treatment objectives vary with the form of 
leishmaniasis; in VL the main objective of treatment is to save the patient's life, as the disease is 
fatal if untreated. Drugs against VL need to be rapidly effective and safe. High drug efficacy is also 
essential to prevent relapses. In CL the primary objective of treatment is to reduce the duration and 
to heal the cutaneous lesion and, for a limited number of species (e.g. L. braziliensis), to prevent the 
occurrence of mucous lesions.
29
   
Pentavalent antimonials, in particular sodium stibogluconate (Pentostam) and meglumine 
antimoniate (Glucantim) (Fig.9), are being used in the treatment of leishmaniasis over more than 
five decades and they are still the first line drugs of choice where resistance is not reported. The 
pentavalent antimoniate (Sb
V
) is considered a pro-drug, which is further converted to trivalent 
antimonite (Sb
III
), the active form of the drug.
28
 Daily injection of 20 mg/kg body weight for 28-30 
days have been the standard treatment for VL in most parts of the world. Its major toxicities are 
cardiac arrhythmias, prolonged QTc interval, ventricular premature beats, ventricular tachycardia, 
ventricular fibrillation and torsades de pointes. Arthralgia, myalgia and elevated hepatic and 
pancreatic enzymes are other common adverse events.
30
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Fig.9 Structures of sodium stibogluconate and meglumine antimoniate. 
  Introduction 
21 
 
Increasing refractoriness to Sb
V
 in India and Nepal led to the adoption of alternative treatment 
strategies. In these regions the drug of choice is amphotericin B (AmB) (Fig.10), a polyene 
antifungal drug widely used to treat systemic fungal infections. AmB shows high affinity for 
ergosterol, the predominant sterol of fungal and leishmanial cell membrane. Despite its high 
efficacy, AmB causes many adverse effects including infusion reactions, nephrotoxicity, 
hypokalemia and myocarditis and thus needs close monitoring and hospitalization. To minimize the 
adverse events of amphotericin B, various lipid formulations have been introduced where 
deoxycholate is replaced with other lipids leading to less exposure of the free drug to organs. Three 
formulations have been extensively tested in VL: liposomal amphotericin B (L-AmB: AmBisome), 
amphotericin B lipid complex (ABL: Albecit) and amphotericin B colloidal dispersion (ABCD: 
Amphocil). L-AmB is the only approved drug by the US Food and Drug Administration. These 
formulation are less toxic and show very high efficacy, but their use is limited by the high cost.
28 
 
  
Fig.10 Amphotericin B. 
 
Another compound known to have antileishmanial activity is miltefosine, an anticancer agent that is 
an alkylphosphocholine (hexadecylphosphocholine). It is the first oral drug used for the treatment of 
VL and its phase I/II/III trials provoked a storm of protection against VL that was followed by 
phase IV trial, which also proved its relevance in outpatient setting in those areas where VL is 
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endemic. Limitations of miltefosine are its relatively high cost, need for monitoring of 
gastrointestinal side effects, teratogenicity and occasional hepatic toxicity and nephrotoxicity.
30
 The 
exact mode of antileishmanial action is still unclear but it has been found that it causes apoptosis-
like processes in Leishmania donovani. Miltefosine (Fig.11) also reduces the lipid content in 
promastigotes membrane and enhances the phosphatidylethanolamine content suggesting a partial 
inhibition of phosphatidylethanolamine-N-methyltransferase that leads to decreased parasite 
proliferation.
31
  
 
 
Fig.11 Miltefosine. 
 
Paromomycin (Fig.12) is an aminoglycosidic antibiotic and has both antileishmanial and 
antibacterial activity. It cures both VL and CL (more effectively) but limited availability restricts its 
use in endemic regions.
28
 Paromomycin is used for the treatment of VL in a parenteral formulation 
and of CL in both topical and parenteral formulations, but it is a second line drug for the treatment 
of leishmaniasis as it can cause different important side effects.
30 
 
 
Fig.12 Paromomycin.
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Other second choice drugs for the treatment of leishmaniasis are sitamquine and pentamidine. 
Sitamaquine (Fig.13) is an 8-aminoquinoline under clinical trials for the treatment of VL with the 
advantage of oral administration. However, despite efficacy, few side effects like vomiting, 
dyspepsia, cyanosis, nephritic syndrome and glomerulonephritis were also observed. The 
mechanism of action involves electrostatic interaction between phospholipid anionic polar head 
groups and positively charged sitamaquine and then with phospholipid acyl chains leading to drug 
insertion within biological membranes.
28,32
 Pentamidine (Fig.13) is an aromatic diamine used in 
early 1980s for the treatment of refractory VL in India. However, its use has been abandoned for 
VL due to its serious toxicities such as insulin-dependent diabetes mellitus and declining efficacy.
30 
 
MeO
HN
N
N
H
O O
N
H
H2N
NH
NH2
NH
Sitamaquine
Pentamidine  
Fig.13 Structures of sitamaquine and pentamidine. 
 
The growing resistance of the parasite to antileishmanial drugs is particularly worrying and suggests 
that monotherapy needs to be converted into multidrug therapy, combining compounds with 
synergistic or additive activity acting at different sites. Advantages are increased efficacy, shorter 
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duration of therapy and lower dose requirement, thereby reducing chances of toxic side effects and 
cost, and preventing the emergence of drug resistance.
30
  
Currently, there is no effective human vaccine available for any form of leishmaniasis but there are 
other alternative treatments other than chemotherapy. Thermotherapy exploits the experimental 
evidence that Leishmania parasites do not multiply at temperatures higher than 39 °C in vitro. 
Thermotherapy with radio-frequency waves has been most commonly studied for both Old and 
New World CL. Clinical trials demonstrated that it was as effective as antimony therapy in treating 
L. braziliensis and L. mexicana infections.
30
 One of the most interesting approaches being explored 
is immunotherapy and targeted therapy. The last one acts by blocking essential biochemical or 
signaling pathways that are indispensable for Leishmania growth and survival, whereas 
immunotherapy involves the use of biological molecules or compounds to modulate immune 
responses in combination with drugs. Recent studies suggest that these two approaches could be 
complementary in VL treatment, leading to a synergistic effect.
33 
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2. OBJECTIVES 
This project is focused on the search and development of new compounds characterized by different 
chemical scaffolds able to inhibit the growth of Plasmodium and/or Leishmania parasites and to 
overcome their mechanisms of resistance. Resistance is the most alarming feature of largely 
diffused and potentially lethal diseases as malaria and leishmaniasis. Unfortunately, at the moment 
even the combination therapies are failing in many regions afflicted by the diseases and alternatives 
are scarcely found. In addition, the available antileishmanial drugs are quite toxic, expensive and 
very often need monitoring and hospitalization. In the light of this dramatic situation, the discovery 
of novel effective, safe and affordable molecules is a very urgent need. 
The strategies at the base of the project are the structural optimization of already known 
antiprotozoal molecules, the development of hybrid compounds and the search of new chemical 
scaffolds. Hybrids’ components should be characterized by different biological functions, distinct 
pharmacophores, reduced toxicity and improved activity.
17
 Consequently, my research project is 
divided into several topics and involves the synthesis of different sets of compounds: 
 
2.1 4-Aminoquinoline derivatives  
Quinoline-type antimalarials remain an attractive class of compounds because their mechanism of 
action and resistance are unrelated and resistance is compound-specific and not class-specific. 
Recently the N-(-)-lupinyl-derivative of 7-chloro-4-aminoquinoline (-)-AM-1 (Table 1) showed 
potent in vitro and in vivo activity against both chloroquine susceptible and resistant strains of P. 
falciparum. However, (-)-AM-1 is synthesized starting from (-)-lupinine, an expensive alkaloid 
isolated from Lupinus luteus whose worldwide production is not sufficient, at present, for large 
market purposes.
34,35
 To overcome this issue and since the activity of 4-aminoquinoline 
antimalarials does not seem to be correlated with the chirality of the drug, we decided to prepare 
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novel not-chiral quinolizidinylalkyl derivatives of 7-chloro-4-aminoquinoline bearing the basic 
head linked to the 4-N of quinoline through longer alkyl chains (Table 1).  
 
Table 1. Parent compound (-)-AM-1 and synthesized compounds. 
 
2.2 Hybrids of 4-aminoquinoline  
Recent studies demonstrated that the histone deacetylases (HDACs) of P. falciparum (PfHDACs) 
have a high homology with the human ones and may be promising targets for new classes of 
antimalarial drugs.
36
 HDACs are Zn-dependent enzymes which play crucial roles in modulating the 
chromatin structure in eukaryotes through regulating the degree of “packaging/unpackaging” of 
chromosomal DNA for transcription. The degree of histone acetylation, regulated by the opposing 
action of histone acetyltransferases and HDACs, is critical for transcriptional control. HDACs also 
regulate gene expression through the acetylation of other proteins such as transcription factors.
36 
Some HDACs inhibitors, among which TSA, apicidin, trapoxin and SAHA (recently approved by 
FDA for the treatment of cutaneous T-cell lymphoma), showed in vitro antimalarial activity also at 
low concentration.
37
 On this basis, we decided to prepare hybrid molecules (Table 2), in which the 
4-aminoquinoline nucleus is condensed with Zn
2+
-chelating moieties, such as hydroxamic acid, 
typical of the antitumor drug SAHA, and dithiolthiones, recently proved to have HDAC inhibitory 
activity.
38 
The quinoline moiety could facilitate the penetration of the compound inside the 
Plasmodium and, in some case, could allow the obtainment of double target compounds (inhibition 
of hemozoin polymerization by the aminoquinoline residue and inhibition of HDAC by the side 
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chain) with improvement of drug efficacy and a reduced resistance onset. The spacer between the 
two moieties should be basic, in order to recall the side chain of chloroquine and to trap the 
molecule into the food vacuole of Plasmodium. For this reason and on the basis of recent 
encouraging results of some aromatic 4-aminoquinoline derivatives prepared in our laboratory,
39
 I 
decided to introduce a 2-(piperazin-1-yl)ethyl spacer (compounds 4, 5, 6 and 7) or an aromatic one: 
in particular, a slightly basic imidazolyl moiety in compound 8 and a completely neutral one in 
compound 9.   
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Table 2. Structures of the synthesized compounds. 
 
2.3 Indeno[2,1-c]quinolines  
A further approach (whose results may appear somewhat more fortuitous) is represented by the 
shrewd superimposition in a single molecular scaffold of the structural features responsible of the 
activity of different antimalarials, or even of non antiplasmodial antimicrobial agents. As P. 
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falciparum and M. tuberculosis share enzymatic components of type II fatty acids biosynthetic 
pathway (FAS-II),
40-42
 I found interesting to superimpose in a single molecular scaffold the 
quinoline ring of chloroquine and the fluorene, that is a substructure of Genz-10850, an inhibitor of 
FAS-II of both P. falciparum and M. tuberculosis,
43,44
 as well as of the potent antimalarial 
lumefantrine and also of our 9-lupinyl- and 9-lupinilydenefluorene endowed with high 
antitubercular activity (MIC= 0.49 µM for the latter)
45,46
 (Fig.14).  
 
Fig.14 Structures of antimalarial and antitubercular compounds. 
 
The formal overlapping of the two substructures gives rise to the indeno[2,1-c]quinoline ring 
system (Fig.14). 
Derivatives of this ring system have been shown
47 
to be good antimycobacterial agents, with MIC in 
the range of 0.43 to 12.9 µM for the best compounds (and their ester prodrugs) that likely act by 
targeting the ATP synthase subunit C (Fig. 15). 
  Objectives 
29 
 
 
Figure 15. Structures of indeno[2,1-c]quinoline derivatives endowed with antimycobacterial activity. 
 
As far as we know, none of these indenoquinoline derivatives has been evaluated for antimalarial 
activity, although during the realization of this project, a paper reporting the study of the in vitro 
antiprotozoal activity of some indeno[2,1-c]quinolines against L.infantum and different species of 
Tripanosoma was published by Upadhayaya et al.
48
 Thus, assuming that the different activities of 
the above compounds are related to the different substituents decorating the common 
indenoquinoline scaffold, a set of novel derivatives has been considered to obtain potential 
antimalarial agents (Table 3).
49 
For this purpose, a chlorine atom has been introduced on ring A either in the position 2, in analogy 
with the 2-bromine of the above antimycobacterial agents, or in position 3, corresponding to the 7-
position of chloroquine. A basic chain in position 6 (ring B) should warrant a reasonable 
hydrophilicity as well as the molecule concentration in the food vacuole of Plasmodium. As first 
possibility, the basic chain has been linked to the quinoline nucleus through a secondary amino 
group, that, like the 4-amino group of chloroquine, would allow the resonance with the protonated 
nitrogen of quinoline. Cyclic basic heads have been preferred to minimize the possibility of 
metabolic dealkylation as observed for chloroquine. The position 7 (ring C) bears a carbonyl group 
that could act as hydrogen bond acceptor, but also an oximino group that, viceversa, could act as 
hydrogen bond donor.
50
 Other functional derivatives of the 7-keto group have been considered, like 
aminoguanidone and 1-imino-4-methylpiperazine. Indeed, the carbonyl group sets up a structural 
analogy with two kinds of benzophenone derivatives. On one hand, 2,5-
  Objectives 
30 
 
bisacylaminobenzophenones (A) (Fig.16) displayed nanomolar antimalarial activity (IC50= 32 nM 
for the best compounds) through the inhibition of farnesyl transferase;
51
 on the other hand, 3,4-
dichloro-4’-trifluoromethylbenzophenone aminoguanidone (B) (Fig.16) was 100% curative when 
administered at the dose of 80-640 mg/kg in infected animals.
52-54
 Unfortunately, this compound 
resulted somewhat hepatotoxic. 
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Fig.16 Structures of benzophenone derivatives endowed with antimalarial activity. 
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Table 3. Structures of the synthesized indenoquinolines. 
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2.4 Riminophenazines  
With the aim to explore the antiprotozoal potentialities of new chemical scaffolds, I took into 
consideration the structure of clofazimine. Clofazimine (Fig.17) is a fat-soluble riminophenazine 
dye used in combination with rifampicin and dapsone as multidrug therapy for the treatment of 
leprosy. It is also endowed with a moderate antimalarial and antileishmanial activity, both in vitro 
and in vivo (murine models).
55
 
I decided to study the effect of the introduction of different side chains containing a bicyclic basic 
moiety, such as pyrrolizidine or quinolizidine, in this kind of scaffold in order to improve the 
antiprotozoal activity. This idea started from the evidence that tetramethylpiperidine-substituted 
phenazines (Fig.17), structurally related to clofazimine, have been described to be endowed with 
activity against multidrug resistant strains of P. falciparum and they seemed to share, at least in 
part, the same target of chloroquine in malarial parasites. However, it has been demonstrated that 
the sensitivity of P. falciparum to the TMP-phenazines is unaffected by the mechanisms, which 
confer resistance to the conventional antimalarial agents, including chloroquine.
56 
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Fig.17 Structures of clofazimine and tetramethylpiperidine-substituted phenazines. 
 
In addition to the quinolizidine moiety, already used for the quinolinic compounds mentioned 
before, I introduced a pyrrolizidine head linked to the phenazine nucleus through an ethyl chain and 
a lupininyl group (both previously prepared in the laboratory) with the aim to better understand the 
role of the bulky basic head and of the length of the linker. To evaluate the role of the steric 
hindrance of the bicyclic basic heads, the smaller pyrrolidinyl derivative was also studied. To 
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complete the study, I also prepared compounds characterized by the replacement of the aniline 
moiety in position 2 with an aminopyridine  (Table 4, B) or by the quaternarization of the basic 
nitrogen in the side chain with a methyl group (36), to evaluate the contribution of the increment of 
polarity to the antiprotozoal activity.
57
 
 
 
 
Compound Series R1 R2 R3 n 
28 A H H a 1 
29 A Cl H a 1 
30 A CH3 H b 0 
31 A H H c 3 
32 A H H c 5 
33 A F H c 3 
34 A F H c 5 
35 A F Cl c 5 
36 A H H d 3 
37 B H H c 3 
38 B H OCH3 c 3 
39 B Cl H c 3 
40 B Cl H e 3 
 
Table 4. Structures of the synthesized phenazines. 
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2.5 Aphidicolin derivatives 
In the search of new scaffolds with potential antileishmanial activity, I took into consideration the 
tetracyclic diterpene aphidicolin. Aphidicolin (Fig.18), a fungal metabolite isolated from 
Nigrospora sphaerica, was first described as a highly active drug for inhibiting cell division and 
synchronizing cell cycles in experimental medicine. Recently, aphidicolin and a series of 
semisynthetic aphidicolan derivatives have shown antileishmanial activity in the micromolar 
range.
58
 In particular, it was found that the esterification (without acetylation) of C-3, C-18 and C-
17 of aphidicolin led to prodrugs with enhanced activity.  
With the aim to explore the potentiality of novel scaffolds as antileishmanial agents, I decided to 
prepare some derivatives (Table 5) through the condensation of aphidicolin with other molecules 
endowed with antileishmanial activity, such as ethyl 3-chloroacetamidobenzoate and eflornithine 
(Fig.18).  
 
 
Fig.18 Moieties used for the hybrids preparation. 
 
 
Ethyl 3-chloroacetamidobenzoate (MF29) was found to be an efficient drug on the promastigote 
stage of three Leishmania species (IC50: 0.3-1.8 μM), acting as antimicrotubule agent.
59
 Eflornithine 
or DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, 
was discovered to have potent antileishmanial activity.
60
 When given as a 2% solution in drinking 
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water 2 days after infection and continued for 4 days, it suppressed liver parasites by 90% and 
spleen parasites by 99%. The idea was to obtain hybrid molecules (41-43; Table 5) where the two 
components were released in the parasite, exhibiting different mechanisms of action and a 
synergistic effect.  
With the aim to evaluate the importance and the influence of the hydrophilicity of these molecules 
on the antileishmanial activity, I esterified the OH in position 18 of the 3-chloroacetanilido benzoyl 
derivative with succinic acid (compound 42). 
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Table 5. Structures of aphidicolin derivatives. 
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2.6 Rosmaricine and derivative  
Another idea took the cue from recent results obtained in our laboratory concerning rosmaricine. 
Rosmaricine (Fig.19) is an alkaloid obtained through the treatment of carnosic acid (Fig.19), a 
natural compound contained in the ethanolic extract of Rosmarinus officinalis, with ammonia and 
O2. Rosmaricine and some of its derivatives were found to be endowed with a modest 
antiplasmodial activity and I found interesting to introduce a basic head in the structure that could 
allow to trap the compound inside the food vacuole of Plasmodium and, consequently, to improve 
the activity. Thus, firstly I optimized the complicated extraction process of carnosic acid from 
rosemary leaves, the synthesis and the purification of rosmaricine. Then, when the procedure was 
well established, I tried to synthesize the diethylaminopropylamine derivative (45) of carnosic acid 
(Fig.19), using the same synthetic pathway of rosmaricine.  
 
 
 
 
Fig.19 Carnosic acid and derivatives. 
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3. CHEMISTRY 
 
3.1 4-Aminoquinoline derivatives 
The synthesis of 4-aminoquinoline derivatives required the preliminary preparation of the 
(octahydro-1H-quinolizin-9a-yl)alkan-1-amines, which were new chemical entities and were 
obtained in six steps, as indicated in Scheme 1. δ-Valerolactam was reacted firstly with sodium 
hydride and then with ethyl 5-bromovalerate to generate the corresponding tertiary amide 47. After 
treatment with soda lime and distillation, the obtained 2,3,4,6,7,8-hexahydro-1H-quinolizine was 
converted into the corresponding perchloric salt 48.
61,62
 Compound 48 was treated with the proper 
Grignard reagent to generate the olefinic quinolizidines (49-51),
62,63
 which underwent a 
hydroboration reaction to obtain the alcoholic derivatives (52-54).
62
 After a Mitsunobu reaction in 
the presence of phthalimide, DEAD and triphenylphosphine and the following acidic hydrolysis,
64
 
the desired (octahydro-1H-quinolizin-9a-yl)alkan-1-amine dihydrochloride salts (58-60) were 
obtained.   
 
 
Scheme 1. Reagents and conditions: a) NaH 60%, dry THF from 0 °C to r.t.; b) ethyl 5-bromovalerate, reflux; c)  Soda 
lime, distillation (160-170 °C); d) HClO4 70%, EtOH; e) ZnBr2, dry THF, from 50 °C to reflux; f) 1N BH3 in THF, 2-
methyl-2-butene, dry THF, r.t.; g) H2O, 6N NaOH, H2O2 35%, r.t.; h) phthalimide, Ph3P, DEAD, dry THF, r.t.; i) 6N 
HCl, reflux.  
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Final compounds 1-3 were prepared by the condensation of 4,7-dichloroquinoline with the proper 
(octahydro-1H-quinolizin-9a-yl)alkan-1-amine in the presence of phenol and DIPEA. 
 
Scheme 2. Reagents and conditions: a) Phenol, DIPEA, 120 °C. 
 
3.2 Hybrids of 4-aminoquinoline 
For the synthesis of compounds 4-7, as first step it was essential the preparation of tert-butyl 4-(2-
aminoethyl)piperazine-1-carboxylate (62). To selectively protect the primary amino group, 2-
(piperazin-1-yl)ethanamine was firstly reacted with ethyl trifluoroacetate and then, after the 
protection of the piperazinyl nitrogen with a Boc group, the alkaline hydrolysis of the 
trifluoroacetate group provided compound 62.
65
 The primary amine carried out a nucleophilic 
substitution on 4,7-dichloroquinoline and, after the cleavage of the Boc group, intermediate 64 was 
obtained (Scheme 3). 
 
Scheme 3. Reagents and conditions: a) ethyl trifluoroacetate, dry THF, 5 °C; b) Boc2O, r.t.; c) NaOH 0.2N, MeOH, 
from 15 to 35 °C; d) DIPEA, 120 °C; e) CF3COOH, r.t. 
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The coupling reaction of intermediate 64 with the dithiolthiones ACS5 and ACS48, previously 
prepared in our laboratory, provided the final compounds 4 and 5 (Scheme 4). 
 
Scheme 4. Reagents and conditions: a) HOBt, DCC, dry DMF, m.w. 
 
The same coupling reaction between intermediate 64 and suberic acid monomethyl ester, followed 
by the formation of the hydroxamic acid through the reaction with hydroxylamine hydrochloride in 
alkaline methanol, provided final compound 6 (Scheme 5).  
 
Scheme 5. Reagents and conditions: a) HOBt, DCC, dry DMF, m.w.; b) NH2OH*HCl, KOH, MeOH, r.t. 
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The synthesis of compound 7 required also the preliminary condensation of ethyl 4-aminocinnamate 
with succinic anhydride in a H2O/THF solution to provide intermediate 66, which reacted with 
intermediate 64 in the presence of coupling reagents. The classic conversion of the ethyl ester (67) 
into hydroxamic acid did not work, probably because the benzylic double bond is a good Michael’s 
acceptor and this is the preferred reaction. Consequently, I found another synthetic route that 
involved the hydrolysis of the ester into carboxylic acid (68) and the following activation of the 
carbonyl group with ethyl chloroformate,
66
 which allowed the attack of the hydroxylamine to obtain 
the final hydroxamic acid 7 (Scheme 6). 
 
Scheme 6. Reagents and conditions: a) H2O/THF (2:1), r.t.; b) compound 62, HOBt, DCC, dry DMF, m.w; c) 1N 
NaOH, EtOH/THF, 60 °C; d) ethyl chloroformate, TEA, dry THF, r.t.; e) NH2OH*HCl, KOH, MeOH, r.t. 
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Compound 8 was prepared through a synthetic route of seven steps (Scheme 7). From the reaction 
between Boc-glycine and 2-bromo-4-nitroacetophenone, intermediate 69 was obtained, which 
underwent an Ugi reaction with ammonium acetate and xilene to provide intermediate 70.
67
 After 
the cleavage of the Boc group and the condensation with 4,7-dichloroquinoline, the obtained 
intermediate 72 was reduced with metallic iron in acetic acid. The amino derivative (73) was finally 
coupled with suberic acid monomethyl ester in a microwave reactor and the ester group was then 
converted into hydroxamic acid with hydroxylamine hydrochloride in a basic methanolic solution to 
get the final compound 8.  
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Scheme 7. Reagents and conditions: a) EtOH, Cs2CO3, dry DMF, r.t.; b) CH3COONH4, xilene, 180 °C; c) CF3COOH, 
r.t.; d) 4,7-dichloroquinoline, phenol, 130 °C; e) Fe, CH3COOH, 70 °C; f) suberic acid monomethyl ester, HOBt, DCC, 
dry DMF, m.w.; g) NH2OH*HCl, KOH, MeOH, r.t.  
 
 
For the synthesis of compound 9, 4-nitrobenzyl bromide was reacted with phthalimide potassium 
salt to obtain intermediate 75, which was treated with hydrazine monohydrate. The amino-
derivative 76 carried out a nucleophilic substitution on 4,7-dichloroquinoline in the presence of 
phenol as both solvent and catalyst. The nitro group was then reduced to amine with metallic iron in 
acetic acid and the obtained compound 78 underwent a coupling reaction with suberic acid 
monomethyl ester. The final conversion into hydroxamic acid to get compound 9 were carried out 
with the same procedure used for compound 8.  
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Scheme 7. Reagents and conditions: a) dry DMF, 50 °C; b) hydrazine monohydrate, EtOH/THF, reflux; c) 4,7-
dichloroquinoline, phenol, 130 °C; d) Fe, CH3COOH, 70 °C; e) suberic acid monomethyl ester, HOBt, DCC, dry DMF, 
m.w.; f) NH2OH*HCl, KOH, MeOH, r.t.  
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3.3 Indeno[2,1-c]quinolines 
The synthesis of the conformationally-constrained indeno[2,1-c]quinolines required the availability 
of the intermediates 2,6-dichloro-7H-indeno[2,1-c]quinolin-7-one 81
68
 and 3,6-dichloro-7H-
indeno[2,1-c]quinolin-7-one 84,
68
 both obtained, respectively, through the condensation of (2-
amino-5-chlorophenyl)(phenyl)methanone 80 or (2-amino-4-chlorophenyl)(phenyl)methanone 83,
69
 
with malonic acid and POCl3. This reaction involved the formation of the acyl chloride by-products 
82 and 85, which were subjected to an intramolecular Friedel-Crafts acylation to get the indeno[2,1-
c]quinoline nucleus (Scheme 8). 
 
Scheme 8. Reagents and conditions: a) malonic acid, POCl3, reflux; b) AlCl3, dry CH2Cl2, from r.t. to reflux. 
 
 
Compounds 81 and 84 were then reacted with different amines to generate the corresponding 2- or 
3-chloro-6-(amino-substituted)-7H-indeno[2,1-c]quinolin-7-ones (10-17), which were converted 
into the corresponding oximes (18-23 and 25) with hydroxylamine hydrochloride in a basic 
hydroalcoholic solution (Scheme 9).  
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Scheme 9. Reagents and conditions: a) dry pyridine, 100 °C; b) NH2OH*HCl, NaOH, EtOH/H2O (2:1), from r.t. to 
reflux. 
 
The oxime 23 was treated with NaH and propionyl chloride to get 2-chloro-6-(4-(pyridin-2-
yl)piperazin-1-yl)-7H-indeno[2,1-c]quinolin-7-one O-propionyl oxime 24 (Scheme 10).
70
 
 
 
 
 
Scheme 10. Reagents and conditions: a) NaH, propionyl chloride, DMSO, r.t. 
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Finally, compound 81 was also converted into the corresponding 6-methoxy derivative 86, that was 
then reacted with aminoguanidine hydrochloride or 1-amino-4-methylpiperazine in the presence of 
an acidic catalyst to obtain, respectively, compounds 26 and 27 (Scheme 11).
71,72
  
 
 
Scheme 11. Reagents and conditions: a) NaOMe, dry THF/MeOH (2:1), reflux; b) aminoguanidine hydrochloride, 
AcOH, EtOH, reflux; c) 1-amino-4-methylpiperazine, 1N HCl, EtOH, reflux. 
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3.4 Riminophenazines 
 
The required iminophenazines hydrochloride 97-101 were prepared by oxidation of the 
corresponding N
1
-(substituted-phenyl)benzene-1,2-diamine (in acid solution) with ferric chloride
73 
(Scheme 12). Compounds 93-96 were prepared as reported in the scheme, whereas compound 92 
was commercially available. 
 
 
 
Scheme 12. Reagents and conditions: a) dry pyridine, reflux; b) SnCl2, EtOH/AcOEt (1:1), reflux; c) FeCl3*6H2O, H2O, 
conc. HCl, AcOH, r.t.   
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Compounds 28-35 were synthesized by reacting, in dioxane solution, the 2-[(4-R-phenyl)amino]-
10-(4-R-phenyl)-2,10-dihydro-3-iminophenazines hydrochloride (97-101) with the suitable cyclic 
alkylamines, ((1S,9aR)- or (1R,9aR)-(octahydro-2H-quinolizin-1yl)alkylamines, (hexahydro-1H-
pyrrolizin-1-yl)alkylamines, (octahydro-1H-quinolizin-9a-yl)alkan-1-amines and 3-(pyrrolidin-1-
yl)propylamine in analogy to the previously described riminophenazines
74,75
 (Scheme 13). 
 
 
Scheme 13. Reagents and conditions: a) R3-(CH2)n-NH2, 1,4-dioxane, reflux. 
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The quaternary ammonium salt 36 was obtained by reacting compound 31 with iodomethane, as 
shown in Scheme 14. 
 
 
Scheme 14. Reagents and conditions: a) CH3I, dry THF, r.t. 
 
 
As reported by Zhang et al.
76
 and by Liu et al.,
77
 phenylpyridinyliminophenazine compounds (37-
40) have been prepared in five steps, as indicated in Scheme 15. The suitable substituted N
1
-
phenylbenzene-1,2-diamines, previously synthesized or commercially available, were condensed 
with 1,5-difluoro-2,4-dinitrobenzene in the presence of triethylamine (TEA). Nitrocompounds (102 
and 103) were reacted with pyridin-3-amine or 6-methoxypyridin-3-amine to afford compounds 
104-106, which after reduction with metallic zinc and acetic acid to the corresponding diamino 
derivatives, underwent a spontaneous oxidative cyclization reaction. The obtained imino 
compounds (107-109) were then reacted with 4-(octahydro-1H-quinolizin-9a-yl)butan-1-amine or 
with N
1
,N
1
-dimethylpropane-1,3-diamine to afford the final products (37-40).  
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Scheme 15. Reagents and conditions: a) TEA, EtOH, r.t.; b) 3-aminopyridine or 6-methoxypyridin-3-amine, TEA, dry 
THF, reflux; c) Zn, AcOH, r.t.; d) air, MeOH, r.t.; e) 4-(octahydro-1H-quinolizin-9a-yl)butan-1-amine or N
1
,N
1
-
dimethylpropane-1,3-diamine, 1,4-dioxane, reflux. 
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3.5 Aphidicolin derivatives 
 
The synthesis of compound 41 required the previous preparation of intermediate 111, which was 
obtained through the conversion of the acid 110 to the corresponding acyl chloride. Compound 110 
was prepared reacting 3-aminobenzoic acid with chloroacetyl chloride.
78
 Intermediate 111 was 
reacted with aphidicolin in the presence of pyridine to get the final compound 41 (Scheme 16). 
 
 
 
Scheme 16. Reagents and conditions: a) dry DMF, r.t.; b) SOCl2, dry CHCl3, 60 °C; c) dry pyridine, r.t. 
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Compound 42 was prepared treating compound 41 with succinic anhydride in the presence of 
pyridine (Scheme 17).
79 
 
 
 
 
 
Scheme 17. Reagents and conditions: a) succinic anhydride, dry pyridine, r.t. 
 
 
 
For the preparation of compound 43 it was necessary to protect the amino groups of eflornithine 
with Boc groups
80
 and to tosylate the OH in position 17 of aphidicoline.
81
 Then the two obtained 
intermediates were condensed to generate compound 112 which, after the cleavage of Boc groups, 
should have provided the final compound 43 (Scheme 18).  
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Scheme 18. Reagents and conditions: a) TsCl, dry pyridine, 4 °C; b) (Boc)2O, DIPEA, MeOH, r.t.; c) DIPEA, dry THF, 
reflux; d) TFA, dry CH2Cl2, r.t. 
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Unfortunately the last step of the synthesis did not generate the expected compound 43, but it 
probably underwent a loss of two molecules of water obtaining compound 44 (Scheme 19), which 
was confirmed by the mass spectrometry analysis. 
 
 
 
Scheme 19. Reagents and conditions: a) TFA, dry CHCl3, r.t.   
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3.6 Rosmaricine and derivative 
 
Before preparing rosmaricine, I had to optimize the extraction of carnosic acid from rosemary leaves, based 
on the procedure described by A. Boido et al.
82
 Firstly I tried to follow the reported method, 
macerating the well-broken leaves in 95% ethanol for two days and repeating the same process 
twice. Afterwards I thought to shorten this step by using ultrasound sonication, making three cycles 
of 1 h. Indeed, this modification was helpful and reduced the extraction time from one week to two 
days.  
In addition, after the ultrasound treatment and the filtration of the formed waxes, I introduced also a 
washing with water, in order to remove all the hydrophilic compounds present in the extract. During 
this operation, I observed very often the formation of rough emulsions that were solved only with 
the use of a centrifuge. Moreover, as carnosol (another alkaloid present in rosemary extract) was 
found to be insoluble in cyclohexane, I introduced a washing with the same solvent after the 
treatment with water, with the aim to remove the compound from the extract of interest.  
The extract was then treated with ammonia and O2 to prepare rosmaricine. I tried different reaction 
conditions in order to evaluate the best parameters and experience demonstrated that a short 
reaction time and the maintenance of a constant pH value (between 8 and 9) by the addition of three 
portions of ammonia, provided the best results in terms of yield and purity. 
In Scheme 20 is reported the proposed mechanism of rosmaricine formation,
82
 which concerns 
different oxidation and rearrangement steps with the final attack of ammonia to obtain rosmaricine. 
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Scheme 20. Proposed mechanism of rosmaricine formation.
82 
 
To prepare rosmaricine derivative (45) I followed the same procedure used for rosmaricine, using 3-
(diethylamino)propylamine in the place of ammonia. Unfortunately, the high-resolution mass 
spectrometry analysis (ESI) revealed that the obtained compound was not the expected one. It was 
probably an oxidation product, both at the cathecolic and at the amino groups level. The 
hypothetical obtained compound (46) is reported below: 
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4. EXPERIMENTAL SECTION 
 
All commercially available solvents and reagents were used without further purification, unless 
otherwise stated. CC= flash column chromatography. Mps: Büchi apparatus, uncorrected. 
1
H-NMR 
spectra: Varian Mercury 300VX spectrometer; CDCl3, DMSO-d6, CD3OD or pyridine-d5; δ in ppm, 
J in Hertz. High-resolution mass spectra (HRMS): FT-Orbitrap mass spectrometer in positive 
electro spray ionization (ESI). Ultrasound sonicator: Eurosonic MU-2.5 l. Centrifuge: HERMLE 
Z206A. Preparative HPLC: Waters 3000 equipped with an Ascentis™ C18 column, 25 cm x 21.2 
mm, 10 μM. Microwave reactor: Biotage® initiator classic. 
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4.1 4-Aminoquinoline derivatives 
 
Ethyl 5-(2-oxopiperidin-1-yl)pentanoate (47) 
 
N
O
COOEt
 
 
A solution of δ-valerolactam (8 g, 80.7 mmol) in 80 ml of anhydrous THF was added dropwise to 
an ice-cooled suspension of NaH (3.4 g, 84.0 mmol) in 100 ml of anhydrous THF. After stirring at 
r.t. for 30 minutes and cooling with an ice-bath, a solution of ethyl 5-bromovalerate (12.8 ml, 80.7 
mmol) in 60 ml of anhydrous THF was added dropwise. The mixture was refluxed under nitrogen 
for 20 h. The cooled resulting mixture was diluted with ethyl acetate and filtered on a celite pad. 
The filtered mixture was evaporated, diluted with ethyl acetate and washed three times with a 
saturated solution of aqueous NH4Cl and two times with brine. The organic layer was dried with 
anhydrous Na2SO4 and evaporated to dryness, resulting in a yellow oil. Yield: 90%. 
1
H NMR 
(CDCl3) δ: 4.12 (q, 2H, J= 2.76 Hz); 3.40-3.36 (m, 2H); 3.28-3.25 (m, 2H); 2.41-2.30 (m,4H); 
2.08-2.07 (m, 2H); 1.79-1.77 (m, 4H); 1.60-1.58 (m, 2H); 1.24 (t; 3H,  J= 2.76 Hz). 
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1,2,3,4,5,6,7,8,9-Octahydroquinolizinium perchlorate (48) 
 
N
ClO4
 
 
Compound 47 (16.5 g, 72,6 mmol) was ground with powdered soda lime (24.8 g) until an intimate 
mixture was obtained. The mixture was placed in a 250 ml round bottom flask fitted with a short-
path distillation apparatus. The system was purged with N2 under vacuum and the flask heated 
slowly. Vigorous gas evolution occurred, followed by distillation of a mixture of ethanol and water 
(80°-105°C) and then organic material (160-170°C). After distillation had stopped, the two-phase 
distillate was diluted with tert-butyl-methyl-ether and washed with brine for three times. The 
aqueous layer was saturated with K2CO3 and washed three times again with tert-butyl-methyl ether. 
The collected organic layers were dried with anhydrous Na2SO4 and evaporated to dryness. The 
resulting yellow oil was poured slowly into an ice-cooled mixture of 8 ml of 70% perchloric acid 
and 100 ml of ethanol. Storage in the freezer overnight followed by filtration gave a light pink solid. 
Yield: 33%. 
1
H NMR (DMSO-d6) δ: 3.60-3.58 (m, 4H); 2.69-2.49 (m, 4H); 2.49-2.48 (m, 4H); 
1.86-1.62 (m, 4H). 
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9a-(Alkyl-enyl)-octahydro-1H-quinolizines (49-51) 
 
 
 
General procedure: A solution of n-bromo-1-alkene (17.3 mmol) in 5 ml of anhydrous THF was 
added dropwise to a mixture of granular magnesium (17.3 mmol) and a catalytic amount of zinc 
bromide in 9 ml of anhydrous THF. After the addition of a iodine crystal to trigger the reaction, the 
mixture was stirred for 4 h at 50 °C under nitrogen. When the Grignard reagent was completely 
formed, 30 ml of anhydrous THF and 1,2,3,4,5,6,7,8,9-octahydroquinolizinium perchlorate (8.65 
mmol) were charged and the resulting mixture was refluxed for 20 h. After cooling, the mixture was 
diluted with 10 ml of a saturated solution of aqueous NH4Cl and acidified with 6N HCl. The 
aqueous layer was separated and extracted three times with diethyl ether, then alkalized and 
saturated with K2CO3 and extracted six times with diethyl ether. The collected organic layers were 
dried with anhydrous Na2SO4 and evaporated to dryness to give an orange oil, which was directly 
used for the next step. 
 
 
9a-(But-3-enyl)-octahydro-1H-quinolizine (49)  
Yield: 89%. 
1
H NMR (CDCl3) δ: 5.92-5.78 (m, 1H); 5.00-4.91 (m, 2H); 2.63-2.55 (m, 2H); 2.44-
2.26 (m, 2H); 1.92-1.23 (m, 13H); 1.22-1.11 (m, 3H). 
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9a-(Hex-5-enyl)-octahydro-1H-quinolizine (50) 
Yield: 63%. 
1
H NMR (CDCl3) δ: 5.92-5.78 (m, 1H); 5.02-4.91 (m, 2H); 2.63-2.55 (m, 2H); 2.44-
2.30 (m, 2H); 2.18-2.01 (m, 2H); 1.92-1.11 (m, 18H). 
9a-(Oct-7-enyl)-octahydro-1H-quinolizine (51) 
Yield: 54%. 
1
H NMR (CDCl3) δ: 5.82-5.77 (m, 1H); 5.03-4.91 (m, 2H); 2.92-2.39 (m, 6H); 2.26-
1.20 (m, 22H). 
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ω-(Octahydro-1H-quinolizin-9a-yl)alkan-1-ols (52-54) 
 
 
 
General procedure: A solution of 9a-(alkyl-enyl)-octahydro-1H-quinolizine (9.3 mmol) in 40 ml of 
anhydrous THF was added dropwise during 30 minutes to an ice-cooled mixture of 1M borane 
tetrahydrofurane complex solution (37.2 mmol) and 2-methyl-2-butene (74.5 mmol) diluted with 7 
ml of anhydrous THF. The mixture was stirred at r.t. for 4.5 h and then diluted with 11 ml of H2O, 
37 ml of aqueous 6N NaOH and 9.2 ml of aqueous H2O2 (35%). The resulting mixture was stirred 
at r.t. for 1 h and the aqueous layer was saturated with Na2CO3, separated from the organic solution 
and extracted three times with diethyl ether. The collected organic layers were evaporated and the 
resulting oil was diluted with diethyl ether and extracted three times with aqueous 6N HCl. The 
aqueous layer was alkalized and saturated with Na2CO3 and extracted several times with diethyl 
ether. The organic layer, dried with anhydrous Na2SO4 and evaporated to dryness, gave a crude oil 
which was purified by CC (neutral alumina, grade IV; petroleum ether/diethyl ether in gradient). 
 
4-(Octahydro-1H-quinolizin-9a-yl)butan-1-ol  (52) 
CC (petroleum ether/diethyl ether in gradient); the obtained oil crystallized spontaneously into a 
white solid, which was rinsed with petroleum ether/diethyl ether (1:1). Yield: 80%. Mp 92.4-93.2 
°C. 
1
H NMR (DMSO-d6) δ: 4.33 (br s, 1H, collapsed with D2O); 3.40-3.30 (m, 2H); 2.50-2.44 (m, 
2H); 2.28-2.24 (m, 2H); 1.52-1.32 (m, 14H); 1.12-0.96 (m, 4H).  
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6-(Octahydro-1H-quinolizin-9a-yl)hexan-1-ol  (53) 
CC (petroleum ether/diethyl ether in gradient); a light yellow oil was obtained. Yield: 74%. 
1
H 
NMR (DMSO-d6) δ: 4.31 (br s, 1H, collapsed with D2O); 3.39-3.30 (m, 3H); 2.51-2.44 (m, 3H); 
2.28-2.25 (m, 2H); 1.50-1.38 (m, 16H); 1.27-1.00 (m, 4H). 
 
8-(Octahydro-1H-quinolizin-9a-yl)octan-1-ol (54) 
CC (petroleum ether/diethyl ether in gradient); a light yellow oil was obtained. Yield: 74%. 
1
H 
NMR (CDCl3) δ: 3.66-3.62 (m, 2H); 2.64-2.55 (m, 2H); 2.42-2.38 (m, 2H); 1.69-1.08 (m, 26H). 1H 
is not visible, probably for the interaction with the solvent.   
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2-(ω-(Octahydro-1H-quinolizin-9a-yl)alkyl)isoindoline-1,3-diones (55-57) 
 
 
 
General procedure: Diethylazodicarbossilate (16.7 mmol) diluted with 6.5 ml of anhydrous THF 
were added dropwise to an ice-cooled mixture of 8-(octahydro-1H-quinolizin-9a-yl)alkan-1-ol (8.0 
mmol), phthalimide (16.0 mmol), triphenylphosphine (16.0 mmol)  and 24 ml of anhydrous THF. 
The resulting mixture was stirred at r.t. for 20 h. The solvent was evaporated and the crude orange 
oil was purified by CC (silica gel; CH2Cl2/MeOH/conc. NH3 in gradient). 
 
2-(4-(Octahydro-1H-quinolizin-9a-yl)butyl)isoindoline-1,3-dione (55) 
A yellow oil was obtained. Yield: 95%. 
1
H NMR (CDCl3) δ: 7.83-7.71 (m, 4H); 3.69-3.47 (m, 2H); 
2.58-2.42 (m, 4H); 1.59-1.17 (m, 18H). 
 
2-(6-(Octahydro-1H-quinolizin-9a-yl)hexyl)isoindoline-1,3-dione (56) 
An orange oil was obtained. Yield: 98%. 
1
H NMR (CDCl3) δ: 7.85-7.80 (m, 2H); 7.73-7.69 (m, 
2H); 3.68 (t, 2H, J= 7.42 Hz); 2.64-2.59 (m, 2H); 2.56-2.40 (m, 2H); 1.68-1.00 (m, 22H). 
 
2-(8-(Octahydro-1H-quinolizin-9a-yl)octyl)isoindoline-1,3-dione (57) 
An orange oil was obtained. Yield: 96%. 
1
H NMR (CDCl3) δ: 7.85-7.81 (m, 2H); 7.73-7.69 (m, 
2H); 3.70-3.65 (m, 2H); 3.48-3.47 (m, 2H); 2.66-2.52 (m, 4H); 1.67-1.09 (m, 24H). 
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ω-(Octahydro-1H-quinolizin-9a-yl)alkan-1-amines dihydrochloride (58-60) 
 
 
 
General procedure: 2-(n-(Octahydro-1H-quinolizin-9a-yl)alkyl)isoindoline-1,3-dione (5.9 mmol) 
were dissolved in 20 ml of aqueous 6N HCl and refluxed for 20 h. The solution was stored in the 
freezer overnight and the precipitated phthalic acid was filtered and washed with a small amount of 
cold water. The filtered aqueous solution was evaporated under vacuum and the resulting 
amorphous solid was crystallized and rinsed with different solvents. 
 
4-(Octahydro-1H-quinolizin-9a-yl)butan-1-amine dihydrochloride (58) 
Solid was crystallized with a mixture of ethanol/diethyl ether (9.5:0.5) and rinsed with diethyl ether 
to give a white solid. Yield: 88%. Mp 221.0-222.7 °C. 
1
H NMR (DMSO-d6) δ: 10.45 (br s, 1H, 
collapsed with D2O); 8.08 (br s, 3H, collapsed with D2O); 3.10-3.02 (m, 2H); 2.89-2.78 (m, 4H); 
1.95-1.03 (m, 18H). 
 
6-(Octahydro-1H-quinolizin-9a-yl)hexan-1-amine dihydrochloride (59) 
Solid was crystallized with a mixture of ethanol/diethyl ether (1:1) and rinsed with diethyl ether to 
give a white solid. Yield: 59%. Mp 184-185 °C. 
1
H NMR (DMSO-d6) δ: 10.56 (br s, 1H, collapsed 
with D2O); 8.10 (br s, 3H, collapsed with D2O); 3.32-3.10 (m, 2H); 2.88-2.85 (m, 2H); 2.72-2.49 
(m, 2H); 1.97-1.12 (m, 22H). 
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8-(Octahydro-1H-quinolizin-9a-yl)octan-1-amine dihydrochloride (60) 
Solid was crystallized with diethyl ether and rinsed with a mixture of diethyl ether/ethanol (9:1) to 
obtain an hazel hygroscopic solid. Yield: 84%. 
1
H NMR (DMSO-d6) δ: 10.27 (br s, 2H, collapsed 
with D2O); 7.99 (br s, 2H, collapsed with D2O); 3.45-2.72 (m, 8H); 1.93-1.01 (m, 24H). 
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7-Chloro-N-(ω-(octahydro-1H-quinolizin-9a-yl)alkyl)quinolin-4-amines (1-2) 
 
n= 2     1
n= 4     2
NCl
HN Nn
 
 
General procedure: A mixture of suitable n-(octahydro-1H-quinolizin-9a-yl)alkan-1-amine 
dihydrochloride (0.88 mmol), 4,7-dichloroquinoline (0.97 mmol), phenol (4.41 mmol) and DIPEA 
(1.76 mmol) was heated under a N2 atmosphere for 5 h at 130 °C. After cooling, the mixture was 
diluted with CH2Cl2 and the resulting organic layer washed three times with 2N NaOH solution and 
then with brine. After driing with anhydrous Na2SO4, the solvent was evaporated to dryness. The 
crude solid was purified by CC (silica gel; different eluents and conditions as indicated for each 
compound).  
 
7-Chloro-N-(4-(octahydro-1H-quinolizin-9a-yl)butyl)quinolin-4-amine (1) 
CC (CH2Cl2/MeOH; 94:6); solid washed with petroleum ether. Yield: 64%. Mp 157.8-159.3 °C. 
1
H 
NMR (CDCl3) δ: 8.54 (d, 1H, J= 5.50 Hz); 7.95 (d, 1H, J= 2.20 Hz); 7.65 (d, 1H, J= 8.80 Hz); 
7.36 (dd, 1H, J= 2.20, 8.80 Hz); 6.43 (d, 1H, J= 5.50 Hz); 4.96 (br s, 1H, collapsed with D2O); 
3.37-3.31 (m, 2H); 2.64-2.42 (m, 4H); 1.84-1.19 (m, 18H). 
 
7-Chloro-N-(6-(octahydro-1H-quinolizin-9a-yl)hexyl)quinolin–4–amine (2) 
CC (CH2Cl2/MeOH; 92:8); amorphous solid crystallized and washed with diethyl ether. Yield: 
46%. Mp 144.6-146.0 °C. 
1
H NMR (CDCl3) δ: 8.53 (d, 1H,  J= 5.22 Hz); 7.96 (d, 1H, J= 2.20 Hz); 
7.65 (d, 1H, J= 8.80 Hz); 7.36 (dd, 1H, J= 2.20, 8.80 Hz);  6.42 (d, 1H, J= 5.22 Hz); 4.96 (br s, 1H, 
collapsed with D2O); 3.35-3.29 (m, 2H); 2.65-2.41 (m, 4H); 1.82-1.12 (m, 22H). 
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7-Chloro-N-(8-(octahydro-1H-quinolizin-9a-yl)octyl)quinolin-4-amine (3) 
 
N
HN
N
Cl  
 
After converting compound 60 into the corresponding free base, a mixture of this amine (170 mg, 
0.64 mmol), 4,7-dichloroquinoline (153 mg, 0.77 mmol) and phenol (301 mg, 3.20 mmol) was 
heated under a N2 atmosphere for 3 h at 130 °C.
4 
After cooling, the mixture was diluted with 
CH2Cl2 and the resulting organic layer washed two times with 2N NaOH solution and then with 
brine, dried with anhydrous Na2SO4 and evaporated to dryness. The crude solid was purified by CC 
(silica gel; CH2Cl2/MeOH; 94:6). The amorphous resulting solid was crystallized and washed with 
diethyl ether. Yield: 55%. Mp 116.8-118.3 °C.  
The product was converted into the corresponding dihydrocloride salt with 1N HCl in ethanol. Mp: 
250-252 °C (dec.) 
1
H NMR  (DMSO-d6 ) δ:  10.20 (br s, 2H);  9.62 (br s, 1H);  8.70 (d, 1H,  J= 8.80 
Hz);  8.52 (d, 1H,  J= 7.15 Hz);  8.06 (s, 1H);  7.76 (d, 1H,  J= 8.80 Hz);  6.85 (d, 1H,  J= 7.15 
Hz); 3.52-3.49 (m, 2H);  3.40-3.35 (m, 2H); 3.09-2.86 (m, 2H);  1.91-1.05 (m, 26H).   
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4.2 Hybrids of 4-aminoquinoline 
 
tert-Butyl 4-(2-(2,2,2-trifluoroacetamido)ethyl)piperazine-1-carboxylate (61) 
 
 
 
Ethyl trifluoroacetate (2.6 g, 0.02 mmol) was added dropwise to an ice-cooled solution of 1-(2-
aminoethyl)piperazine (2.4 g, 0.02 mmol) and 2.5 ml of anhydrous THF. After stirring for 45 
minutes at r.t. and under a N2 atmosphere, the mixture was cooled with an ice-bath and (Boc)2O (4 
g, 0.02 mmol)  dissolved in 5 ml of anhydrous THF was added dropwise. The obtained solution was 
stirred for 24 h at r.t. The solvent was evaporated and the obtained residue was rinsed with ethyl 
acetate and washed with brine. The organic layer was dried with anhydrous Na2SO4 and evaporated 
to dryness to obtain a brown oil that crystallized with diethyl ether. After washing with a mixture of 
diethyl ether/petroleum ether (1:1), a slightly pink solid was obtained. Yield: 85%. Mp 98.0-99.1°C.  
1
H NMR (CDCl3) δ: 7.02 (br s, 1H, collapsed with D2O); 3.49-3.42 (m, 6H); 2.58 (t, 2H, J= 6.05 
Hz); 2.44 (t, 4H, J= 6.05 Hz); 1.46 (s, 9H). 
                                                                                                                                                    
 
 
 
 
 
 
N
N
N
H
F3C
O O
O
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tert-Butyl 4-(2-aminoethyl)piperazine-1-carboxylate (62) 
 
 
N
N
H2N
O
O
 
 
 
40 ml of 0.2 N NaOH were added drowise to an ice-cooled solution of compound 61 (2.36 g, 7.25 
mmol) and 30 ml of methanol, keeping the internal temperature below 15 °C. Once the addition was 
over, the mixture was warmed to 35 °C and stirred for 48 h. The solvent was evaporated and the 
aqueous phase was saturated with K2CO3 and extracted with chloroform. The organic layer was 
dried with anhydrous Na2SO4 and evaporated to dryness to obtain a yellow oil that was purified by 
CC (CH2Cl2/MeOH/ conc. NH3 in gradient); the product eluted with 10% of MeOH and 1% of NH3. 
A yellow oil was obtained. Yield: 94%. 
1
H NMR (CDCl3) δ: 3.42 (t, 4H, J= 4.95 Hz ); 2.79 (t, 2H, 
J= 6.05 Hz); 2.45-2.37 (m, 6H); 1.65 (br s, 2H, collapsed with D2O); 1.45 (s, 9H). 
 
 
 
 
 
 
 
 
 
 
 
 
  Experimental section 
71 
 
tert-Butyl 4-(2-((7-chloroquinolin-4-yl)amino)ethyl)piperazine-1-carboxylate (63) 
 
N
N
HN
O
O
NCl  
 
4,7-Dichloroquinoline (380 mg, 1.92 mmol) was added to a solution of compound 62 (400 mg, 1.74 
mmol), DIPEA (0.5 ml, 3.49 mmol) and phenol (820 mg, 8.72 mmol). The mixture was stirred at 
120 °C under nitrogen for 4.5 h and then diluted with CH2Cl2 and washed with 2 N NaOH and 
brine. The organic layer was dried with anhydrous Na2SO4 and evaporated to dryness to obtain a 
yellow oil that was purified by CC (CH2Cl2/MeOH in gradient); the product eluted with 6% of 
MeOH. A white solid was obtained. Yield: 73%. Mp 149.0-150.0 °C. 
1
H NMR (CDCl3) δ: 8.53 (d, 
1H, J= 5.50 Hz); 7.96 (d, 1H, J= 2.20 Hz); 7.65 (d, 1H, J= 8.80 Hz); 7.37 (dd, 1H, J= 2.20, 8.80 
Hz); 6.37 (d, 1H, J= 5.50 Hz); 5.89 (br s, 1H, collapsed with D2O); 3.48 (t, 4H, J= 4.68 Hz); 3.38-
3.32 (m, 2H); 2.79 (t, 2H, J= 6.05 Hz); 2.48 (t, 4H, J= 4.68 Hz); 1.46 (s, 9H). 
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7-Chloro-N-(2-(piperazin-1-yl)ethyl)quinolin-4-amine (64) 
 
N
NH
HN
NCl  
 
A solution of compound 63 (500 mg, 1.28 mmol) and 2.5 ml of CF3COOH was refluxed for 4.5 h. 
The mixture was then diluted with CH2Cl2 and water and alkalized with solid K2CO3. The obtained 
white precipitate was filtered and washed with water and diethyl ether. The filtrate was extracted 
several times with CH2Cl2 and the organic layer was dried with anhydrous Na2SO4 and evaporated 
to dryness. The obtained residue was recrystallized with CH2Cl2 and rinsed with diethyl ether to 
obtain a white solid. Yield: 83%. Mp 146.8-148.1 °C. 
1
H NMR (CDCl3) δ: 8.53 (d, 1H, J= 5.20 
Hz); 7.96 (d, 1H, J= 2.20 Hz); 7.65 (d, 1H, J= 8.80 Hz); 7.38 (dd, 1H, J= 2.20, 8.80 Hz); 6.37 (d, 
1H, J= 5.20 Hz); 6.00 (br s, 1H, collapsed with D2O); 3.37-3.29 (m, 2H); 2.98-2.94 (m, 4H); 2.79-
2.73 (m, 2H); 2.57-2.53 (m, 4H). 
1H is not visible, probably for the interaction with the solvent.   
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(4-(2-(7-Chloroquinolin-4-ylamino)ethyl)piperazin-1-yl)(4-(3-thioxo-3H-1,2-dithiol-4-
yl)phenyl)methanone (4) 
 
 
 
Compound 64 (150 mg, 0.52 mmol) was dissolved in 0.8 ml of anhydrous DMF and charged into a 
0.5-2 ml microwave vial. To the solution HOBt (80 mg, 0.52 mmol), DCC (110 mg, 0.52 mmol) 
and 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (130 mg, 0.52 mmol) were added. The mixture 
was stirred in a microwave reactor at 55 °C for 1 h. After the filtration of the obtained DCU, the 
solvent was evaporated and the obtained residue was diluted with CH2Cl2 and washed with a 
saturated solution of NaHCO3, water and brine. The organic layer was dried with anhydrous 
Na2SO4 and evaporated to dryness and the obtained residue was purified by CC (CH2Cl2/MeOH in 
gradient), using the Flash Chromatography Purification System Biotage SP-1; the product eluted 
with 3.5% of MeOH. After washing with diethyl ether, an orange solid was obtained. Yield: 79%. 
Mp 101.0-103.0 °C. 
1
H NMR (CDCl3) δ: 8.54 (d, 1H, J= 5.50 Hz); 8.44 (s, 1H); 7.96 (d, 1H, J= 
2.20 Hz); 7.67 (d, 1H, J= 8.80 Hz); 7.69 (d, 2H, J= 8.25 Hz); 7.48 (d, 2H, J= 8.25 Hz); 7.39 (dd, 
1H, J= 2.20, J= 9.08 Hz); 6.39 (d, 1H, J= 5.50 Hz); 5.82 (br s, 1H, collapsed with D2O); 3.85-3.81 
(m, 2H); 3.59-3.56 (m, 2H); 3.39-3.33 (m, 2H); 2.84-2.80 (m, 2H); 2.67-2.50 (m, 4H). 
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(4-(2-(7-Chloroquinolin-4-ylamino)ethyl)piperazin-1-yl)(2-thioxo-1,3-dithiol-4-yl)methanone 
(5) 
 
 
 
Compound 64 (150 mg, 0.52 mmol) was dissolved in 0.8 ml of anhydrous DMF and charged into a 
0.5-2 ml microwave vial. To the solution HOBt (80 mg, 0.52 mmol), DCC (110 mg, 0.52 mmol) 
and 2-thioxo-1,3-dithiole-4-carboxylic acid (90 mg, 0.52 mmol) were added. The mixture was 
stirred in a microwave reactor at 55 °C for 1 h. After the filtration of the obtained DCU, the solvent 
was evaporated and the obtained residue was diluted with CH2Cl2 and washed with a saturated 
solution of NaHCO3, water and brine. The organic layer was dried with anhydrous Na2SO4 and 
evaporated to dryness. The obtained residue was washed with diethyl ether and then purified by CC 
(CH2Cl2/MeOH in gradient); the product eluted with 5% of MeOH. After washing with diethyl 
ether, a yellow solid was obtained. Yield: 51%. Mp 191.9-193.7 °C. 
1
H NMR (DMSO-d6) δ: 8.38 
(d, 1H, J= 5.22 Hz); 8.21 (d, 1H, J= 9.08 Hz); 7.87 (s, 1H); 7.77 (d, 1H, J= 2.20 Hz); 7.44 (dd, 1H, 
J= 2.20, 9.08 Hz); 7.20 (br s, 1H, collapsed with D2O); 6.49 (d, 1H, J= 5.22 Hz); 3.64-3.57 (m, 4H); 
3.42-3.38 (m, 2H); 2.70-2.60 (m, 2H); 2.52-2.45 (m, 4H). 
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Methyl 8-(4-(2-(7-chloroquinolin-4-ylamino)ethyl)piperazin-1-yl)-8-oxooctanoate (65) 
 
N
N
HN
NCl
O
COOMe
 
 
Compound 64 (260 mg, 0.89 mmol) was dissolved in 1 ml of anhydrous DMF and charged into a 
0.5-2 ml microwave vial. To the solution HOBt (140 mg, 0.89 mmol), DCC (180 mg, 0.89 mmol) 
and suberic acid monomethylester (0.16 ml, 0.89 mmol) were added. The mixture was stirred in a 
microwave reactor at 55 °C for 1 h. After the filtration of the DCU, the solvent was evaporated and 
the obtained residue was diluted with CH2Cl2 and washed with 2 N NaOH and brine. The organic 
layer was dried with anhydrous Na2SO4 and evaporated to dryness to obtain a residue that was 
purified by CC (CH2Cl2/MeOH in gradient), using the Flash Chromatography Purification System 
Biotage SP-1; the product eluted with 4% of MeOH. A yellow amorphous solid was obtained. 
Yield: 79%. 
1
H NMR (CDCl3) δ: 8.53 (d, 1H, J= 5.50 Hz); 7.96 (d, 1H, J= 2.20 Hz); 7.65 (d,1H, J= 
9.08 Hz); 7.37 (dd, 1H, J= 2.20, 9.08 Hz); 6.38 (d, 1H, J= 5.50 Hz); 5.84 (br s, 1H, collapsed with 
D2O); 3.65 (s, 3H); 3.54-3.49 (m, 4H); 3.38-3.31 (m, 2H); 2.82-2.79 (m, 2H); 2.57-2.49 (m, 4H); 
2.35-2.24 (m, 4H); 1.65-1.58 (m, 4H); 1.39-1.32 (m, 4H). 
 
 
 
 
 
  Experimental section 
76 
 
8-(4-(2-(7-Chloroquinolin-4-ylamino)ethyl)piperazin-1-yl)-N-hydroxy-8-oxooctanamide (6) 
 
 
 
A solution of KOH (760 mg, 13.53 mmol) in 4.5 ml of methanol was added to an ice-cooled 
suspension of hydroxylamine hydrochloride (940 mg, 13.53 mmol) in 2.4 ml of methanol. After 
stirring for few minutes, the precipitated KCl was filtered off and the filtrate was charged into a 
flask containing compound 65 (310 mg, 0.68 mmol) and KOH (570 mg, 1.02 mmol). The mixture 
was refluxed for 4 h. The solvent was evaporated and the obtained residue was diluted with 15 ml 
of water. After acidification with glacial acetic acid (pH= 6), the aqueous phase was extracted with 
a mixture of CH2Cl2/MeOH. 
The organic layer was dried with anhydrous Na2SO4 and evaporated to dryness to obtain an 
amorphous solid that was crystallized and rinsed with diethyl ether. A pale yellow solid was 
obtained. Yield: 51%. Mp 58.2-60.0 °C.  
The product was converted into the corresponding dihydrochloride salt with 1N HCl in ethanol. Mp 
213.6-215.2 °C. 
1
H NMR (DMSO-d6) δ: 11.49 (br s, 1H, collapsed with D2O); 10.35 (br s, 1H, 
collpased with D2O); 9.78 (br s, 1H, collapsed with D2O); 8.81 (d, 1H, J= 9.37 Hz); 8.66 (d, 1H, J= 
6.61 Hz); 8.11 (s, 1H); 7.79 (d, 1H, J= 9.37 Hz); 7.03 (d, 1H, J= 6.61 Hz); 4.45 (br s, 1H, collapsed 
with D2O); 4.10-3.98 (m, 2H); 3.70-3.35 (m, 7H, 1H collapsed with D2O); 3.20-2.87 (m, 4H); 2.39-
2.35 (m, 2H); 1.95-1.89 (m, 2H); 1.52-1.42 (m, 3H); 1.24-1.18 (m, 3H).      
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(E)-4-((4-(3-Ethoxy-3-oxoprop-1-en-1-yl)phenyl)amino)-4-oxobutanoic acid (66) 
 
 
 
A solution of ethyl (E)-3-(4-aminophenyl)acrylate (500 mg, 2.62 mmol) and succinic anhydride 
(968 mg, 9.68 mmol) in a mixture of H2O/THF (2:1) was stirred at r.t. for 40 minutes. The obtained 
precipitate was filtered, washed several times with water and then with diethyl ether. A white solid 
was obtained. Yield: 83%. Mp 178.1-180.2 °C. 
1
H NMR (DMSO-d6) δ: 12.13 (s, 1H, collapsed 
with D2O); 10.16 (s, 1H, collapsed with D2O); 7.70-7.52 (m, 4H); 7.56 (d, 1H, J=15.96 Hz); 6.49 
(d, 1H, J= 15.96 Hz); 4.21-4.13 (m, 2H); 2.53 (q, 4H, J= 7.15 Hz); 1.23 (t, 3H, J= 7.15 Hz).   
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Ethyl (E)-3-(4-(4-(4-(2-((7-chloroquinolin-4-yl)amino)ethyl)piperazin-1-yl)-4-
oxobutanamido)phenyl)acrylate (67) 
 
 
 
 
Compound 64 (200 mg, 0.69 mmol) was dissolved in 1 ml of anhydrous DMF and charged into a 
0.5-2 ml microwave vial. To the solution HOBt (104 mg, 0.69 mmol), DCC (142 mg, 0.69 mmol) 
and compound 66 (200 mg, 0.69 mmol) were added. The mixture was stirred in a microwave 
reactor at 55 °C for 1 h. After the filtration of the DCU, the solvent was evaporated and the obtained 
residue was diluted with CH2Cl2 and washed with water, a solution of NaHCO3 at 5% (w/w) and 
brine. The organic layer was dried with anhydrous Na2SO4 and evaporated to dryness to obtain an 
oily residue that was crystallized and rinsed with diethyl ether. The obtained solid residue was 
purified by CC (silica gel; CH2Cl2/MeOH in gradient); the product eluted with 4% of MeOH. The 
fraction containing the desired product was rinsed with a mixture of diethyl ether/MeOH (9:1) to 
provide a white solid. Yield: 67%. Mp 192.2-193.4 °C. 
1
H NMR (DMSO-d6) δ: 10.15 (s, 1H, 
collapsed with D2O); 8.39 (d, 1H, J= 5.20 Hz); 8.21 (d, 1H, J= 9.07 Hz); 7.77 (s, 1H); 7.67-3.62 (m, 
4H); 7.56 (d, 1H, J= 15.96 Hz); 7.45 (d, 1H, J= 9.07 Hz); 7.19 (br s, 1H, collapsed with D2O); 6.49-
6.45 (m, 2H); 4.16 (q, 2H, J= 7.15 Hz); 3.52-3.38 (m, 6H); 2.64-2.58 (m, 6H); 2.43-2.39 (m, 4H); 
1.24 (t, 3H, J= 7.15 Hz). 
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(E)-3-(4-(4-(4-(2-((7-Chloroquinolin-4-yl)amino)ethyl)piperazin-1-yl)-4-
oxobutanamido)phenyl)acrylic acid (68) 
 
 
 
1 N NaOH (0.4 ml) was added to a solution of compound 67 (200 mg, 0.36 mmol) in EtOH/THF 
(1:1) and the mixture was stirred at 60 °C for 2 h. After cooling to r.t., 0.5 N HCl was added until 
pH= 6 and a copious precipitate formed. It was filtered and washed with water to obtain a white 
solid. Yield: 79%. Mp 202.1-204.5 °C. 
1
H NMR (DMSO-d6) δ: 12.20 (br s, 1H, collapsed with 
D2O); 10.14 (s, 1H, collapsed with D2O); 8.41-8.38 (m, 1H); 8.21 (d, 1H, J= 8.80 Hz); 7.78-7.76 
(m, 1H); 7.61-7.40 (m, 5H); 7.21 (br s, 1H, collapsed with D2O); 6.52-6.49 (m, 1H); 6.38 (d, 1H, J= 
15.96 Hz); 3.56-3.08 (m, 8H); 2.63-2.20 (m, 8H). 
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(E)-4-(4-(2-((7-Chloroquinolin-4-yl)amino)ethyl)piperazin-1-yl)-N-(4-(3-(hydroxyamino)-3-
oxoprop-1-en-1-yl)phenyl)-4-oxobutanamide (7) 
 
 
 
Potassium hydroxide (19.5 mg, 0.28 mmol) was added to an ice-cooled solution of hydroxylamine 
hydrochloride (16 mg, 0.28 mmol) in 0.5 ml of methanol. The mixture was stirred at 0 °C for 1 h. 
Meanwhile, ethyl chloroformate (23.5 mg, 0.21 mmol) was added to a suspension of compound 68 
(75 mg, 0.14 mmol) and TEA (39 µl, 0.28 mmol) in 1.5 ml of anhydrous THF. The mixture was 
stirred at r.t. for 1.5 h. The hydroxylamine suspension was filtered to remove the formed KCl and 
the filtrate was charged into the flask containing the activated carboxylic acid. The mixture was 
stirred at r.t. for 3 h, then the unreacted compound 68 was filtered off. The filtrate was evaporated to 
obtain a residue that, after diluition with water, was filtered and washed with water. The solid was 
suspended in water and alkalized with 2 N NaOH, obtaining a colloidal suspension. 0.5 N HCl was 
added very slowly and when pH= 8 was reached, the formation of a precipitate was observed. It was 
filtered and washed with water to collect a cream-coloured solid that was purified by C-18 HPLC 
(phase A: water + 0.1% TFA; phase B: MeOH + 0.1% TFA), with the following elution method:  
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Time (min.) % A % B Flow (ml/min.) 
0 86 14 0 
1 86 14 14 
21 0 100 14 
26 0 100 14 
30 86 14 14 
34 86 14 14 
35 86 14 0 
 
The obtained product was converted into the corresponding dihydrochloride salt with 1 N HCl in 
EtOH to get a white solid. Yield: 12%. Mp 172.5-175.1 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.10 (br 
s, 1H, collapsed with D2O); 8.30-8.27 (m, 2H); 7.59-7.42 (m, 6H); 6.45-6.38 (m, 3H); 3.55-3.10 (m, 
10H); 2.60-2.23  (m, 6H). 
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2-(4-Nitrophenyl)-2-oxoethyl (tert-butoxycarbonyl)glycinate (69) 
 
 
 
A mixture of Boc-glycine (2.9 g, 16.40 mmol), cesium carbonate (2.7 g, 8.30 mmol) and 50 ml of 
ethanol was stirred under argon at r.t. for 30 minutes. Then the solvent was evaporated and the 
residue diluted with 50 ml of anhydrous DMF. 2-Bromo-4-nitroacetophenone (4.0 g, 16.40 mmol) 
was added and the mixture stirred under argon at r.t. for 2 h. The solvent was evaporated and the 
residue diluted with ethyl acetate, observing the formation of a precipitate of CsBr that was filtered 
and washed with ethyl acetate. The filtrate was evaporated and the obtained residue was purified by 
CC (silica gel; cyclohexane/ethyl acetate in gradient), using the Flash Chromatography Purification 
System Biotage SP-1; the product eluted with 11% of ethyl acetate. The fraction containing the 
desired product was rinsed with a mixture of diethyl ether/ petroleum ether (1:1) to collect a cream-
coloured solid. Yield: 68%. Mp 113.9-116.9 °C. 
1
H NMR (CDCl3) δ: 8.34 (dd, 2H, J= 1.93, 8.50 
Hz); 8.07 (dd, 2H, J= 1.93, 8.50 Hz); 5.41 (s, 2H); 5.05 (br s, 1H, collapsed with D2O); 4.11 (d, 2H, 
J= 5.78 Hz); 1.45 (s, 9H).  
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tert-Butyl ((4-(4-nitrophenyl)-1H-imidazol-2-yl)methyl)carbamate (70) 
 
 
 
 A mixture of compound 69 (3.6 g, 10.64 mmol), ammonium acetate (5.2 g, 135.80 mmol) and 80 
ml of xylene was stirred under nitrogen at 180 °C for 4 h, removing the forming water with a Dean-
Stark apparatus. The mixture was diluted with ethyl acetate and washed with water, a solution of 
NaHCO3 at 5% (w/w) and brine. The organic layer was dried with anhydrous Na2SO4 and 
evaporated to dryness to obtain a residue that was purified by CC (silica gel; cyclohexane/ethyl 
acetate in gradient), using the Flash Chromatography Purification System Biotage SP-1; the product 
eluted with 20% of ethyl acetate. The fraction containing the desired product was rinsed with a 
mixture of diethyl ether/ petroleum ether (3:7) to collect a reddish solid. Yield: 52%. Mp 204.9-
206.9 °C. 
1
H NMR (DMSO-d6) δ: 12.17 (br s, 1H, collapsed with D2O); 8.18 (d, 2H, J= 8.80 Hz); 
7.98 (d, 2H, J= 8.80 Hz); 7.83 (s, 1H); 7.31 (br s, 1H, collapsed with D2O); 4.18 (d, 2H, J= 5.77 
Hz); 1.39 (s, 9H). 
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(4-(4-Nitrophenyl)-1H-imidazol-2-yl)methanamine (71) 
 
 
 
Compound 70 (1.6 g, 5.03 mmol) was stirred in 4 ml of TFA at r.t. for 1 h. A mixture of diethyl 
ether/ petroleum ether (1:1) was added and the formation of a yellow precipitate was observed. It 
was filtered, washed with diethyl ether/MeOH (8:2) and dissolved in water. After alkalization with 
K2CO3, water was evaporated and the obtained residue was purified by flash CC (silica gel; 
CH2Cl2/MeOH/conc. NH3, 10:1:0.1). the fraction containing the product was rinsed with a mixture 
of diethyl ether/petroleum ether (7:3) to obtain a brown solid. Yield: 80%. Mp 193.3-194.9 °C. 
1
H 
NMR (DMSO-d6) δ: 8.19 (dd, 2H, J= 2.20, 8.80 Hz); 7.97 (dd, 2H, J= 2.20, 8.80 Hz); 7.81 (s, 1H); 
3.75 (d, 2H, J= 2.47Hz).  
3H are not visible, probably for the interaction with the solvent.  
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7-Chloro-N-((4-(4-nitrophenyl)-1H-imidazol-2-yl)methyl)quinolin-4-amine (72) 
 
 
 
A mixture of compound 71 (750 mg, 3.44 mmol), 4,7-dichloroquinoline (819 mg, 4.13 mmol) and 
phenol (2.1 g, 17.20 mmol) was stirred under nitrogen at 130 °C for 3 h. Then it was put into a 250 
ml flask and diluted with a mixture of CH2Cl2/MeOH (9:1) and 2 N NaOH. The obtained precipitate 
was filtered and washed with water and diethyl ether to collect a mustard-coloured solid. Yield: 
92%. Mp 270.6-273.4 °C. 
1
H NMR (DMSO-d6) δ: 12.41 (br s, 1H, collapsed with D2O); 8.41-8.30 
(m, 2H); 8.21-8.18 (m, 2H); 8.03-7.96 (m, 3H); 7.89 (s, 1H); 7.82 (s, 1H); 7.53-7.50 (m, 1H); 6.48 
(s, 1H); 4.60 (s, 2H). 
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N-((4-(4-Aminophenyl)-1H-imidazol-2-yl)methyl)-7-chloroquinolin-4-amine (73) 
 
 
 
A mixture of compound 72 (600 mg, 1.58 mmol), metallic iron (441 mg, 7.90 mmol) and 15 ml of 
glacial acetic acid was stirred at r.t. for 1.5 h. The solvent was evaporated and the obtained residue 
was diluted with a mixture of ethyl acetate/MeOH (9:1). After cooling with an ice-bath, 50 ml of 
water was added and the mixture was alkalized with K2CO3. The two layers were separated and the 
organic one was washed with water and brine and then dried with anhydrous Na2SO4 and 
evaporated to dryness to obtain a residue that was purified by CC (silica gel; CH2Cl2/MeOH in 
gradient), using the Flash Chromatography Purification System Biotage SP-1; the product eluted 
with 7% of MeOH. The fraction containing the desired product was rinsed with diethyl 
ether/petroleum ether (3:7) to obtain a nut-brown solid. Yield: 67%. Mp 152.3-156.5 °C. 
1
H NMR 
(DMSO-d6) δ: 11.80 (s, 1H, collapsed with D2O); 8.36 (d, 1H, J= 5.50 Hz); 8.31 (d, 1H, J= 9.08 
Hz); 7.90 (s, 1H, collapsed with D2O); 7.79 (d, 1H, J= 2.20); 7.47 (dd, 1H, J= 2.20, 9,08 Hz); 7.36 
(d, 2H, J= 8.25 Hz); 7.13 (s, 1H); 6.56-6.52 (m, 3H); 5.00 (br s, 2H, collapsed with D2O); 4.50 (d, 
2H, J= 5.50 Hz).  
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Methyl 8-(4-(2-((7-chloroquinolin-4-ylamino)methyl)-1H-imidazol-5-yl)phenylamino)-8-
oxooctanoate (74) 
 
NCl
HN
H
N
O
COOMe
N
H
N
 
 
 
Compound 73 (286 mg, 0.82 mmol) was dissolved in 2 ml of anhydrous DMF and charged into a 
microwave vial. To the solution HOBt (124 mg, 0.82 mmol), DCC (169 mg, 0.82 mmol) and 
suberic acid monomethylester (0.15 ml, 0.82 mmol) were added. The mixture was stirred in a 
microwave reactor at 58 °C for 1 h. After the filtration of the DCU, the solvent was evaporated and 
the obtained residue was diluted with CH2Cl2 and washed with water, then with a solution of 
NaHCO3 at 5% (w/w) and finally with brine. In the organic layer a precipitate formed and it was 
filtered, washed with water and then purified by CC (silica gel; CH2Cl2/MeOH in gradient), using 
the Flash Chromatography Purification System Biotage SP-1; the product eluted with 8% of MeOH. 
A white solid was obtained. Yield: 68%. Mp 103.1-104.2 °C. 
1
H NMR (DMSO-d6) δ: 12.05 (br s, 
1H, collapsed with D2O); 9.82 (s, 1H); 8.38 (d, 1H, J= 5.20 Hz); 8.32 (d, 1H, J= 8.80 Hz); 7.96 (br 
s, 1H, collapsed with D2O); 7.80 (s, 1H); 7.62-7.48 (m, 4H); 7.39 (s, 1H); 6.51 (d, 1H, J= 5.50 Hz); 
4.55 (d, 2H, J= 5.20 Hz); 3.56 (s, 3H); 2.30-2.25 (m, 4H); 1.59-1.48 (m, 4H); 1.30-1.25 (m, 4H).  
1H is not visible, probably for the interaction with the solvent.    
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N
1
-(4-(2-(((7-Chloroquinolin-4-yl)amino)methyl)-1H-imidazol-5-yl)phenyl)-N8-
hydroxyoctanediamide (8) 
 
 
 
Potassium hydroxide (432 mg, 7.70 mmol) was added to an ice-cooled solution of hydroxylamine 
hydrochloride (535 mg, 7.70 mmol) in 1.4 ml of methanol. The mixture was stirred at 0 °C for 10 
minutes. The hydroxylamine suspension was filtered to remove the formed KCl and the filtrate was 
charged into a flask containing compound 74 (200 mg, 0.39 mmol) and further KOH (32 mg, 0.57 
mmol). The mixture was stirred at r.t. for 4 h and then the solvent was evaporated. The obtained 
residue was diluted with a small amount of water and 0.1 N HCl was added until the formation of a 
colloidal suspension. After the addition of CH2Cl2, the obtained precipitate was filtered and washed 
with CH2Cl2 and diethyl ether. A white solid was obtained. Yield: 61%. Mp 157.2-158.8 °C.  
The product was converted into the corresponding dihydrochloride salt with 1 N HCl in ethanol. Mp 
218.8-220.5 °C. 
1
H NMR (DMSO-d6) δ: 10.35 (s, 1H, collapsed with D2O); 10.20 (br s, 2H, 
collapsed with D2O); 8.76-8.68 (m, 2H); 8.14 (s, 1H); 8.00 (s, 1H); 7.85-7.70 (m, 5H); 7.04 (d, 1H, 
J= 7.15 Hz); 5.24-5.19 (m, 2H); 2.33-2.28 (m, 2H); 1.97-1.91 (m, 2H); 1.60-1.43 (m, 4H); 1.32-
1.21 (m, 4H).   
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2-(4-Nitrobenzyl)isoindoline-1,3-dione (75) 
 
 
 
A suspension of 1-(bromomethyl)-4-nitrobenzene (2 g, 9.26 mmol), potassium phthalimide (1.7 g, 
9.26 mmol) and 27 ml of anhydrous DMF was stirred under nitrogen at 50 °C for 12 h. The mixture 
was poured into cold water and the obtained white precipitate was filtered and washed with water 
and ethanol. The solid was purified by CC (silica gel; CH2Cl2), using the Flash Chromatography 
Purification System Biotage SP-1. The fraction containing the desired product was rinsed with 
diethyl ether to obtain a white solid. Yield: 72%. Mp 172.2-173.5 °C. 
1
H NMR (CDCl3) δ: 8.18 (dd, 
2H, J= 2.20, 8.80 Hz); 7.90-7.87 (m, 2H); 7.77-7.72 (m, 2H); 7.49 (dd, 2H, J= 2.20, 8.80 Hz); 8.92 
(s, 2H). 
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(4-Nitrophenyl)methanamine (76) 
 
 
 
Hydrazine hydrate (0.43 ml, 8.86 mmol) was added to a suspension of compound 75 (500 mg, 1.77 
mmol) in 70 ml of EtOH/THF (9:1) and the mixture was refluxed under nitrogen for 24 h. After 
cooling with an ice-bath, 39 ml of a 1 M solution of oxalic acid were slowly added. The obtained 
mixture was refluxed for 30 minutes and then, after cooling to r.t., it was alkalized with 2 N NaOH 
(pH= 12). The formed white precipitate was filtered and washed with water. The filtrate was 
extracted with CH2Cl2 and the organic layer was washed with brine, dried with anhydrous Na2SO4 
and evaporated to dryness. An orange oil was obtained, which was directly used in the next step 
without further purification. 
1
H NMR (CDCl3) δ: 8.19 (dd, 2H, J= 1.95, 7.15 Hz); 7.50 (dd, 2H, J= 
1.95, 7.15 Hz); 4.02 (s, 2H). 2H are not visible, probably for the interaction with the solvent. 
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7-Chloro-N-(4-nitrobenzyl)quinolin-4-amine (77) 
 
 
 
A mixture of compoun 76 (217 mg, 1.43 mmol), 4,7-dichloroquinoline (311 mg, 1.57 mmol) and 
phenol (1.3 g, 14.24 mmol) was stirred under nitrogen at 130 °C for 3.5 h and then diluted with 
CH2Cl2/MeOH (9.5:0.5). After washing with 2 N NaOH, water and brine, the organic layer was 
dried with anhydrous Na2SO4 and evaporated to dryness. The obtained residue was purified by CC 
(silica gel; CH2Cl2/MeOH in gradient), using the Flash Chromatography Purification System 
Biotage SP-1; the product eluted with 2.7% of MeOH. The fraction containing the desired product 
was rinsed with diethyl ether to obtain a cream-coloured solid. Yield: 59%. Mp 209.8-210.9 °C 
(dec.). 
1
H NMR (DMSO-d6) δ: 8.37-8.29 (m, 2H); 8.20-8.15 (m, 3H, 1H collapsed with D2O); 7.80 
(d, 1H, J= 1.43 Hz); 7.62 (d, 2H, J= 9.15 Hz); 7.47 (dd, 1H, J= 1.43, 8.80 Hz); 6.31 (d, 1H, J= 6.05 
Hz); 4.68 (d, 2H, J= 6.05 Hz). 
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N-(4-Aminobenzyl)-7-chloroquinolin-4-amine (78) 
 
 
 
A mixture of compound 77 (776 mg, 2.47 mmol), metallic iron (691 mg, 12.37 mmol) and 10 ml of 
acetic acid was stirred vigorously at 70 °C for 1.5 h. The solvent was evaporated and the residue 
was diluted with CH2Cl2/MeOH (9:1) and water and the mixture was neutralized with NaHCO3. 
The two layers were separated and the organic one was washed with water and brine, dried with 
anhydrous Na2SO4 and evaporated to dryness. The obtained residue was rinsed with petroleum ether 
and diethyl ether to generate a white solid. Yield: 66%. Mp 143.5-145.1 °C. 
1
H NMR (DMSO-d6) 
δ: 8.36-8.29 (m, 2H); 7.85 (t, 1H, J= 6.05 Hz, collapsed with D2O); 7.77 (d, 1H, J= 1.43 Hz); 7.51-
7.45 (m, 1H); 7.02 (dd, 2H, J= 1.95, 8.80 Hz); 6.49 (dd, 2H, J= 1.95, 8.80 Hz); 6.38 (d, 1H, J= 6.05 
Hz); 4.97 (br s, 2H, collapsed with D2O); 4.30 (d, 2H, J= 6.05 Hz).  
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Methyl 8-((4-(((7-chloroquinolin-4-yl)amino)methyl)phenyl)amino)-8-oxooctanoate (79) 
 
 
 
Compound 78 (200 mg, 0.71 mmol) was dissolved in 0.8 ml of anhydrous DMF and charged into a 
0.5-2 ml microwave vial. To the solution HOBt (107 mg, 0.71 mmol), DCC (145 mg, 0.71 mmol) 
and suberic acid monomethylester (0.13 ml, 0.71 mmol) were added. The mixture was stirred in a 
microwave reactor at 55 °C for 1 h. After the filtration of the DCU, the solvent was evaporated and 
the residue was diluted with 2 N NaOH. The obtained precipitate was filtered, washed with water 
and then purified by CC (silica gel; CH2Cl2/MeOH in gradient); the product eluted with 2% of 
MeOH. The fraction containing the desired product was rinsed with diethyl ether/CH2Cl2 (9:1) to 
obtain a white solid. Yield: 56%. Mp 166.4-167.0 °C. 
1
H NMR (CDCl3) δ: 8.52 (d, 1H, J= 6.20 
Hz); 7.97 (d, 1H, J= 2.20 Hz); 7.70 (d, 1H, J= 9.15 Hz); 7.55 (d, 2H, J= 8.80 Hz); 7.42 (br s, 1H, 
collapsed with D2O); 7.38-7.29 (m, 3H); 6.42 (d, 1H, J= 6.20 Hz); 5.37 (br s, 1H, collapsed with 
D2O); 4.47 (d, 2H, J= 6.20 Hz); 3.65 (s, 3H); 2.38-2.25 (m, 4H); 1.78-1.60 (m, 4H); 1.42-1.36 (m, 
4H).  
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N
1
-(4-(((7-Chloroquinolin-4-yl)amino)methyl)phenyl)-N8-hydroxyoctanediamide (9) 
 
 
 
Potassium hydroxide (544 mg, 9.69 mmol) was added to an ice-cooled solution of hydroxylamine 
hydrochloride (674 mg, 9.69 mmol) in 1.7 ml of methanol. The mixture was stirred at 0 °C for 10 
minutes. The hydroxylamine suspension was filtered to remove the formed KCl and the filtrate was 
charged into a flask containing compound 79 (220 mg, 0.48 mmol) and further KOH (41 mg, 0.73 
mmol). The mixture was stirred at r.t. for 5 h and then the solvent was evaporated. The obtained 
residue was diluted with a small amount of water and acetic acid was added until the formation of a 
precipitate (pH= 5). It was filtered and washed with water to obtain a white solid. Yield: 92%. Mp 
173.1-174.4 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.35 (s, 1H, collapsed with D2O); 9.93 (s, 1H, 
collapsed with D2O); 9.67 (br s, 1H, collapsed with D2O); 8.63 (d, 1H, J= 7.95 Hz); 8.42 (d, 1H, J= 
6.05 Hz); 7.98 (s, 1H); 7.71 (d, 1H, J= 7.95 Hz); 7.57 (d, 2H, J= 8.80 Hz); 7.32 (d, 2H, J= 8.80 Hz); 
6.68 (d, 1H, J= 6.05 Hz); 4.61 (s, 2H); 2.35-2.21 (m, 2H); 1.98-1.92 (m, 2H); 1.59-1.45 (m, 4H); 
1.32-1.21 (m, 4H). 1H is not visible, probably for the interaction with the solvent. 
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4.3 Indeno[2,1-c]quinolines 
 
2,6-Dichloro-7H-indeno[2,1-c]quinolin-7-one (81) 
 
 
 
Method A: A mixture of malonic acid (2.9 g; 27.6 mmol), (2-amino-5-
chlorophenyl)(phenyl)methanone (80; 3.2 g; 13.8 mmol) and POCl3 (48 ml) was refluxed for 4 h 
under nitrogen. After cooling, the mixture was slowly poured into water and crushed ice, under a 
vigorous agitation. After the addition of CH2Cl2 (400 ml), the formed insoluble yellow solid was 
collected through filtration and washed successively with CH2Cl2, methanol, ethyl acetate and n-
hexane. The aqueous phase was extracted with CH2Cl2 and the organic layer was dried with 
anhydrous Na2SO4 and evaporated to dryness. The obtained solid residue was washed with CH2Cl2, 
methanol, ethyl acetate and n-hexane. The two crude solids were joined and submitted to a 
digestion with CH2Cl2 to get yellow crystals of the desired product (81). Yield: 43%. Mp 283.2-
283.6 °C (dec). 
1
H NMR (TFA-d) δ: 9.05 (d, 1H, J= 3.85 Hz): 8.58 (t, 1H, J= 6.60 Hz); 8.33 (d, 2H, 
J= 3.85 Hz); 8.16 (t, 1H, J= 6.60 Hz); 8.02-7.96 (m, 2H).  
The organic washing solvents of the two solids, containing the by-product 2,6-dichloro-4-
phenylquinoline-3-carbonyl chloride (82), were joined and evaporated to dryness and purified by 
CC (silica gel; cyclohexane/ethyl acetate in gradient). The obtained residue was rinsed with 
petroleum ether to get white crystals. Yield: 26%. Mp 168.2-169.9 °C. 
1
H NMR (CDCl3) δ: 8.05 (d, 
1H, J= 9.08 Hz); 7.77 (dd, 1H, J= 2.48, 9.08 Hz); 7.60-7.56 (m, 4H); 7.40-7.38 (m, 2H). 
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Method B: To an ice-cooled solution of 2,6-dichloro-4-phenylquinoline-3-carbonyl chloride (82; 
1.2 g; 3.6 mmol) in 24 ml of anhydrous CH2Cl2, AlCl3 (1.2 g; 8.9 mmol) was added and the mixture 
was stirred under nitrogen at r.t. for 3.5 h and then was refluxed for 30 minutes. After cooling, the 
mixture was poured into water and crushed ice and the obtained precipitate was filtered and washed 
with methanol, ethyl acetate and n-hexane to get a yellow solid. Yield: 93%. Mp 283.0-283.5 °C 
(dec). 
1
H NMR (TFA-d) δ: 9.05 (d, 1H, J= 3.85 Hz): 8.58 (t, 1H, J= 6.6 Hz); 8.33 (d, 2H, J= 4.68 
Hz); 8.16 (t, 1H, J= 6.32 Hz); 8.02-7.96 (m, 2H). 
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3,6-Dichloro-7H-indeno[2,1-c]quinolin-7-one (84) 
 
 
 
Method A: A mixture of malonic acid (671 mg; 6.45 mmol), (2-amino-4-
chlorophenyl)(phenyl)methanone (83; 1 g; 4.31 mmol) and POCl3 (20 ml) was refluxed for 4 h 
under nitrogen. After cooling, the mixture was slowly poured into water and crushed ice under a 
vigorous agitation. The obtained precipitate was filtered and washed with water. The filtrate was 
extracted with CH2Cl2 and the organic layer was dried with anhydrous Na2SO4 and evaporated to 
dryness. The two solid residues were mixed and purified by CC (silica gel; cyclohexane/ethyl 
acetate in gradient). The obtained residue was rinsed with CH2Cl2, methanol and ethyl acetate to get 
255 mg of yellow crystals of the desired product (84). Yield: 35%. Mp 247.6-248.0 °C. 
1
H HMR 
(DMSO-d6) δ: 8.74 (d, 1H, J= 9.08 Hz); 8.62 (d, 1H, J= 7.43 Hz); 8.08 (d, 1H, J= 2.2 Hz); 7.79-
7.74 (m, 3H); 7.72-7.63 (m, 1H).  
The fraction containing the by-product 2,7-dichloro-4-phenylquinoline-3-carbonyl chloride (85) 
was evaporated and washed with petroleum ether to give white crystals. Yield: 20%. Mp 97.8-99.3 
°C. 
1
H NMR (CDCl3) δ: 8.11 (d, 1H, J= 2.2 Hz); 7.59-7.55 (m, 4H); 7.50 (dd, 1H, J= 2.2, 9.08 Hz); 
7.39-7.36 (m, 2H). 
 
Method B: To an ice-cooled solution of 3,6-dichloro-4-phenylquinoline-3-carbonyl chloride (85; 
500 mg; 1.5 mmol) in 6 ml of anhydrous CH2Cl2, AlCl3 (495 mg; 3.7 mmol) was added and the 
mixture was stirred under nitrogen at r.t. for 4 h and then was refluxed for 30 minutes. After 
cooling, the mixture was poured into water and crushed ice and the obtained precipitate was filtered 
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and washed with CH2Cl2, methanol, ethyl acetate and n-hexane to get a yellow solid. Yield: 79%. 
Mp 247.1-248.0 °C (dec). 
1
H NMR (DMSO-d6) δ: 8.74 (d, 1H, J= 9.08 Hz); 8.62 (d, 1H, J= 7.43 
Hz); 8.08 (d, 1H, J= 2.2 Hz); 7.79-7.74 (m, 3H); 7.72-7.63 (m, 1H). 
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2- or 3-Chloro-6-(amino-substituted)-7H-indeno[2,1-c]quinolin-7-ones (10-17) 
 
 
 
General procedure: a suspension of the indenoquinoline 81 or 84 (1.67 mmol) and the appropriated 
amine (3.33 mmol) in 7 ml of dry pyridine was heated at 100 °C for 20 h. The reaction mixture was 
poured into iced water (150-200 ml) and when it was possible, the precipitate was filtered, 
otherwise it was extracted with ethyl acetate or dichloromethane. The organic layer was dried with 
anhydrous Na2SO4 and evaporated to dryness. The residue was purified by CC (silica gel; 
CH2Cl2/MeOH or cyclohexane/ethyl acetate in gradient as indicated for each compound). 
 
2-Chloro-6-(2-(piperidin-1-yl)ethylamino)-7H-indeno[2,1-c]quinolin-7-one (10) 
CC (CH2Cl2/MeOH in gradient up to 98:2); the residue was washed with hot ethanol and then with 
diethyl ether to obtain a red solid. Yield: 52%. Mp 169.7-170.5 °C. 
1
H NMR (CDCl3) δ: 8.13 (d, 
1H, J= 2.20 Hz); 7.95 (d, 1H, J= 7.42 Hz); 7.68-7.53 (m, 4H); 7.51-7.40 (m, 2H, 1H collapsed with 
D2O); 3.83-3.79 (m, 2H); 2.75-2.60 (m, 6H); 1.74-1.70 (m, 4H); 1.54-1.50 (m, 2H). HRMS (ESI) 
m/z Calcd for C23H23ClN3O [M+H]
+
: 392.15297; found: 392.15238. 
 
3-Chloro-6-(2-(piperidin-1-yl)ethylamino)-7H-indeno[2,1-c]quinolin-7-one (11) 
CC (CH2Cl2/MeOH in gradient up to 97:3); the residue was rinsed with a mixture of petroleum 
ether/diethyl ether (6:4) to obtain a brick-red solid. Yield: 40%. Mp 161.0-163.5 °C. 
1
H NMR 
(CDCl3) δ: 8.11 (d, 1H, J= 9.07 Hz); 7.94 (d, 1H, J= 7.42 Hz); 7.68-7.66 (m, 2H); 7.53 (t, 1H, J= 
7.42 Hz); 7.42 (m, 2H, 1H collapsed with D2O); 7.21 (d, 1H, J= 9.07 Hz); 3.84-3.82 (m, 2H); 2.76 
  Experimental section 
100 
 
(m, 2H); 2.63 (m, 4H); 1.74 (m, 4H); 1.51 (m, 2H). HRMS (ESI) m/z Calcd for C23H23ClN3O 
[M+H]
+
: 392.15297; found: 392.15237. 
 
3-Chloro-6-(2-morpholinoethylamino)-7H-indeno[2,1-c]quinolin-7-one (12) 
CC (CH2Cl2/MeOH in gradient up to 98:2); the residue was rinsed with a mixture of petroleum 
ether/diethyl ether (8:2) to obtain a red solid. Yield: 44%. Mp 174.5-175.8 °C. 
1
H NMR (CDCl3) δ: 
8.13 (d, 1H, J= 8.80 Hz); 7.95 (d, 1H, J= 7.42 Hz); 7.70-7.67 (m, 2H); 7.55 (t, 1H, J= 6.60 Hz); 
7.46-7.41 (m, 2H, 1H collapsed with D2O); 7.22 (dd, 1H, J= 1.92, 8.80 Hz); 3.85 (m, 6H); 2.80-
2.68 (m, 6H). HRMS (ESI) m/z Calcd for C22H21ClN3O2 [M+H]
+
: 394.13223; found: 394.13168. 
The product was converted into the corresponding dihydrochloride salt (yellow solid) with 1 N HCl 
in ethanol. Mp 267.6-269.8 °C (dec). 
 
2-Chloro-6-(2-(4-methylpiperazin-1-yl)ethylamino)-7H-indeno[2,1-c]quinolin-7-one (13) 
CC (CH2Cl2/MeOH in gradient up to 90:10); the residue was recrystallized with diethyl ether and 
rinsed with petroleum ether to obtain a red solid. Yield: 52%. Mp 175.9-177.7 °C. 
1
H NMR 
(CDCl3) δ: 8.13 (d, 1H, J= 2.20 Hz); 7.95 (d, 1H, J= 7.42 Hz); 7.68-7.50 (m, 4H); 7.45-7.36 (m, 
2H, 1H collapsed with D2O); 3.78-3.72 (m, 2H); 2.74-2.65 (m, 10H); 2.39 (s, 3H). HRMS (ESI) 
m/z Calcd for C22H24ClN4O [M+H]
+
: 407.16386; found: 407.16327. 
The product was converted into the corresponding trihydrochloride salt (yellow solid) with 1 N HCl 
in ethanol. Mp 246.6-248.0 °C (dec.). 
 
3-Chloro-6-(2-(4-methylpiperazin-1-yl)ethylamino)-7H-indeno[2,1-c]quinolin-7-one (14) 
CC (CH2Cl2/MeOH in gradient); the residue was rinsed with petroleum ether to obtain a dark 
orange solid. Yield: 48%. Mp 141.7-142.3 °C. 
1
H NMR (CDCl3) δ: 8.10 (d, 1H, J= 8.80 Hz); 7.94 
(d, 1H, J= 7.15 Hz); 7.69-7.60 (m, 2H); 7.54 (t, 1H, J= 7.15 Hz); 7.45-7.40 (m, 2H, 1H collapsed 
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withD2O); 7.20 (dd, 1H, J= 1.93, 8.80 Hz); 3.78-3.72 (m, 2H); 2.72-2.68 (m, 10 H); 2.34 (s, 3H). 
HRMS (ESI) m/z Calcd for C22H24ClN4O [M+H]
+
: 407.16386; found: 407.16330. 
The product was converted into the corresponding trihydrochloride salt (yellow solid)with 1 N HCl 
in ethanol. Mp 243.8-245.0 °C (dec). 
 
2-Chloro-6-(4-methylpiperazin-1-yl)-7H-indeno[2,1-c]quinolin-7-one (15) 
Compound 15 was obtained as a by-product of the reaction to generate the 2-chloro-6-(2-(4-
methylpiperazin-1-yl)ethylamino)-7H-indeno[2,1-c]quinolin-7-one (13), because 2-(4-
methylpiperazin-1-yl)ethanamine used was impure of 1-methylpiperazine. CC (CH2Cl2/MeOH in 
gradient up to 95:5); the residue was rinsed with diethyl ether to obtain a red solid. Yield: 6%. Mp 
170.0-171.3 °C. 
1
H NMR (CDCl3) δ: 8.29 (s, 1H); 8.02 (d, 1H, J= 7.43 Hz); 7.72-7.67 (m, 2H); 
7.61-7.56 (m, 2H); 7.45 (t, 1H, J= 7.43 Hz); 3.73-3.70 (m, 4H); 2.69-2.66 (m, 4H); 2.40 (s, 3H). 
HRMS (ESI) m/z Calcd for C21H18ClN3O [M+H]
+
: 364.12166; found: 364.12094. 
The product was converted into the corresponding dihydrochloride salt (brick red solid) with 1 N 
HCl in ethanol. Mp 259.0-260.5 °C (dec). 
 
2-Chloro-6-(4-(pyridin-2-yl)piperazin-1-yl)-7H-indeno[2,1-c]quinolin-7-one (16) 
CC (cyclohexane/ethyl acetate in gradient up to 6:4); the residue was rinsed with petroleum ether to 
obtain a red solid. Yield: 91%. Mp 180.2-181.5 °C (dec). 
1
H NMR (CDCl3) δ: 8.31 (s, 1H); 8.24 (d, 
1H, J= 4.68 Hz); 8.04 (d, 1H, J= 7.42 Hz); 7.76-7.70 (m, 2H); 7.63-7.45 (m, 4H); 6.72 (d, 1H, J= 
8.8 Hz); 6.70 (t, 1H, J= 5.77 Hz); 3.90-3.86 (m, 4H); 3.74-3.71 (m, 4H). . HRMS (ESI) m/z Calcd 
for C25H20ClN4O [M+H]
+
: 427.13256; found: 427.13168. 
The product was converted into the corresponding dihydrochloride salt (red solid) with 1 N HCl in 
ethanol. Mp 192.3-193.2 °C (dec). 
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2-Chloro-6-(1H-imidazol-1-yl)-7H-indeno[2,1-c]quinolin-7-one (17) 
The residue was rinsed with a mixture of diethyl ether/methanol (9:1) and then with hot diethyl 
ether to obtain a dark yellow solid. Yield: 71%. Mp 262.3-263.6 °C (dec). HRMS (ESI) m/z Calcd 
for C19H11ClN3O [M+H]
+
: 332.05906; found: 332.05893. 
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2- or 3-Chloro-6-(amino-substituted)-7H-indeno[2,1-c]quinolin-7-one oximes (18-25) 
 
 
 
General procedure: Hydroxylamine hydrochloride (1.58 mmol) and sodium hydroxide (2.65 mmol) 
were added to an ice-cooled suspension of the proper ketone compound (0.53 mmol) in 10 ml of a 
mixture of ethanol/H2O (2:1). After stirring for 15 minutes at r.t., the mixture was refluxed for 2 h. 
The ethanol was evaporated and the alkaline aqueous solution was neutralized with 1N HCl. When 
possible, the obtained suspension was filtered and the aqueous solution was extracted with CH2Cl2 
and the organic layer was dried with anhydrous Na2SO4 and evaporated to dryness. The crude 
residue was purified as indicated for each compound. 
 
2-Chloro-6-(2-(piperidin-1-yl)ethylamino)-7H-indeno[2,1-c]quinolin-7-one oxime (18) 
The residue was purified by C-18 HPLC (phase A (H2O/CH3CN 97:3 + 0.1 TFA)/phase B 
(H2O/CH3CN 70:30 + 0.1 TFA) (70:30). The product was converted into the corresponding 
dihydrochloride salt to get a yellow solid. Yield: 35%. Mp 251.0-252.5 °C (dec). 
1
H NMR (DMSO-
d6) (18*2HCl) δ: 10.33 (br s, 1H, collapsed with D2O); 8.51-8.44 (m, 3H); 8.16-8.15 (m, 2H, 1H 
collapsed with D2O); 7.77 (d, 1H, J= 7.98 Hz); 7.64 (m, 2H); 4.48 (br s, 2H, collapsed with D2O); 
4.23-4.22 (m, 2H); 3.55-3.54 (m, 2H); 3.42-3.41 (m, 2H); 3.02-3.01 (m, 2H); 1.79-1.43 (m, 6H).  
HRMS (ESI) m/z Calcd for C23H24ClN4O [M+H]
+
: 407.16386; found: 407.16329. 
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3-Chloro-6-(2-(piperidin-1-yl)ethylamino)-7H-indeno[2,1-c]quinolin-7-one oxime (19) 
The residue was purified by CC (C-18; CH3CN/H2O/TFA; 30:70:0.1) and the product was 
converted into the corresponding dihydrochloride salt to get a yellow solid. Yield: 16%. Mp 225.0-
230.0 °C (dec). 
1
H NMR (DMSO-d6) (19*2HCl) δ: 10.03 (br s, 1H, collapsed with D2O); 8.62 (d, 
1H, J= 8.52 Hz); 8.48 (m, 2H); 7.98 (br s, 1H, collapsed with D2O); 7.66-7.61 (m, 3H); 7.44 (d, 1H, 
J= 8.52 Hz); 4.44 (br s, 2H, collapsed with D2O); 4.14 (m, 2H); 3.59-3.56 (m, 2H); 3.40 (m, 2H); 
3.02-3.00 (m, 2H); 1.79-1.43 (m, 6H). HRMS (ESI) m/z Calcd for C23H24ClN4O [M+H]
+
: 
407.16386; found: 407.16327. 
 
3-Chloro-6-(2-morpholinoethylamino)-7H-indeno[2,1-c]quinolin-7-one oxime (20) 
The residue was purified by CC (ethyl acetate/MeOH 90:10) and C-18 HPLC (phase A 
(H2O/CH3CN 97:3 + 0.1 TFA)/phase B (H2O/CH3CN 70:30 + 0.1 TFA) (70:30). The product was 
converted into the corresponding dihydrochloride salt to get a yellow solid. Yield: 33%. Mp 230.0-
231.0 °C (dec). 
1
H NMR (DMSO-d6) (20*2HCl) δ: 11.01 (br s, 1H, collapsed with D2O); 8.63 (d, 
1H, J= 8.25 Hz); 8.48 (m, 2H); 8.21 (br s, 2H, 1 H collapsed with D2O); 7.64 (m, 2H); 7.48 (d, 1H, 
J= 8.25 Hz); 4.43-4.24 (m, 6H, 2H collapsed with D2O); 3.90 (m, 3H); 3.51-3.40 (m, 5H).  
1H is not visible, probably for the interaction with the solvent. HRMS (ESI) m/z Calcd for 
C22H22ClN4O2 [M+H]
+
: 409.14313; found: 409.14258. 
 
2-Chloro-6-(2-(4-methylpiperazin-1-yl)ethylamino)-7H-indeno[2,1-c]quinolin-7-one oxime 
(21) 
The residue was purified by CC (ethyl acetate/MeOH/conc. NH3 in gradient up to 89:10:1). The 
product was converted into the corresponding trihydrochloride salt to get a yellow solid. Yield: 
49%. Mp 221.0-222.8 °C (dec). 
1
H NMR (DMSO-d6) (21*3HCl) δ: 11.25 (br s, 1H, collapsed with 
D2O); 8.56-8.49 (m, 3H); 7.99-7.96 (m, 2H, 1H collapsed with D2O); 7.76-7.64 (m, 3H); 4.45 (br s, 
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3H, collapsed with D2O); 4.06-4.05 (m, 2H); 3.58-3.57 (m, 4H); 3.37-3.28 (m, 6H); 2.83 (s, 3H). 
HRMS (ESI) m/z Calcd for C22H25ClN5O [M+H]
+
: 422.17476; found: 422.17422. 
 
3-Chloro-6-(2-(4-methylpiperazin-1-yl)ethylamino)-7H-indeno[2,1-c]quinolin-7-one oxime 
(22) 
The residue was purified by CC (ethyl acetate/MeOH/conc. NH3 in gradient up to 89:10:1). The 
product was converted into the corresponding trihydrochloride salt and digested with hot MeOH to 
get a yellow solid. Yield: 47%. Mp 224.2-226.0 °C (dec). 
1
H NMR (DMSO-d6) (22*3HCl) δ: 11.57 
(br s, 1H, collapsed with D2O); 8.64 (d, 1H, J= 9.08 Hz); 8.48 (m, 2H); 8.36 (m, 1H); 8.20 (m, 1H, 
collapsed with D2O); 7.67 (m, 2H); 7.52-7.49 (m, 1H); 5.01 (br s, 3H, collapsed with D2O); 4.22 
(m, 2H); 3.72-7.62 (m, 4H); 3.41 (m, 6H); 2.84 (s, 3H). HRMS (ESI) m/z Calcd for C22H25ClN5O 
[M+H]
+
: 422.17476; found: 422.17422. 
 
2-Chloro-6-(4-(pyridin-2-yl)piperazin-1-yl)-7H-indeno[2,1-c]quinolin-7-one oxime (23) 
The residue was rinsed with diethyl ether to obtain a yellow solid. Yield: 87%. Mp 224.2-225.5 °C 
(dec). 
1
H NMR (CDCl3) δ: 8.60 (d, 1H, J= 2.48 Hz); 8.56 (d, 1H, J= 8.00 Hz); 8.49 (d, 1H, J= 8.00 
Hz); 8.15-8.14 (m, 1H); 7.84 (d, 1H, J= 9.07); 7.72-7.55 (m, 4H); 6.89 (d, 1H, J= 9.07 Hz); 6.69- 
6.65 (m, 1H); 3.70 (m, 4H); 3.59 (m, 4H).  
1H is not visible, probably for the interaction with the solvent. HRMS (ESI) m/z Calcd for 
C25H21ClN5O [M+H]
+
: 442.14346; found: 442.14282. 
The product was converted into the corresponding dihydrochloride salt (green solid) with 1 N HCl 
in ethanol. Mp 228.2-231.4 °C (dec). 
 
2-Chloro-6-(1H-imidazol-1-yl)-7H-indeno[2,1-c]quinolin-7-one oxime (25) 
The formed precipitate was filtered and washed with water. The residue was then digested with 
MeOH to obtain a green-yellow solid. Yield: 48%. Mp 271.0-273.0 °C (dec.). 
1
H NMR (DMSO-d6) 
  Experimental section 
106 
 
δ: 9.54 (m, 1H); 8.91 (m, 1H); 8.77 (m, 1H); 8.57 (m, 1H); 8.20 (m, 2H); 8.03 (m, 1H); 7.81-7.74 
(m, 3H).  
1H is not visible, probably for the interaction with the solvent. HRMS (ESI) m/z Calcd for 
C19H12ClN4O [M+H]
+
: 347.06996; found: 347.06996. 
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2-Chloro-6-(4-(pyridin-2-yl)piperazin-1-yl)-7H-indeno[2,1-c]quinolin-7-one O-propionyl 
oxime (24) 
 
 
 
To an ice-cooled suspension of compound 23 (150 mg; 0.33 mmol) in 10 ml of DMSO, NaH (32 
mg; 1.33 mmol) was added. After stirring for 30 min., propionyl chloride (114 μl; 1.33 mmol) was 
added and the mixture was stirred at r.t. under nitrogen for 15 h. Finally, the reaction mixture was 
poured into 100 ml of iced water and extracted with CH2Cl2. The organic layer was dried with 
anhydrous Na2SO4 and evaporated to dryness. The crude product was washed with n-hexane and 
diethyl ether to obtain an orange solid. Yield: 80%. Mp 173.1-175.2 °C (dec). 
1
H NMR (CDCl3) δ: 
8.42 (d, 2H, J= 7.97 Hz); 8.22 (d, 2H, J= 4.68 Hz); 7.85 (d, 1H, J= 9.08 Hz); 7.63 (dd, 2H, J= 1.1, 
5.78); 7.60-7.47 (m, 2H); 6.75 (d, 1H, J= 9.08 Hz); 6.62 (dd, 1H, J= 4.68 Hz); 3.90-3.86 (m, 4H); 
3.74-3.71 (m, 4H); 2.75-2.67 (m, 2H); 1.35 (t, 3H, J= 7.7 Hz). HRMS (ESI) m/z Calcd for 
C28H24ClN5O2 [M+H]
+
: 498.16968; found: 498.16891. 
The product was converted into the corresponding dihydrochloride salt (light green solid) with 1 N 
HCl in ethanol. Mp 199.0-205.0 °C (dec). 
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2-Chloro-6-methoxy-7H-indeno[2,1-c]quinolin-7-one (86) 
 
 
 
To a suspension of compound 81 (500 mg; 1.70 mmol), in 50 ml of a mixture of anhydrous 
THF/MeOH (2:1), sodium methoxide (897 mg; 6.00 mmol) was added and the mixture was 
refluxed under nitrogen for 5 h. The solvent was evaporated and the crude residue was diluted with 
250 ml of CH2Cl2 and washed first with water and then with brine. The organic layer was dried with 
anhydrous Na2SO4 and evaporated to dryness. The crude product was rinsed with diethyl ether to 
obtain a yellow solid. Yield: 87%. Mp 222.2-223.1 °C (dec). 
1
H NMR (CDCl3) δ: 8.30 (d, 1H, J= 
1.93 Hz); 8.00 (d, 1H, J= 6.88 Hz); 7.81 (d, 1H, J= 9.07 Hz); 7.75 (d, 1H, J= 1.93 Hz); 7.73-7.57 
(m, 2H); 7.50-7.46 (m, 1H); 4.20 (s, 3H).  
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2-(2-Chloro-6-methoxy-7H-indeno[2,1-c]quinolin-7-ylidene)hydrazine-1-carboximidamide 
hydrochloride (26) 
 
 
 
Aminoguanidine hydrochloride (48 mg; 0.44 mmol) was added to a suspension of compound 86 
(130 mg; 0.44 mmol) in 20 ml of ethanol. After the addition of a catalytic amount of acetic acid, the 
mixture was refluxed for 24 h and then the solvent was evaporated to dryness. The crude residue 
was digested with hot ethanol and then rinsed with ethyl acetate to obtain an orange solid. Yield: 
37%. Mp 236.0-237.0 °C. 
1
H NMR (DMSO-d6) δ: 11.61 (br s, 1H, collapsed with D2O); 8.66-8.38 
(m, 3H, 1H collapsed with D2O); 7.89-7.64 (m, 7H, 2H collapsed with D2O); 4.15 (s, 3H). HRMS 
(ESI) m/z Calcd for C18H15ClN5O [M+H]
+
: 352.09651; found: 352.09595. 
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N-(2-Chloro-6-methoxy-7H-indeno[2,1-c]quinolin-7-ylidene)-4-methylpiperazin-1-amine 
hydrochloride (27) 
 
 
 
Compound 86 (180 mg; 0.61 mmol) was added to a solution of 1-amino-4-methylpiperazine (110 
μl; 0.91 mmol) and 1 N HCl (0.9 ml) in 20 ml of ethanol. The mixture was refluxed for 20 h and 
then the solvent was evaporated to dryness. The crude residue was digested and rinsed with ethyl 
acetate to generate an orange solid. Yield: 88%. Mp 201.7-203.5 °C (dec). 
1
H NMR (DMSO-d6) δ: 
11.02 (br s, 1H, collapsed with D2O); 8.60 (s, 1H); 8.50 (d, 1H, J= 7.70 Hz); 8.29 (d, 1H, J= 7.70 
Hz); 7.87 (d, 1H, J= 9.08 Hz); 7.77 (d, 1H, J= 9.08 Hz); 7.67-7.63 (m, 2H); 4.09 (s, 3H); 3.51-3.43 
(m, 8H); 2.85 (s, 3H). HRMS (ESI) m/z Calcd for C22H21ClN4O [M+H]
+
: 393.14821; found: 
393.14755. 
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4.4 Riminophenazines 
 
N-(4-Fluorophenyl)-2-nitroaniline (88) 
 
 
 
A mixture of 1-fluoro-2-nitrobenzene (3.0 ml, 28.35 mmol), 4-fluoroaniline (3.7 ml, 38.84 mmol) 
and 3.4 ml of pyridine was stirred under nitrogen at 120 °C for 6 h. After cooling, the mixture was 
diluted with water, alkalized with 6 N NaOH and extracted with CH2Cl2. The organic layer was 
dried with anhydrous Na2SO4 and evaporated to dryness to obtain a residue that was purified by CC 
(silica gel; cyclohexane/AcOEt in gradient); the product eluted with 6% of ethyl acetate. The 
fraction containing the desired product was rinsed with petroleum ether to collect an orange solid. 
Yield: 65%. Mp 81.5-82.6 °C. 
1
H NMR (CDCl3) δ: 9.40 (br s, 1H, collapsed with D2O); 8.22-8.19 
(dd, 1H, J= 1.46, 9.08 Hz); 7.38-7.33 (m, 1H); 7.27-7.23 (m, 2H); 7.15-7.03 (m, 3H); 6.79-6.74 (t, 
1H, J= 7.62 Hz). 
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3-Chloro-4-fluoro-N-(2-nitrophenyl)aniline (89) 
 
 
 
A mixture of 1-fluoro-2-nitrobenzene (3.0 ml, 28.35 mmol), 3-chloro-4-fluoroaniline (5.7 g, 38.84 
mmol) and 3.4 ml of pyridine was stirred under nitorgen at 120 °C for 6 h. After cooling, the 
mixture was diluted with water, alkalized with 6 N NaOH and extracted with CH2Cl2. The organic 
layer was dried with anhydrous Na2SO4 and evaporated to dryness to obtain a residue that was 
purified by CC (silica gel; cyclohexane/AcOEt in gradient); the product eluted with 6% of ethyl 
acetate. The fraction containing the desired product was rinsed with petroleum ether to collect an 
orange solid. Mp 114.0-115.1 °C. Another fraction containing the desired product mixed with an 
impurity was purified by a further CC (silica gel; cyclohexane/AcOEt in gradient), using the Flash 
Chromatography Purification System Biotage SP-1; the product eluted with 7% of ethyl acetate. 
The obtained product was rinsed with petroleum ether to collect an orange solid. Mp 114.2-115.3 
°C. Total yield: 47%. 
1
H NMR (CDCl3) δ: 9.34 (s, 1H); 8.21 (dd, 1H; J= 1.65, 8.80 Hz); 7.43-7.34 
(m, 2H); 7.19-7.08 (m, 2H); 6.85-6.80 (m, 2H). 
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N-(4-Chlorophenyl)-2-nitroaniline (90) 
 
 
 
A mixture of 1-fluoro-2-nitrobenzene (2.5 ml, 20.00 mmol), 4-chloroaniline (3.5 g, 27.00 mmol) 
and 3.0 ml of pyridine was stirred under nitorgen at 120 °C for 8 h. After cooling, the mixture was 
diluted with water, alkalized with 6 N NaOH and extracted with CH2Cl2. The organic layer was 
dried with anhydrous Na2SO4 and evaporated to dryness to obtain a residue that was purified by CC 
(silica gel; cyclohexane/AcOEt in gradient); the product eluted with 6% of ethyl acetate. The 
fraction containing the desired product was rinsed with diethyl ether to collect an orange solid. 
Yield: 42%. Mp 143.0-145.3 °C. 
1
H-NMR (CDCl3) δ: 9.40 (s, 1H); 8.21 (dd, 1H, J= 1.38, 8.53 Hz); 
7.43-7.37 (m, 3H); 7.25-7.19 (m, 3H); 6.83-6.80 (m, 1H). 
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2-Nitro-N-(p-tolyl)aniline (91) 
 
 
 
A mixture of 1-fluoro-2-nitrobenzene (0.7 ml, 7.08 mmol), 4-chloroaniline (1.0 g, 9.70 mmol) and 
1.0 ml of pyridine was stirred under nitorgen at 120 °C for 6 h. After cooling, the mixture was 
diluted with water, alkalized with 6 N NaOH and extracted with CH2Cl2. The organic layer was 
dried with anhydrous Na2SO4 and evaporated to dryness to obtain a residue that was purified by CC 
(silica gel; cyclohexane/AcOEt in gradient), using the Flash Chromatography Purification System 
Biotage SP-1; the product eluted with 5% of ethyl acetate. The fraction containing the desired 
product was rinsed with ethanol to collect an orange solid. Yield: 81%. Mp 66.2-67.0 °C. 
1
H-NMR 
(CDCl3) δ: 9.45 (br s, 1H, collapsed with D2O); 8.20 (dd, 1H, J= 1.43 Hz); 7.36 (t, 1H, J= 8.80 Hz); 
7.27-7.12 (m, 5H); 6.77 (t, 1H, J= 8.80 Hz); 2.38 (s, 3H). 
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N
1
-(4-Fluorophenyl)benzene-1,2-diamine (93) 
 
 
 
SnCl2*2H2O (7.8 g, 8.60 mmol) was added portionwise to a solution of compound 88 (2 g, 8.60 
mmol) in 34 ml of EtOH/AcOEt (1:1). The mixture was refluxed for 6 h and then the solvent was 
evaporated. The obtained residue was diluted with water and alkalized with 6 N NaOH. The formed 
precipitate was filtered and washed with ethyl acetate and then the filtrate was separated and the 
aqueous layer extracted with ethyl acetate. The collected organic layer was dried with anhydrous 
Na2SO4 and evaporated to dryness to obtain an oily residue which crystallized with diethyl 
ether/petroleum ether (7:3). A pale pink solid was obtained. Yield: 86%. Mp 63.3-64.1 °C. H NMR 
(CDCl3) δ: 7.42-7.38 (m, 4H); 6.70-6.68 (m, 4H); 5.10 (s, 1H, collapsed with D2O); 3.74 (s, 2H, 
collapsed with D2O). 
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N
1
-(3-Chloro-4-fluorophenyl)benzene-1,2-diamine (94) 
 
 
 
SnCl2*2H2O (3.4 g, 15.00 mmol) was added portionwise to a solution of compound 89 (1 g, 3.75 
mmol) in 14 ml of EtOH/AcOEt (1:1). The mixture was refluxed for 8 h and then the solvent was 
evaporated. The obtained residue was diluted with water and alkalized with 6 N NaOH. The formed 
precipitate was filtered and washed with ethyl acetate and then the filtrate was separated and the 
aqueous layer extracted with ethyl acetate. The collected organic layer was dried with anhydrous 
Na2SO4 and evaporated to dryness. The obtained residue was rinsed with petroleum ether/diethyl 
ether (9:1) to collect a cream-coloured solid. Yield: 86%. Mp 101.2-102.6 °C. 
1
H NMR (CDCl3) δ: 
7.07-6.94 (m, 3H); 6.82-6.70 (m, 3H); 6.58-6.53 (m, 1H); 5.12 (s, 1H, collapsed with D2O); 3.73 (br 
s, 2H, collapsed with D2O). 
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N
1
-(4-Chlorophenyl)benzene-1,2-diamine (95) 
 
 
 
Compound 90 (1.4 g, 5.6 mmoli), Pd/C 10% (280 mg, 2.63 mmol) and 35 ml of ethanol were 
charged into an hydrogenation flask and treated with H2 at atmospheric pressure for 6 h. Pd/C was 
filtered on a celite pad and the filtrate was evaporated to collect a brown solid, which was directly 
used in the next step without further purification. Yield: 87%. Mp 95.0-98.0 °C. 
1
H-NMR (CDCl3) 
δ: 7.05-6.93 (m, 4H); 6.84-6.78 (m, 2H); 6.67 (d, 2H, J= 8.25 Hz); 5.25 (s, 1H); 4.10 (s, 2H). 
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N
1
-(p-Tolyl)benzene-1,2-diamine (96) 
 
 
 
A mixture of compound 91 (700 mg, 3.00 mmol), metallic iron (837 mg, 15.00 mmol) and 10 ml of 
acetic acid was stirred at 70 °C for 45 minutes. After cooling, the solvent was evaporated and the 
residue was diluted with 2 N NaOH and CH2Cl2. The formed Fe(OH)2 was filtered and the filtrate 
was separated. The aqueous phase was extracted with CH2Cl2 and the organic layer was dried with 
anhydrous Na2SO4 and evaporated to dryness. The obtained residue was rinsed with petroleum ether 
to collect a brown solid. Yield: 76%. Mp 71.0-74.0 °C. 
1
H-NMR (CDCl3) δ: 7.11-7.02 (m, 4H); 
6.83-6.75 (m, 4H); 4.09 (br s, 2H, collapsed with D2O); 2.27 (s, 3H). 1H is not visible, probably for 
the interaction with the solvent.  
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N,5-bis(Substituted phenyl)-3-imino-3,5-dihydrophenazin-2-amines hydrochloride (75-101) 
 
 
 
General procedure: A solution of FeCl3*6H2O (9.25 mmol) in 13.4 ml of water and 0.33 ml of 
concentrated HCl was added to a solution of the proper N
1
-(substituted phenyl)benzene-1,2-diamine 
92-96 (3.34 mmol) and 7 ml of acetic acid. The mixture was stirred at r.t. for 4 h and then the 
obtained precipitate was filtered and washed with water and absolute ethanol. 
 
3-Imino-N,5-diphenyl-3,5-dihydrophenazin-2-amine hydrochloride (97) 
A dark brown solid was obtained. Yield: 93%. Mp 300.0-302.0 °C (dec.). 
1
H NMR in CDCl3 δ: 
9.91 (s, 1H, collapsed with D2O); 8.12 (d, 1H, J= 8.25 Hz); 7.81-7.67 (m, 3H); 7.64-7.42 (m, 5H); 
7.39-7.26 (m, 3H); 7.20-7.15 (m, 2H); 7.03 (d, 1H, J= 8.25 Hz); 6.34-6.27 (m, 2H).  
1H is not visible, probably for the interaction with the solvent. 
 
  
N,5-bis(4-Fluorophenyl)-3-imino-3,5-dihydrophenazin-2-amine hydrochloride (98) 
A dark violet solid was obtained. Yield: 90%. Mp 307.0-309.0 °C (dec.). 
1
H NMR (DMSO-d6) δ: 
9.70 (s, 1H, collapsed with D2O); 9.36 (s, 2H, collapsed with D2O); 8.24-8.14 (m, 1H); 7.82-7.60 
(m, 6H); 7.51-7.46 (m, 2H); 7.38-7.25 (m, 2H); 7.19 (s, 1H); 7.06-7.03 (m, 1H); 6.20 (s, 1H). 
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N,5-bis(3-Chloro-4-fluorophenyl)-3-imino-3,5-dihydrophenazin-2-amine hydrochloride (99) 
Solid rinsed with diethyl ether to collect a dark violet solid. Yield: 85%. Mp > 300 °C. 
1
H NMR 
(DMSO-d6) δ: 9.72 (s, 1H, collapsed with D2O); 9.33 (s, 2H, collapsed with D2O); 8.20-8.14 (m, 
2H); 8.03-8.00 (m, 1H); 7.97-7.63 (m, 3H); 7.58-7.49 (m, 3H); 7.32-7.18 (m, 2H); 6.24 (s, 1H). 
 
 
N,5-bis(4-Chlorophenyl)-3-imino-3,5-dihydrophenazin-2-amine hydrochloride (100) 
A dark brown solid was obtained. Yield: 86%. Mp >300 °C. 
1
H-NMR (DMSO-d6) δ: 9.24 (s, 1H); 
8.19 (m, 2H); 7.98 (d, 2H, J= 6.33 Hz); 7.84-7.82 (m, 1H); 7.79-7.73 (m, 4H); 7.59-7.49 (m, 2H); 
7.45 (d, 2H, J= 6.33 Hz); 7.37 (s, 1H); 7.16-7.14 (m, 1H); 6.20 (s, 1H). 
 
 
3-Imino-N,5-di-p-tolyl-3,5-dihydrophenazin-2-amine hydrochloride (101) 
The residue was purified by CC (silica gel; CH2Cl2/MeOH/ conc. NH3 in gradient); the product 
eluted with the 6% of MeOH. A dark brown solid was obtained. Yield: 70%. Mp >300 °C. 
1
H-NMR 
(DMSO-d6) δ: 9.42 (br s, 3H, collapsed with D2O); 8.05-8.03 (m, 1H); 7.64-7.55 (m, 6H); 7.36-7.29 
(m, 4H); 7.12 (s, 1H); 6.92-6.89 (m, 1H); 6.08 (s, 1H); 2.52 (s, 3H); 2.35 (s, 3H). 
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3-[ω-(Azacycloalkyl)alkyl]imino)-N,5-diphenyl-3,5-dihydrophenazin-2-amines (Series A: 28-
35) 
 
 
 
General procedure: Differently substituted phenazine hydrochloride (97-101; 1.6 mmol) and the 
proper amine (1.6 mmol) were dissolved in 7 ml of 1,4-dioxane and refluxed for 5 h. After cooling, 
the solvent was evaporated and the obtained mixture diluted with H2O and aqueous 6N NaOH and 
extracted several times with diethyl ether. The organic layer was dried with anhydrous Na2SO4 and 
evaporated to dryness. The crude product was purified by CC (CH2Cl2/MeOH/conc. NH3 in 
gradient) and the purified fraction was treated with the indicated solvent.  
 
3-[(Hexahydro-1H-pyrrolizin-7a-yl)methylimino]-N,5-diphenyl-3,5-dihydrophenazin-2-amine 
(28)  
Solid rinsed with petroleum ether to obtain brick-red crystals. Yield: 45%. Mp 160.0-162.0 °C 
(dec.). 
1
H NMR (CDCl3) δ: 7.75-7.63 (m, 4H); 7.54 (d, 2H, J= 7.70 Hz); 7.37-7.30 (m, 4H); 7.23-
7.02 (m, 4H); 6.51 (d, 1H, J= 7.70 Hz); 5.32 (s, 1H); 3.60 (s, 2H); 3.27 (s, 2H); 2.84-2.80 (m, 2H); 
2.07-1.91 (m, 5H); 1.79-1.73 (m, 3H). 1H is not visible, probably for the interaction with the 
solvent. HRMS (ESI) m/z calcd for C32H32N5 [M+H]
+
: 486.26577; found: 486.26483. The obtained 
solid was converted into the corresponding dihydrochloride salt with 1N HCl in ethanol. Mp 189.0-
191.5 °C (dec.). 
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N,5-bis(4-Chlorophenyl)-3-[(hexahydro-1H-pyrrolizin-7a-yl)methylimino]-3,5-
dihydrophenazin-2-amine (29) 
Solid rinsed with diethyl ether to give brick-red crystals. Yield: 11%. Mp 168.4-169.4 °C (dec.). 
1
H 
NMR (CDCl3) δ: 8.62 (br s, 1H, collapsed with D2O); 7.68 (d, 3H, J= 7.70 Hz); 7.32-7.20 (m, 6H); 
7.18-7.09 (m, 2H); 6.86 (s, 1H); 6.41 (d, 1H, J= 7.98 Hz); 5.28 (s, 1H); 3.20-3.09 (m, 4H); 2.69 (s, 
2H); 1.97-1.67 (m, 6H); 1.65-1.61 (m, 2H). HRMS (ESI) m/z calcd for C32H30N5Cl2 [M+H]
+
: 
554.18783; found: 554.18695. The obtained solid was converted into the corresponding 
dihydrochloride salt with 1N HCl in ethanol. Mp 199.0-202.0 °C (dec.). 
 
3-{[(1S,9aR)-(Octahydro-2H-quinolizin-1-yl)methyl]imino}-2-(4-tolylamino)-5-(4-tolyl)-3,5-
dihydrophenazine (30) 
Solid rinsed with petroleum ether to collect a dark red solid. Yield: 61%. Mp 173.0-175.0 °C. 
1
H-
NMR (CDCl3) δ: 7.75-7.63 (m, 1H); 7.50-7.45 (m, 2H); 7.42-7.32 (m, 8H); 6.83 (s, 1H); 6.47-6.45 
(m, 1H); 5.37 (s, 1H); 3.40-3.34 (m, 2H); 2.85-2.78 (m, 2H); 2.53 (s, 3H); 2.35 (s, 3H); 2.10-1.92 
(m, 4H); 1.87-1.65 (m, 3H); 1.54-1.36 (m, 7H). 1H is not visible, probably for the interaction with 
the solvent. HRMS (ESI) m/z calcd for C36H40N5 [M+H]
+
: 542.32837. Found: 542.32715. 
The product was converted into the corresponding dihydrocloride salt with 1N HCl in ethanol. Mp: 
235-237 °C (dec.). 
1
H-NMR (DMSO-d6)  δ: 10.59 (br s, 1H, collapsed with D2O); 10.48 (br s, 1H, collapsed with 
D2O); 9.75 (br s, 1H, collapsed with D2O); 8.17 (d, 1H, J= 7.43 Hz); 7.78-7.60 (m, 6H); 7.39-7.20 
(m, 5H); 7.02 (d, 1H, J= 7.43 Hz); 5.81 (s, 1H); 3.93-3.91 (m, 1H); 3.24-3.07 (m, 7H); 2.58 (s, 3H); 
2.35 (s, 3H); 1.95-1.79 (m, 4H); 1.53-1.38 (m, 5H); 0.86-0.84 (m, 1H). 
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 3-[4-(Octahydro-1H-quinolizin-9a-yl)butylimino]-N,5-diphenyl-3,5-dihydrophenazin-2-amine 
(31) 
Solid rinsed with a mixture of diethyl ether/petroleum ether (1:1) to give dark red crystals. Yield: 
37%. Mp 157.9-158.7 °C. 
1
H NMR (CDCl3) δ: 7.75-7.63 (m, 4H); 7.37-7.33 (m, 6H); 7.18-7.09 (m, 
3H); 6.93 (s, 1H); 6.50-6.47 (m, 1H); 5.27 (s, 1H); 3.16-3.11 (m, 2H); 2.59-2.54 (m, 2H); 2.43-2.40 
(m, 2H); 1.67-1.14 (m, 18H). 1H is not visible, probably for the interaction with the solvent. HRMS 
(ESI) m/z Calcd for C37H42N5 [M+H]
+
: 556.34402; found: 556.34283. 
The product was converted into the corresponding dihydrochloride salt with 1N HCl in ethanol. Mp 
260-261 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.28 (br s, 1H, collapsed with D2O); 10.15-10.07 (m, 
2H, collapsed with D2O); 8.18 (d, 1H, J= 8.25 Hz); 7.92-7.84 (m, 3H); 7.82-7.72 (m, 4H); 7.54-
7.45 (m, 4H); 7.31 (s, 1H); 7.28-7.23 (m, 1H); 7.05 (d, 1H, J= 8.25 Hz); 5.73 (s, 1H); 3.20-3.07 (m, 
4H); 2.92-2.89 (m, 2H); 1.88-1.13 (m, 18H). 
 
3-[6-(Octahydro-1H-quinolizin-9a-yl)hexylimino]-N,5-diphenyl-3,5-dihydrophenazin-2-amine 
(32) 
Solid rinsed with petroleum ether and few drops of diethyl ether to give dark red crystals. Yield: 
52%. Mp 129.2-130.6 °C. 
1
H NMR (CDCl3) δ: 7.75-7.70 (m, 4H); 7.66-7.33 (m, 6H); 7.19-7.06 (m, 
3H); 6.92 (s, 1H); 6.48 (d, 1H, J= 7.98 Hz); 5.28 (s, 1H); 3.15-3.11 (m, 2H); 2.64-2.60 (m, 2H); 
2.57-2.44 (m, 2H); 1.61-1.11 (m, 22H). 1H is not visible, probably for the interaction with the 
solvent. HRMS (ESI) m/z Calcd for C39H46N5 [M+H]
+
: 584.37532; found: 584.37421. 
The product was converted into the corresponding dihydrochloride salt with 1N HCl in ethanol. Mp 
207.3-209.0 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.26-10.03 (m, 3H, collapsed with D2O); 8.19 (d, 
1H, J= 8.53 Hz); 7.90-7.84 (m, 3H); 7.75-7.73 (m, 4H); 7.54-7.45 (m, 4H); 7.31-7.25 (m, 2H); 7.05 
(d, 1H, J= 8.53 Hz); 5.72 (s, 1H); 4.98-3.08 (m, 4H); 2.90-2.72 (m, 2H); 1.90-1.10 (m, 22H). 
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N,5-bis(4-Fluorophenyl)-3-[4-(octahydro-1H-quinolizin-9a-yl)butylimino]-3,5-
dihydrophenazin-2-amine (33) 
Solid recrystallized with a mixture of diethyl ether/petroleum ether (1:1) and rinsed with diethyl 
ether to give dark brown crystals. Yield: 35%. Mp 135.3-137.0 °C. 
1
H NMR (CDCl3) δ: 7.70 (m, 
1H); 7.42-7.05 (m, 8H); 6.75 (s, 1H); 6.48 (m, 1H); 5.26 (s, 1H); 3.16 (m, 2H); 2.68-2.47 (m, 4H); 
1.61-1.19 (m, 18H). 1H is not visible, probably for the interaction with the solvent. HRMS (ESI) 
m/z Calcd for C37H40N5F2 [M+H]
+
: 592.32518; found: 592.32410. 
The product was converted into the corresponding dihydrochloride salt with 1N HCl in ethanol. Mp 
214-215 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.23-10.05 (m, 3H, collapsed with D2O); 8.19 (m, 1H); 
7.75-7.10 (m, 12H); 5.76 (s, 1H); 3.27-2.94 (m, 6H); 1.72-1.22 (m, 18H). 
 
N,5-bis(4-Fluorophenyl)-3-[6-(octahydro-1H-quinolizin-9a-yl)hexylimino]-3,5-
dihydrophenazin-2-amine (34) 
Solid rinsed with a mixture of diethyl ether/petroleum ether (1:1) to give dark red crystals. Yield: 
23%. Mp 128.5-130.0 °C. 
1
H NMR (CDCl3) δ: 7.69 (m, 1H); 7.46-6.91 (m, 10H); 6.73 (s, 1H); 6.48 
(m, 1H); 5.26 (s, 1H); 3.44-3.13 (m, 2H); 2.63-2.46 (m, 4H); 1.62-1.12 (m, 22H). 1H is not visible, 
probably for the interaction with the solvent. HRMS (ESI) m/z Calcd for C39H44N5F2 [M+H]
+
: 
620.35648; found: 620.35535. 
The product was converted into the corresponding dihydrochloride salt with 1N HCl in ethanol. Mp 
213-214 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.18 (br s, 1H, collapsed with D2O); 9.96 (m, 2H, 
collapsed with D2O); 8.18 (d, 1H, J= 7.70 Hz); 7.82-7.74 (m, 6H); 7.50-7.45 (m, 2H); 7.39-7.33 (m, 
2H); 7.19 (s, 1H); 7.10 (d, 1H, J= 7.70 Hz); 5.72 (s, 1H); 3.41-3.14 (m, 4H); 3.10-2.94 (m, 2H); 
1.79-1.01 (m, 22H). 
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N,5-bis(3-Chloro-4-fluorophenyl)-3-[6-(octahydro-1H-quinolizin-9a-yl)hexylimino]-3,5-
dihydrophenazin-2-amine (35) 
Solid rinsed with diethyl ether to give brick-red crystals. Yield: 25%. Mp 108.2-109.4 °C (dec.). 
1
H 
NMR (DMSO-d6) δ: 8.76 (br s, 1H, collapsed with D2O); 7.99-7.88 (m, 1H); 7.85-7.82 (m, 1H); 
7.63-7.59 (m, 3H); 7.45-7.42 (m, 2H); 7.22 (m, 2H); 6.61 (s, 1H); 6.53 (m, 1H); 5.18 (s, 1H); 3.50-
3.32 (m, 2H); 2.18-2.72 (m, 2H); 2.32 (m, 2H); 1.50-1.05 (m, 22H). HRMS (ESI) m/z Calcd for 
C39H42N5Cl2F2 [M+H]
+
: 688.27853; found: 688.27771. 
The product was converted into the corresponding dihydrochloride salt with 1N HCl in ethanol. Mp 
245-247 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.23-9.97 (m, 3H, collapsed with D2O); 8.21-8.01 (m, 
2H); 7.97 (d, 1H, J= 8.80 Hz); 7.84-7.75 (m, 3H); 7.64-7.48 (m, 3H); 7.31-7.21 (m, 1H); 7.19 (d, 
1H, J= 8.80 Hz); 5.77 (s, 1H); 3.58-3.42 (m, 4H); 3.38-2.94 (m, 4H); 1.84-1.02 (m, 20H). 
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5-Methyl-9a-{4-[10-phenyl-3-(phenylamino)phenazin-2(10H)-ylideneamino]butyl}-
decahydroquinolizinium iodide (36) 
 
 
 
Iodomethane (4 µl, 0.05 mmol) was added to a solution of compound 31 (30 mg, 0.05 mmol) in 1.5 
ml of anhydrous THF and the mixture was stirred at r.t. for 72 h. The obtained precipitate was 
filtered and washed with a mixture of THF/diethyl ether (1:1) to provide a dark red solid. Yield: 
65%. Mp 191.0-192.5 °C. 
1
H NMR (CDCl3) δ: 7.77-7.69 (m, 4H); 7.36-7.25 (m, 4H); 7.11-6.99 (m, 
6H); 6.56-6.40 (m, 1H); 5.30 (s, 1H); 4.02-3.47 (m, 4H); 3.27 (s, 3H); 3.15-3.07 (m, 2H); 2.10-1.20 
(m, 18H). 1H is not visible, probably for the interaction with the solvent. HRMS (ESI) m/z Calcd 
for C38H44N5 [M+H]
+
: 570.35967; found: 570.35858. 
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N
1
-(5-Fluoro-2,4-dinitrophenyl)-N
2
-(4-substitutedphenyl)benzene-1,2-diamines (102, 103) 
 
 
 
General procedure: 1,5-Difluoro-2,4-dinitrobenzene (10.86 mmol) and TEA (10.94 mmol) were 
added to a solution of the proper N
1
-((4-substituted)phenyl)benzene-1,2-diamine (10.86 mmol) in 
40 ml of ethanol. The mixture was stirred at r.t. for 1.5 h. The formed suspension was filtered and 
the resulting solid washed with ethanol.  
 
N
1
-(5-Fluoro-2,4-dinitrophenyl)-N
2
-phenylbenzene-1,2-diamine (102) 
Yield: 93%. Mp 163.6-164.7 °C. 
1
H-NMR (CDCl3) δ: 9.60 (br s, 1H, collapsed with D2O); 9.13 (d, 
1H, J= 7.70 Hz); 7.36-7.24 (m, 5H); 7.07-6.99 (m, 4H); 6.65 (d, 1H, J= 13.20 Hz); 5.65 (br s, 1H, 
collapsed with D2O).  
 
N
1
-(4-Chlorophenyl)-N
2
-(5-fluoro-2,4-dinitrophenyl)benzene-1,2-diamine (103) 
Yield: 94%. Mp 211.7-214.0 °C. 
1
H NMR (CDCl3) δ: 9.6 (br s, 1 H, collapsed with D2O); 9.14 (d, 1 
H, J= 7.70 Hz); 7.36-7.21 (m, 5 H); 7.10-7.04 (m, 1 H); 6.97-6.93 (m, 2 H); 6.67-6.63 (m, 1 H); 
5.63 (br s, 1 H, collapsed with D2O).  
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N
1
-(Substituted phenyl)-N
2
-[2,4-dinitro-5-(substituted pyridin-3-ylamino)phenyl]benzene-1,2-
diamines (104-106) 
 
 
 
General procedure: Pyridine-3-amine (5.38 mmol) and TEA (4.89 mmol) were added to a solution 
of the proper N
1
-(5-fluoro-2,4-dinitrophenyl)-N
2
-((4-substitutedphenyl)benzene)-1,2-diamine 102, 
103 (4.89 mmol) in 18 ml of THF and the mixture was refluxed for 20 h. The formed precipitate 
was filtered and washed with THF and CH2Cl2.  
 
N
1
-[2,4-Dinitro-5-(pyridin-3-ylamino)phenyl]-N
2
-phenylbenzene-1,2-diamine (104) 
Yield: 88%. Mp 213.4-215.2 °C. 
1
H-NMR (DMSO-d6) δ: 9.70 (br s, 1H, collapsed with D2O); 9.48 
(br s, 1H, collapsed with D2O); 8.99 (s, 1H); 8.40-8.37 (m, 2H); 7.62-7.60 (m, 2H); 7.36-7.32 (m, 
1H); 7.20-7.10 (m, 5H); 6.85-6.82 (m, 4H); 5.96 (s, 1H). 
 
N
1
-(4-Chlorophenyl)-N
2
-[2,4-dinitro-5-(pyridin-3-ylamino)phenyl]benzene-1,2-diamine (105) 
Yield: 94%. Mp 211.7-214.0 °C. 
1
H NMR (CDCl3) δ: 9.72 (s, 1H, collapsed with D2O); 9.49 (s, 1H, 
collapsed with D2O); 9.01 (s, 1H); 8.41 (m, 2 H); 7.77 (s, 1H, collapsed with D2O); 7.61 (m, 1H); 
7.38-7.15 (m, 6H); 6.90-6.80 (m, 3 H); 5.94 (s, 1H).  
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N
1
-[5-(6-Methoxypyridin-3-ylamino)-2,4-dinitrophenyl]-N
2
-phenylbenzene-1,2-diamine (106)  
Yield: 85%. Mp 189.9-191.3 °C. 
1
H-NMR (DMSO-d6) δ: 9.59 (s, 1 H, collapsed with D2O); 9.43 (s, 
1 H, collapsed with D2O); 8.98 (s, 1 H); 7.95 (d, 1H, J= 2.47 Hz); 7.61 (s, 1H); 7.51 (dd; 1H, J= 
2.47; 8.80 Hz); 7.20-7.10 (m, 5H); 6.85-6.76 (m, 5H); 5.77 (s, 1H); 3.34 (s, 3H). 
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3-Imino-N-(substituted pyridin-3-yl)-5-(substituted phenyl)-3,5-dihydrophenazin-2-amines 
(107-109) 
 
 
 
General procedure: Zinc powder (36.16 mmol) was added portion wise into a suspension of the 
proper N
1
-(substituted phenyl)-N
2
-[2,4-dinitro-5-(substituted pyridin-3-ylamino)phenyl]benzene-
1,2-diamine 104-106 (1.81 mmol) in 10 ml of glacial acetic acid cooled with an ice-water bath. The 
mixture was stirred at r.t. until the color turned to light green and then filtered and washed with 
glacial acetic acid and methanol. The filtrate was concentrated and the residue was treated with 
water and alkalized with conc. NH3. The formed precipitate was filtered, washed with water and 
then dissolved in methanol. The solution was stirred under air overnight. The formed solid was 
filtered and washed with methanol and diethyl ether. The crude product was directly used for the 
next step. 
 
3-Imino-5-phenyl-N-(pyridin-3-yl)-3,5-dihydrophenazin-2-amine (107) 
Yield: 84%. Mp 206.3-209.5 °C (dec.). 
1
H NMR (DMSO-d6) δ: 9.90 (br s, 2H, collapsed with 
D2O); 8.55 (s, 1H); 8.28 (d, 1H, J= 2.80 Hz); 7.80-7.63 (m, 5H); 7.57 (d, 2H, J= 7.15 Hz); 7.42-
7.38 (m, 1H); 7.25-7.18 (m, 2H); 6.65 (s, 1H); 6.42 (d, 1H, J= 8.80 Hz); 5.42 (s, 1H). 
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5-(4-Chlorophenyl)-3-imino-N-(pyridin-3-yl)-3,5-dihydrophenazin-2-amine (108) 
Yield: 42%. Mp 190.0-194.0 °C. 
1
H NMR (DMSO-d6) δ: 9.91 (br s, 2H, collapsed with D2O); 8.54 
(s, 1H); 2.28 (d, 1H, J= 2.80 Hz); 7.89-7.78 (m, 3H); 7.62-7.58 (m, 3H); 7.41-7.39 (m, 1H); 7.22-
7.20 (m, 2H); 6.64 (s, 1H); 6.51-6.43 (m, 1H); 5.42 (s, 1H).  
 
3-Imino-N-(6-methoxypyridin-3-yl)-5-phenyl-3,5-dihydrophenazin-2-amine (109) 
Yield: 49%. Mp 191.2-193.0 °C. 
1
H NMR (DMSO-d6) δ: 9.12 (br s, 2H, collapsed with D2O); 8.15 
(d, 1H, J= 2.75 Hz); 7.79-7.66 (m, 4H); 7.59-7.56 (m, 1H); 7.47 (d, 2H, J= 7.15 Hz); 7.18-7.15 (m, 
2H); 6.89 (d, 1H, J= 8.53 Hz); 6.39-6.37 (m, 1H); 6.36 (s, 1H); 5.31 (s, 1H); 3.86 (s, 3H). 
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N-(Substituted pyridin-3-yl)-3-(aminoalkyl)-5-substituted phenyl-3,5-dihydrophenazin-2-
amines (series B: 37-40) 
 
 
 
General procedure: The proper phenazine 107-109 (0.56 mmol) and the 4-(octahydro-1H-
quinolizin-9a-yl)butan-1-amine or N’,N’-dimethylpropane-1,3-diamine (1.12 mmol) were dissolved 
in 5 ml of 1,4-dioxane and refluxed for 24 h (compounds 37 and 38) or 4 h (compounds 39 and 40). 
After cooling, the solvent was evaporated and the obtained mixture diluted with CH2Cl2 and washed 
three times with water. The organic layer was dried with anhydrous Na2SO4 and evaporated to 
dryness. The crude product was purified as indicated.  
 
3-{[4-(Octahydro-1H-quinolizin-9a-yl)butyl]imino}-5-phenyl-N-(pyridin-3-yl)-3,5-
dihydrophenazin-2-amine dihydrochloride (37) 
The amorphous residue was digested with diethyl ether. The filtrate was evaporated and washed 
with a mixture of petroleum ether/diethyl ether (1:1). The solid was converted into the 
corresponding dihydrochloride salt with 1N HCl in ethanol. Yield: 38%. Mp 218.0-219.8 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.75 (s, 1H, collapsed with D2O); 10.22 (s, 1H, collapsed with D2O); 
10.05 (s, 1H, collapsed with D2O); 8.52 (d, 1H, J= 5.28 Hz); 8.35-8.26 (m, 2H); 7.93-7.67 (m, 9H); 
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7.12-7.10 (m, 1H); 5.76 (s, 1H); 3.19-3.06 (m, 4H); 2.91-2.88 (m, 2H); 1.89-1.56 (m, 14H); 1.22-
1.18 (m, 4H). HRMS (ESI) m/z Calcd for C36H41N6 [M+H]
+
: 557.33927; found: 557.33838. 
 
N-(6-Methoxypyridin-3-yl)-3-{[4-(octahydro-1H-quinolizin-9a-yl)butyl]imino}-5-phenyl-3,5-
dihydrophenazin-2-amine dihydrochloride (38) 
The amorphous residue was purified by CC (neutral alumina, grade IV; CH2Cl2/MeOH in gradient). 
The obtained solid was converted into the corresponding dihydrochloride salt with 1N HCl in 
ethanol. Yield: 24%. Mp 217.6-219.0 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.28-10.22 (m, 3H, 
collapsed with D2O); 8.24-8.18 (m, 2H); 7.92-7.71 (m, 6H); 7.21-6.92 (m, 5H); 5.72 (s, 1H); 3.91 
(s, 3H); 3.19-2.88 (m, 6H); 1.89-1.55 (m, 14H); 1.34-1.22 (m, 4H). HRMS (ESI) m/z Calcd for 
C37H43N6O [M+H]
+
: 587.34984; found: 587.34906. 
 
5-(4-Chlorophenyl)-3-{[4-(octahydro-1H-quinolizin-9a-yl)butyl]imino}-N-(pyridin-3-yl)-3,5-
dihydrophenazin-2-amine trihydrochloride (39) 
The amorphous residue was purified by CC (silica gel; CH2Cl2/MeOH in gradient). The obtained 
solid was converted into the corresponding trihydrochloride salt with 1N HCl in ethanol. Yield: 
86%. Mp 228.0-231.0 °C (dec.). 
1
H NMR (DMSO-d6) δ: 10.74 (s, 1H, collapsed with D2O); 10.22-
10.13 (m, 2H, collapsed with D2O); 8.83 (s, 1H); 8.53-8.51 (m, 1H); 8.27-8.24 (m, 2H); 8.05-7.97 
(m, 3H); 7.85-7.77 (m, 4H); 7.69 (s, 1H); 7.14-7.11 (m, 1H); 5.79-5.77 (m, 1H); 3.44-3.39 (m, 2H); 
3.28-3.07 (m, 2H); 2.91-2.87 (m, 2H); 1.91-1.01 (m, 18H). 1H is not visible, probably for the 
interaction with the solvent. HRMS (ESI) m/z Calcd for C36H40N6Cl [M+H]
+
: 591.30030; found: 
591.29919. 
 
 
 
  Experimental section 
134 
 
N
1
-[10-(4-Chlorophenyl)-3-(pyridin-3-ylamino)phenazin-2(10H)-ylidene]-N
3
,N
3
-
dimethylpropane-1,3-diamine (40) 
The amorphous residue was purified by CC (silica gel; CH2Cl2/MeOH in gradient). The obtained 
dark red oil was crystallized with a mixture of petroleum ether/diethyl ether (95:5) to give a dark 
red solid. Yield: 45%. Mp 115.5-117.5 °C. 
1
H NMR (DMSO-d6) δ: 8.60-8.58 (m, 1H); 8.35-8.33 
(m, 1H); 7.80-7.60 (m, 4H); 7.32-7.28 (m, 3H); 7.23-7.15 (m, 2H); 6.86 (s, 1H); 6.49-6.46 (m, 1H); 
5.29 (s, 1H); 3.20 (t, 2H, J= 6.83 Hz); 2.36 (t, 2H, J= 6.83 Hz); 2.22 (s, 6H); 1.82 (q, 2H, J= 7.15 
Hz). 1H is not visible, probably for the interaction with the solvent. HRMS (ESI) m/z Calcd for 
C28H28N6Cl [M+H]
+
: 483.20640; found: 483.20581. 
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4.5 Aphidicolin derivatives 
 
3-(2-Chloroacetamido)benzoic acid (110) 
 
 
COOHN
H
O
Cl
 
 
 
Chloroacetyl chloride (0.58 ml, 7.29 mmol) was added dropwise to a solution of 3-aminobenzoic 
acid (1 g, 7.29 mmol) in 5 ml of anhydrous DMF. The mixture was stirred under nitrogen at r.t. for 
20 h and then poured into 50 ml of iced water. The obtained white precipitate was filtered and 
washed twice with water and twice with petroleum ether. A white solid was obtained. Yield: 92%. 
Mp 225.5-226.6 °C. 
1
H NMR (DMSO-d6) δ: 10.48 (s, 1H, collapsed with D2O); 8.21 (s, 1H); 7.79 
(d, 1H, J= 7.15 Hz); 7.64 (d, 1H, J= 7.15 Hz); 7.43 (t, 1H, J= 7.15 Hz); 4.22 (s, 2H). 1H is not 
visible, probably for the interaction with the solvent.    
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3-(2-Chloroacetamido)benzoyl chloride (111) 
 
Cl
O
N
H
O
Cl
 
 
Compound 110 (300 mg, 1.40 mmol) was added to a solution of 1.5 ml of SOCl2 and 0.5 ml of 
anhydrous chloroform heated at 60 °C. The solution was stirred under nitrogen at 60 °C for 4.5 h 
and then diluted with 3 ml of petroleum ether. The obtained precipitate was filtered and washed 
with petroleum ether to obtain a cream-coloured solid. Yield: 75%. Mp 97.8-100.2 °C. 
1
H NMR 
(DMSO-d6) δ: 10.54 (s, 1H, collapsed with D2O); 8.21 (s, 1H); 7.80 (d, 1H, J= 7.15 Hz); 7.63 (d, 
1H, J= 7.15 Hz); 7.43 (t, 1H, J= 7.15 Hz); 4.24 (s, 2H).   
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(3,9-Dihydroxy-4-(hydroxymethyl)-4,11b-dimethyltetradecahydro-8,11a-
methanocyclohepta[a]naphthalen-9-yl)methyl 3-(2-chloroacetamido)benzoate (41) 
 
 
 
Compound 111 (58 mg, 0.25 mmol) was added dropwise to an ice-cooled solution of aphidicolin 
(65 mg, 0.19 mmol) in 1 ml of anhydrous pyridine. The mixture was stirred at r.t. for 2.5 h and then 
diluted with few drops of water, in order to quench the unreacted acyl chloride. Pyridine was 
evaporated and the obtained residue was diluted with water and ethyl acetate, acidified with 1 N 
HCl (pH= 1-2) and extracted with ethyl acetate. The organic layer was dried with anhydrous 
Na2SO4 and evaporated to dryness to obtain a residue that was purified by CC (silica gel; 
CH2Cl2/MeOH in gradient); the product eluted with 2% of MeOH. The fraction containing the 
desired product and a by-product was purified again by another CC in the same conditions. The 
fractions containing the purified product were gathered up, crystallized and rinsed with diethyl ether 
to provide a white solid. Yield: 21%. Mp 129.2-131.0 °C. 
1
H NMR (pyridine-d5) δ: 11.62 (s, 1H, 
collapsed with D2O); 8.79 (s, 1H); 8.46 (d, 1H, J= 7.15 Hz); 8.18 (d, 1H, J= 7.15 Hz); 7.57 (t, 1H, 
J= 7.15 Hz); 4.78-4.63 (m, 3H); 4.17 (s, 1H); 4.06-4.04 (m, 1H); 3.86-3.84 (m, 1H); 3.11-3.08 (m, 
2H); 2.77-2.52 (m, 2H); 2.48-2.17 (m, 2H); 2.07-1.80 (m, 6H); 1.63-1.30 (m, 7H); 1.21 (s, 3H); 
1.17-1.14 (m, 2H); 0.98 (s, 3H). 3H are not visible, probably for the interaction with the solvent.    
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4-((9-(((3-(2-Chloroacetamido)benzoyl)oxy)methyl)-3,9-dihydroxy-4,11b-
dimethyltetradecahydro-8,11a-methanocyclohepta[a]naphthalen-4-yl)methoxy)-4-
oxobutanoic acid (42) 
 
 
 
A solution of compound 41 (10 mg, 18.72 mmol), 0.3 ml of anhydrous pyridine and succinic 
anhydride (2 mg, 18.72 mmol) was stirred at r.t. for 20 h. The mixture was diluted with few drops 
of water and acidified with H2SO4 at 30% (pH= 2). After a first extraction with ethyl acetate to 
isolate unreacted 41, the aqueous layer was saturated with NaCl and extracted with CH2Cl2. The 
organic layer was dried with anhydrous Na2SO4 and evaporated to dryness to obtain a residue that 
was rinsed by settling with diethyl ether. An amorphous solid was obtained. Yield: 50%. 
1
H NMR 
(pyridine-d5) δ: 13.30 (s, 1H, collapsed with D2O); 9.56 (s, 1H, collapsed with D2O); 8.92 (s, 1H); 
8.22-8.18 (m, 1H); 7.82-7.80 (m, 1H); 7.65-7.63 (m, 1H); 4.38-4.23 (m, 2H); 3.75 (s, 1H); 3.63-
3.61 (m, 1H); 3.45-3.37 (m, 2H); 3.20-3.16 (m, 1H); 2.98 (s, 2H); 2.65-2.62 (m, 1H); 2.38-1.84 (m, 
4H); 1.79-1.37 (m, 6H); 1.28-0.86 (m, 8H); 0.81 (s, 3H); 0.71-0.69 (m, 2H); 0.58 (s, 3H). 2H are 
not visible, probably for the interaction with the solvent.   
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((3R,4R,4aR,6aS,9R,11bS)-3,9-Dihydroxy-4-(hydroxymethyl)-4,11b-dimethyltetradecahydro-
8,11a-methanocyclohepta[a]naphthalen-9-yl)methyl 4-methylbenzenesulfonate (112) 
 
 
 
Tosyl chloride (52 mg, 0.27 mmol) was added dropwise during 20 minutes to an ice-cooled solution 
of aphidicolin (60 mg, 0.18 mmol) in 2.2 ml of anhydrous pyridine. The mixture was stirred at 0 °C 
for 2 h and then left in the fridge for 18 h. After warming to r.t., 90 µl of water were added to 
quench the unreacted tosyl chloride and then the solvent was evaporated. The residue was diluted 
with water and extracted with ethyl acetate. The organic layer was dried with anhydrous Na2SO4 
and evaporated to dryness to obtain a residue that was purified by CC (silica gel; cyclohexane/ethyl 
acetate in gradient); the product eluted with 40% of ethyl acetate. The fraction containing the 
desired product was rinsed with diethyl ether to give a white solid. Yield: 56%. Mp 132.5-134.5 °C. 
1
H NMR (CDCl3) δ: 7.78 (d, 2H, J= 8.80 Hz); 7.36 (d, 2H, J= 8.80 Hz); 3.90 (d, 1H, J= 9.15 Hz); 
3.81 (d, 1H, J= 9.15 Hz); 3.68 (s, 1H); 3.49-3.33 (m, 2H); 2.48 (s, 3H); 2.42-2.38 (m, 1H); 2.15-
1.64 (m, 12H, 3H collapsed with D2O); 1.54-1.21 (m, 7H); 1.01-0.98 (m, 4H); 0.80-0.68 (m, 1H); 
0.68 (s, 3H). 
 
 
 
 
 
 
  Experimental section 
140 
 
2,5-Bis((tert-butoxycarbonyl)amino)-2-(difluoromethyl)pentanoic acid (113) 
 
 
 
Boc anhydride (1.25 g, 5.17mmol) was dissolved in 3.3 ml of methanol and added dropwise to a 
solution of eflornithine hydrochloride (250 mg, 1.14 mmol) in 22 ml of methanol. After the addition 
of DIPEA (2 ml, 11.43 mmol), the mixture was stirred at r.t. for 5 h. Further Boc anhydride (498 
mg, 2.28 mmol) was charged and the mixture stirred again at r.t. for 22 h. the solvent was 
evaporated and the residue diluted with 25 ml of water, acidified with acetic acid (pH= 4-5) and 
extracted with ethyl acetate. The organic layer was dried with anhydrous Na2SO4 and evaporated to 
dryness to obtain a residue that crystallized spontaneously in the fridge during the night. The solid 
was rinsed with petroleum ether to give white crystals. The filtrate was evaporated to obtain an oily 
residue that was purified by CC (silica gel; CH2Cl2/MeOH in gradient); the product eluted with 4% 
of MeOH. A white solid was obtained. Yield: 66%. Mp 144.3-146.2 °C. 
1
H NMR (DMSO-d6) δ: 
7.29 (br s, 1H, collapsed with D2O); 6.78 (br s, 1H, collapsed with D2O); 6.25 (t, 1H, J= 57.3 Hz); 
2.90-2.81 (m, 2H); 1.79-1.68 (m, 2H); 1.43-1.28 (m, 20H). 1H is not visible, probably for the 
interaction with the solvent.   
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((3R,4R,4aR,6aS,9R,11bS)-3,9-Dihydroxy-4-(hydroxymethyl)-4,11b-dimethyltetradecahydro-
8,11a-methanocyclohepta[a]naphthalen-9-yl)methyl 2,5-bis((tert-butoxycarbonyl)amino)-2-
(difluoromethyl)pentanoate (114) 
 
 
 
Compound 112 (32 mg, 0.07 mmol) was added to a solution of compound 113 (25 mg, 0.07 mmol) 
and DIPEA (50 µl, 0.29 mmol) in anhydrous THF. The mixture was refluxed for 18 h and then the 
solvent was evaporated. The residue was diluted with CH2Cl2 and washed with 0.1 N HCl, water 
and brine. The organic layer was dried with anhydrous Na2SO4 and evaporated to dryness to obtain 
a residue that was purified by CC (silica gel; CH2Cl2/MeOH in gradient); the product eluted with 
1% of MeOH. A yellow amorphous solid was obtained. Yield: 43%. 
1
H NMR (CDCl3) δ: 5.88 (t, 
1H, J= 57.3 Hz); 4.85 (br s, 1H, collapsed with D2O); 4.18-4.05 (m, 2H); 3.66 (s, 1H); 3.47 (d, 1H, 
J= 9.15 Hz); 3.37 (d, 1H, J= 9.15 Hz); 3.18 (s, 1H, collapsed with D2O); 3.12-3.08 (m, 2H); 2.43-
2.38 (m, 2H, 1H collapsed with D2O); 2.13-1.64 (m, 16H); 1.55-1.20 (m, 20H); 0.98-0.88 (m, 7H); 
0.69 (s, 3H). 2H are not visible, probably for the interaction with the solvent.   
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((3R,4R,4aR,6aS,9R,11bS)-3,9-Dihydroxy-4-(hydroxymethyl)-4,11b-dimethyltetradecahydro-
8,11a-methanocyclohepta[a]naphthalen-9-yl)methyl 2,5-diamino-2-
(difluoromethyl)pentanoate (43) 
 
 
 
A solution of compound 114 (25 mg, 0.04 mmol) and TFA (27 µl, 0.36 mmol) in 0.5 ml of CH2Cl2 
was stirred at r.t. for 2 h. Further TFA (27 µl, 0.36mmol) was added and after 1 h another addition 
was made (50 µl, 0.65 mmol). The mixture was stirred for further 20 h at r.t. The solvent was 
evaporated and the residue diluted with ethanol. The obtained white precipitate was filtered and the 
filtrate, which contained the desired product, was evaporated to dryness. The residue was 
crystallized and rinsed with diethyl ether to obtain a nut-brown solid.  
The NMR analysis and the mass spectrometry assay revealed that the obtained compound was not 
the expected one. Indeed, it underwent a loss of two molecules of water to generate the following 
compound (44). Yield (referred to compound 44): 68%. Mp 139.0-143.0 °C. 
1
H NMR (CD3OD) δ: 
6.47 (t, 1H, J= 57.3 Hz); 5.02 (s, 1H); 4.35-4.11 (m, 3H); 3.52-3.41 (m, 1H); 3.01 (t, 2H, J= 6.55 
Hz); 2.23-1.59 (m, 13H); 1.51-1.30 (m, 6H); 1.15-0.98 (m, 8H). 7H are not visible, probably for the 
interaction with the solvent.    
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4.6 Rosmaricine and derivative 
 
Rosmaricine 
 
 
 
150 g of rosemary dry leaves were divided into three 500 ml flasks and each portion was suspended 
in 200 ml of ethanol and kept in an ultrasound sonicator for 1 h (from 25 to 60 °C). After cooling, 
the mixture was filtered on a Buchner funnel and washed with ethanol. The filtrate was evaporated 
and stored in the absence of light. The residual leaves were treated twice with the same procedure. 
All the filtrates were gathered, diluted with ethanol and concentrated at 100 ml of solvent volume. 
The mixture was filtered again to remove the most waxes as possible and the filtrate was 
evaporated. The obtained residue was diluted with ethyl acetate and washed several times with 
water. The organic layer was dried with anhydrous Na2SO4 and evaporated to dryness and the rough 
solid was washed several times with cyclohexane.  
Assuming that 150 g of rosemary leaves contained 1.5% of carnosic acid,
82
 the dry extract was 
diluted with 150 ml of ethanol, treated with 33% NH3 (1.8 ml) and stirred at r.t. for 24 h in contact 
with air. Further 33% NH3 was added after 19 h (0.3 ml) and after 21 h (0.45 ml) in order to keep 
the pH constant (8-9). The mixture was evaporated, diluted with CHCl3 and extracted with 5% 
H2SO4. The aqueous layer was charged into a flask, cooled with an ice-bath and alkalized with NH3 
till pH= 9. The formed precipitate was filtered and washed with water to collect 90 mg of a nut-
brown solid, which corresponded to the desired product. The filtrate was extracted with CHCl3 and 
the organic layer was then extracted with 20% HCl. The aqueous layer was alkalized again with 
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NH3 till pH= 9 and extracted with CHCl3. The organic layer was dried with anhydrous Na2SO4 and 
evaporated to dryness to collect an amorphous solid that was crystallized with diethyl 
ether/petroleum ether (9.5:0.5). Finally crystals were rinsed with diethyl ether to obtain 233 mg of a 
nut-brown solid corresponding to the desired product. Yield (referred to dry leaves): 0.22%. Mp 
198.2-202.5 °C. 
1
H-NMR (DMSO-d6) δ: 8.05 (br s, 2H, collapsed with D2O); 6.77 (s, 1H); 4.37 (d, 
1H, J= 2.47 Hz); 3.72 (d, 1H, J= 2.47 Hz); 3.30 (br s, 2H, collapsed with D2O); 3.26-3.09 (m, 2H); 
1.84-1.70 (m, 1H); 1.60-1.18 (m, 5H); 1.11 (d, 3H, J= 6.88 Hz); 1.07 (d, 3H, J= 6.88 Hz); 0.94 (s, 
3H); 0.77 (s, 3H).  
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Reaction of the alcoholic rosmary extract with diethylaminopropylamine 
 
H
OH
HO
O
O
N
H
N
 
 
Assuming that 150 g of rosemary leaves contained 1.5% of carnosic acid,
82
 the dry extract was 
diluted with 200 ml of ethanol, treated with 5 ml of 3-(diethylamino)propylamine and stirred at r.t. 
for 24 h in contact with air. The mixture was evaporated, diluted with CHCl3 and extracted with 5% 
H2SO4. The aqueous layer was charged into a flask, cooled with an ice-bath and alkalized with NH3 
till pH= 9. The mixture was extracted with CHCl3 and the organic layer was then extracted with 
20% HCl. As the desired product did not pass in the aqueous phase, the organic layer was alkalized 
with NH3, washed with water and dried with anhydrous Na2SO4. After evaporation of the solvent, 
the residue was washed with diethyl ether and petroleum ether and the rough brown solid was 
purified by CC (silica gel, CH2Cl2/MeOH in gradient); the product eluted with 4% of MeOH. The 
fraction containing the desired product was rinsed with petroleum ether/diethyl ether (8:2) to collect 
a reddish solid. The high resolution mass spectrometry assay (ESI) revealed that the obtained 
compound was not the expected one. It was probably an oxidation product, both at the cathecolic 
and at the amino groups level. The hypothetical obtained compound (46) is reported below, but it 
couldn’t be established for sure. Yield (referred to compound 46): 2.1%. Mp 120.0-122.5 °C (dec.). 
1
H-NMR (CDCl3) δ: 8.77 (br s, 1H, collapsed with D2O); 6.24 (s, 1H); 4.56 (d, 1H, J= 8.25 Hz); 
3.63-3.05 (m, 6H); 2.85-2.81 (m, 1H); 2.74-2.69 (m, 1H); 2.62-2.59 (m, 1H); 2.32-2.31 (m, 2H); 
2.09-1.98 (m, 3H); 1.59-1.54 (m, 2H); 1.47-1.25 (m, 9H); 1.08-1.06 (d, 3H, J= 6.60 Hz); 1.00-0.85 
(m, 9H). HRMS (ESI) m/z calcd for C27H40N2O6 (46) [M+H]
+
: 489.29646; found: 489.29584. 
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5. BIOLOGICAL ASSAYS 
 
In vitro studies on the antimalarial activity and on cytotoxicity have been carried out in the 
laboratory of Prof. Donatella Taramelli, Department of Pharmacological and Biomolecular Sciences 
of the University of Milan. 
 
5.1 Plasmodium falciparum cultures and drug susceptibility assay 
 
P. falciparum cultures were carried out according to Trager and Jensen with slight modifications.
83
 
The CQ-susceptible strains D10 and 3D7 and the CQ-resistant strain W2 were maintained at 5% 
hematocrit (human type A-positive red blood cells) in RPMI 1640 (EuroClone, Celbio) medium 
with the addition of 1% AlbuMax (Invitrogen, Milan, Italy), 0.01% hypoxanthine, 20 mM Hepes, 
and 2 mM glutamine. All the cultures were maintained at 37 °C in a standard gas mixture consisting 
of 1% O2, 5% CO2, and 94% N2. 
Compounds were dissolved in either water or DMSO and then diluted with medium to achieve the 
required concentrations (final DMSO concentration <1%, which is non toxic to the parasite). Drugs 
were placed in 96-well flat-bottomed microplates (COSTAR) and serial dilutions made. 
Asynchronous cultures with parasitaemia of 1-1.5% and 1% final hematocrit were aliquoted into the 
plates and incubated for 72 h at 37 °C. Parasite growth was determined spectrophotometrically 
(OD650) by measuring the activity of the parasite lactate dehydrogenase (pLDH), according to a 
modified version of the method of Makler in control and drug-treated cultures.
84
 The antimalarial 
activity is expressed as 50% inhibitory concentrations (IC50); each IC50 value is the mean and 
standard deviation of at least three separate experiments performed in duplicate. 
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5.2 Promastigote stage of Leishmania spp cultures and antileishmanial activity 
 
Promastigote stage of L. infantum strain MHOM/TN/80/IPT1 (kindly provided by Dr. M. 
Gramiccia and Dr. T. Di Muccio, ISS, Rome), L. tropica (MHOM/IT/2012/ISS3130) and L. 
braziliensis (MHOM/IT/2006/ISS2848) were cultured in RPMI 1640 medium (EuroClone) 
supplemented with 15% heat-inactivated fetal calf serum (EuroClone), 20 mM Hepes, and 2 mM L-
glutamine at 22 °C. 
To estimate the 50% inhibitory concentration (IC50), the MTT (3-[4.5-dimethylthiazol-2-yl]-2.5-
diphenyltetrazolium bromide) method
85,86
 was used with modifications. Compounds were dissolved 
in DMSO and then diluted with medium to achieve the required concentrations. Drugs were placed 
in 96 wells round-bottom microplates and seven serial dilutions made. Amphotericin B was used as 
the reference antileishmanial drug. Parasites were diluted in complete medium to 5 x 10
6
 
parasites/mL and 100 μL of the suspension was seeded into the plates, incubated at 22 °C for 72 
hours and then 20 µL of MTT solution (5 mg/mL) was added into each well for 3 hours. The plates 
were then centrifuged, the supernatants discarded and the resulting pellets dissolved in 100 µL of 
lysing buffer consisting of 20% (w/v) of a solution of SDS (Sigma), 40% of N,N-
dimethylformamide (Merck) in H2O. The absorbance was measured spectrophotometrically at a test 
wavelength of 550 nm and a reference wavelength of 650 nm. The results are expressed as IC50 
which is the dose of compound necessary to inhibit cell growth by 50%; each IC50 value is the mean 
± standard deviation of at least three separate experiments performed in duplicate. 
 
 
 
 
 
  Biological assays 
149 
 
5.3 Cytotoxicity assay 
 
The long-term human microvascular endothelial cell line (HMEC-1) immortalized by SV 40 large T 
antigen
87 
was maintained in MCDB 131 medium (Invitrogen, Milan, Italy) supplemented with 10% 
fetal calf serum (HyClone, Celbio, Milan, Italy), 10 ng/ml of epidermal growth factor (Chemicon), 
1 µg/ml of hydrocortisone, 2 mM glutamine, 100 U/ml of penicillin, 100 µg/ml of streptomycin, 
and 20 mM Hepes buffer (EuroClone). Unless stated otherwise, all reagents were from Sigma Italia, 
Milan, Italy. For the cytotoxicity assays, cells were treated with serial dilutions of test compounds 
for 72 h and cell proliferation evaluated using the MTT assay already described.
88 
The results are 
expressed as IC50, which is the dose of compound necessary to inhibit cell growth by 50%. Each 
IC50 value is the mean and standard deviation of at least three separate experiments performed in 
duplicate. 
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6. RESULTS AND DISCUSSION 
 
6.1 4-Aminoquinoline derivatives 
The synthesized compounds 1-3 have been tested in vitro against D10 (CQ-S) strain and W2 (CQ-
R) strain of P.falciparum. Their antiplasmodial activity was quantified as inhibition of parasite 
growth, expressed as IC50 (nM), and it is reported in Table 5. The activities of the related compound 
(-)-AM-1
35
 and of chloroquine as reference drug have been also reported. The ratios between the 
IC50 of each compound against the CQ-R and CQ-S strains of P. falciparum are also indicated. This 
value (resistance index, R.I.) is suggestive of cross resistance between the compound and 
chloroquine. Cytotoxicity on the human endothelial cell line HMEC-1 or on the murine cell line 
WEHI Clone 13 was assayed using the MTT test and the selectivity index (S.I.; IC50 HMEC-1 or 
WEHI 13/IC50W2 strain) was calculated (Table 5). 
 
Table 5. Antimalarial activity of 4-aminoquinoline derivatives and (-)-AM-1 on D10 and W2 strains of P. falciparum 
and their cytotoxicity on the human cell line HMEC-1 or on the murine cell line WEHI Clone 13. 
 
Compound 
D10 (CQ-S) 
IC50 (nM)
a
 
W2 (CQ-R) 
IC50 (nM)
a
 
R.I.
b
 
HMEC-1 
IC50 (nM)
c
 
WEHI 13 
IC50 (nM)
c
 
S.I.
d
 
1 22.5±9.6 475.3±145.7 21.2 >26939 n.t. >56.7 
2 27.1±7.9 194.3±74.6 7.2 9211.2±938.3 n.t. 47.4 
3 8.9±3.7 25.9±3.7 2.8 5494.8±697.5 n.t. 212 
(-)-AM-1
35 26.4±15.3 41.9±19.9 1.6 n.t. 9206 220 
CQ 19.8±4.6 320.3±50.9 16.2 >38000 n.t. >118 
n.t.: not tested. 
a
Results are expressed as IC50 ± SD of at least three different experiments, each performed in duplicate. 
b
Ratio between IC50 (W2) and IC50 (D10) calculated for each compound. 
c
The cytotoxicity evaluation has been performed using the MTT assay. 
d
Ratio between IC50 (HMEC-1 or WEHI 13) and IC50 (W2) calculated for each compound. 
 
 
All compounds showed IC50 comparable to that of chloroquine against the D10 (CQ-S) strain of P. 
falciparum, whereas the activity against the W2 (CQ-R) strain greatly improved with the elongation 
of the alkyl chain (n= 8; IC50= 26 nM, 12-fold more active than chloroquine and 1.6-fold more 
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active than (-)-AM-1), with very low resistance index. Moreover, results clearly showed that there 
was a linear improvement of antiplasmodial activity with the gradual increase of the number of 
terms of the alkyl chain. The most interesting compound (3), in addition to its excellent 
antiplasmodial activity, showed also a good resistance index and a remarkable safety profile, with a 
selectivity index similar to that of (-)-AM-1 and to that of chloroquine.  
 
 
6.2 Hybrids of 4-aminoquinoline 
The synthesized compounds 4-9 have been tested in vitro against D10 (CQ-S) strain and W2 (CQ-
R) strain of P. falciparum. Their antiplasmodial activity, expressed as IC50±SD (nM), and their 
selectivity index are reported in Table 6. Even the reference drug (SAHA) and some intermediates 
(65, 67, 68 and 74) were tested as terms for comparison, in order to better evaluate the importance 
of the hydroxamic acid group for the antiplasmodial activity. Cytotoxicity on the human endothelial 
cell line HMEC-1 of almost all compounds is also indicated. 
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Table 6. Antimalarial activity of hybrids of 4-aminoquinoline on D10 and W2 strains of P. falciparum and their 
cytotoxicity on the human cell line HMEC-1. 
 
Compound 
D10 (CQ-S) 
IC50 (nM)
a
 
W2 (CQ-R) 
 IC50 (nM)
a
 
R.I.
b
 
HMEC-1 
 IC50 (nM)
c
 
S.I.
d
 
4 105.9±25.0 2037.5±212.4 19.2 13929±2672 7 
5 262.9±74.3  2775.4±159.9 10.5 32597±3306 12 
6 664.2±131.0  846.2±174.1 1.3 23435±931 28 
7 675.8±93.1 506.7±178.3 0.7 82107±17378 162 
8 362.4±75.5  267.6±102.6 0.7 13722±3129 51 
9 359.5±162.3 384.1±109.2 1.1 9820±2499 26 
65 524.7±172.3 994.5±295.5 1.9 >108460 >109 
67 40.2±6.2 76.0±10.9 1.9 n.t. - 
68 1133.4±323.2 >9328 >8.2 >93278 >10 
74 1796.9±388.7 853.0±306.0 0.5 80163±22607 94 
SAHA 138.6±4.5 177.1±14.6 1.3 908 5 
CQ 20.1±6.1 305.8±44.2 15.3 >38000 >124 
n.t.: not tested. 
a
Results are expressed as IC50 ± SD of at least three different experiments, each performed in duplicate. 
b
Ratio between IC50 (W2) and IC50 (D10) calculated for each compound. 
c
The cytotoxicity evaluation has been performed using the MTT assay. 
d
Ratio between IC50 (HMEC-1) and IC50 (W2) calculated for each compound. 
 
All the tested hybrid compounds were able to inhibit the in vitro growth of the considered strains of 
P. falciparum, with IC50 in the nanomolar or low micromolar range (IC50 against CQ-S= 105.9-
675.8 nM and IC50 against CQ-R= 267.6-2775.4 nM). Results showed that the presence of a 
dithiolthione moiety (compounds 4 and 5) was not positive for the activity against the W2 (CQ-R) 
strain of P. falciparum, as it was much lower than the activity against the D10 (CQ-S) strain, 
suggesting that this modification could favor the outbreak of resistance mechanisms. Moreover, 
their selectivity indexes were quite low, even if better than that of SAHA. Concerning the other 
compounds (6-9), despite the loss of potency compared to chloroquine and SAHA, the presence of 
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an hydroxamic acid group seemed useful to contrast resistance onset, leading to very low resistance 
indexes (0.7-1.1). It is well-known that hydroxamic acid groups possess an antiproliferative and not 
specific activity, but in this case the presence of the quinoline moiety decreased the cytotoxicity of 
the hybrids (S.I.= 26-162), compared to the reference drug SAHA (S.I.= 5). In particular, compound 
7 exhibited a very high S.I., suggesting that, quite unexpectedly, the cinnamoyl moiety could be 
useful to obtain more selective compounds.  
The importance of the hydroxamic acid group as Zn
2+
-chelating moiety for the antiplasmodial 
activity was confirmed by comparing compound 7 to the corresponding carboxylic acid (68) and 
comparing compound 8 to the corresponding methyl ester (74). A particular and unexpected case is 
that of the ethyl cinnamate derivative (67), which showed a great antiplasmodial activity on both 
CQ-S and CQ-R strains of P. falciparum, much higher than the activity of the corresponding 
hydroxamic acid (compound 7). This could be explained with the fact that probably, as the ester is 
more lipophilic, it could easily pass the membranes and, once inside the Plasmodium, it could exert 
its antiplasmodial activity. In this case, the mechanism of action could be ascribed to the quinoline 
moiety or also to the cinnamoyl moiety, that could react with different substrates as a Michael 
reaction acceptor. It would be interesting also to evaluate the real mechanism of action of these 
hybrids, first of all evaluating their ability to inhibit HDAC enzimes of P.falciparum and also 
performing the BHIA (β-hematin inhibitory activity) assay,89 that underlines the ability to inhibit β-
hematin formation (chloroquine’s mechanism of action). 
 
6.3 Indeno[2,1-c]quinolines 
All compounds were tested in vitro against D10 and/or 3D7 (CQ-S) and W2 (CQ-R) strains of P. 
falciparum. Their antiplasmodial activity was quantified as inhibition of parasite growth, expressed 
as IC50 (µM), and it is reported in Table 7. Resistance index (R.I.), cytotoxicity on the human 
endothelial cell line HMEC-1 and the selectivity index (S.I.) on W2 strain were also indicated 
(Table 7). 
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Table 7. In vitro antimalarial activities and cytotoxicity on the human cell line HMEC-1 of the prepared indeno[2,1-
c]quinolines. 
 
Comp. 
D10 (CQ-S) 
IC50 (µM)
a
 
R.I. 
(W2/D10)
b 
3D7 (CQ-S) 
IC50 (µM)
a
 
R.I. 
(W2/3D7)
b
 
W2 (CQ-R) 
IC50 (µM)
a
 
HMEC-1 
IC50 (µM)
c
 
S.I.
d
 
10 n.t. - 1.713±0.992 0.4 0.626±0.191 n.t. - 
11 n.t. - 2.339±0.351 0.5 1.172±0.216 n.t. - 
12 3.757±0.421 0.7 6.775±1.117 0.4 2.554±0.671 n.t. - 
13 0.703±0.050 0.8 1.031±0.242 0.5 0.568±0.231 1.937±0.715 3.4 
14 0.468±0.186 1.1 n.t. - 0.534±0.186 3.125±0.642 5.9 
15 1.636±0.181 0.7 n.t. - 1.186±0.262 4.034±1.220 3.4 
16 6.077±0.686 1.1 n.t. - 6.936±2.525 n.t. - 
17 n.t.
e 
- n.t.
e 
- n.t.
e 
n.t.
e 
- 
18 0.850±0.181 0.3 0.843±0.096 0.3 0.255±0.119 3.122±0.491 12.0 
19 n.t. - 0.530±0.193 0.5 0.244±0.125 2.342±0.058 9.6 
20 2.839±0.745 1.0 5.390±1.357 0.5 2.728±0.753 n.t. - 
21 0.667±0.050 1.0 0.818±0.175 0.8 0.699±0.187 2.585±0.719 3.7 
22 0.676±0.064 1.6 n.t. - 1.055±0.328 2.938±0.233 2.8 
23 6.612±2.427 1.0 n.t. - 6.807±2.628 >38.000 >5.6 
24 4.046±1.019 1.0 n.t. - 4.160±0.540 >35000 >8.4 
25 >5.000 - n.t. - >5000 n.t. - 
26 0.360±0.020 1.2 n.t. - 0.432±0.105 1.723±0.128 4.0 
27 4.578±1.236 0.7 n.t. - 3.157±0.623 5.279±0.454 1.7 
CQ 0.020±0.005 16 0.012±0.003 26 0.316±0.051 >38.000 >120 
n.t.: not tested 
a
The results are expressed as IC50 ± SD of at least three different experiments each performed in duplicate or triplicate. 
b
Ratio between the IC50 values of each compound against the two strains of P. falciparum. 
c
The cytotoxic activity was assayed in vitro using the MTT assay.  
d
IC50 HMEC/IC50 W2 strain of P. falciparum.  
e
Compound 17 could not be tested for solubility problems. 
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Table 8. Inhibition of β-hematin formation (BHIA method). 
Compound 
IC50   
Drug: haemin molar ratio
a
 
18 >4
b
 
CQ 1.71± 0.6 
a
The IC50  represent the molar equivalents of test compounds, relative to haemin, 
required to inhibit β-hematin by50%. (Results represent the mean of three different 
experiment, each performed in duplicate. 
b
Higher concentration could not be used for solubility problems. 
 
 
All the tested compounds, with the exception of 17 and 25, were able to inhibit the in vitro growth 
of the considered CQ-S (IC50= 0.36-6.61 µM) and CQ-R (IC50= 0.24-6.94 µM) strains of P. 
falciparum. Among them, six compounds (13, 14, 18, 19, 21 and 26) exhibited IC50< 1 µM on all 
the tested strains, suggesting that the presence of the indeno[2,1-c]quinoline scaffold is suitable for 
the antimalarial activity, which can be modulated through the modifications of the substituents. 
Interestingly, resistance index was always very low (range 0.3-1.6); this is indicative that this kind 
of compounds do not share the same resistance mechanisms of CQ. Moreover, the W2 (CQ-R) 
strain is often more sensitive to our compounds than the CQ-S strains and this unusual result 
confers interest to this class of compounds, despite their moderate potency. 
In addition, the ability of a representative compound (18) to inhibit β-hematin formation was 
evaluated using the BHIA (β-hematin inhibitory activity) assay.89 Results reported in Table 8 shows 
that compound 18 has no, or very low ability to interfere with the process of heme crystallization, 
compared to CQ. Therefore the mechanism of the antiplasmodial activity of compound 18 and, 
likely, of this class of compounds, should be different from that of CQ. 
Unfortunately, the most potent compounds tested on a human endothelial cell line exhibited a fairly 
high toxicity, which however is in line with what observed with the indenoquinoline derivatives 
described by Upadhayaya et al.
48
 This result, could be related to the chemical similarity of these 
compounds to the known antiproliferative agent TAS-103. 
 
  Results and discussion 
156 
 
Concerning the structure-activity relationships (SAR), we can observe the following: 
a) the presence of the chlorine in position 2 or 3 of the indenoquinoline nucleus is generally 
irrelevant, except for the two couples of compounds 10, 11 and 21, 22 where the 3-chloro-
substituted compound is clearly less active on W-2 (CQ-R) strain of P. falciparum. 
b) When R is a piperidinoethylamino moiety, 7-carbonyl derivatives are less active than 
corresponding oximes, whereas the opposite happens for compounds 14 and 22; the other 
compounds didn’t present significant differences in their antimalarial potency. 
c) Differently from what reported for the analogous bromo-derivatives,
47
 the esterification of the 
oxime group with propionic acid improved only modestly the activity (25 vs 23). 
d) Among the basic heads inserted in position 6 of the indenoquinoline nucleus, the 
piperidinoethylamino and methylpiperazinoethylamino moieties seem associated to the better 
activity, whereas the more polar morpholino- and 2-pyridinyl-4-piperazinyl derivatives are clearly 
less potent. 
e) The shift of the basic side chain to position 7 showed contrasting results, with the 
aminoguanidone derivative 26 exhibiting a good activity, whereas the product of condensation of 2-
chloro-6-methoxyindeno[2,1-c]quinolin-7-one with 1-amino-4-methylpiperazine (27) was scarcely 
active. Compound 26 could represent a starting point to prepare new analogs, bearing different 
substituents in position 6. 
 
6.4 Riminophenazines 
Riminophenazines were tested in vitro against D10 (CQ-S) and W2 (CQ-R) strains of P. 
falciparum. Their antiplasmodial activity was quantified as inhibition of parasite growth, expressed 
as IC50 (µM), and it is reported in Table 9. Resistance index (R.I.), cytotoxicity on the human 
endothelial cell line HMEC-1 and the selectivity index (S.I.) were also indicated (Table 9). 
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Table 9. In vitro data on antiplasmodial activity against D10 and W2 strains of P. falciparum and cytotoxicity on the 
human endothelial cell line (HMEC-1). 
 
Compound 
D10 (CQ-S) 
IC50 (µM)
a
 
W2 (CQ-R) 
IC50 (µM)
a
 
R.I.
b
 
HMEC-1 
IC50 (µM)
c
 
S.I.
d
 
28 0.34±0.02 0.29 ±0.03 0.9 1.90±0.37 6.5 
29 0.19 ±0.04 0.45 ±0.10 2.4 0.98±0.10 2.2 
30 0.21±0.04 0.40±0.11 1.9 1.57±0.34 4.0 
31 0.21±0.03 0.27±0.03 1.3 1.23±0.03 4.5 
32 0.17±0.05 0.21±0.07 1.2 1.24±0.12 6.0 
33 0.24±0.02 0.39±0.05 1.6 1.96±0.25 5.0 
34 0.28±0.08 0.34±0.07 1.2 1.87±0.10 5.5 
35 0.31±0.06 0.57±0.03 1.9 1.35±0.17 2.4 
36 0.19±0.03 0.27±0.03 1.4 11.06±3.70 41 
37 0.28±0.05 0.21±0.06 0.8 3.89±0.73 18 
38 0.81±0.25 0.35±0.12 0.4 6.32±1.64 18 
39 0.22±0.03 0.18±0.05 0.8 2.33±1.03 13 
40 0.40±0.03 0.28±0.04 0.7 4.66±1.61 16 
Clofazimine 4.82 ±0.82 7.02±1.10 1.5 18.59
a
 2.6 
CQ 0.02±0.005
e
 0.36±0.06
e
 16 >38 >119 
n.t.: not tested. 
a
Results are expressed as IC50 ± SD of at least three different experiments, each performed in duplicate. 
b
Ratio between IC50 (W2) and IC50 (D10) calculated for each compound. 
c
The cytotoxicity evaluation has been performed using the MTT assay. 
d
Ratio between IC50 (HMEC-1 or WEHI 13) and IC50 (W2) calculated for each compound. 
e
Mean value from many different experiments. 
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All compounds were also tested in vitro against different species of Leishmania promastigotes and 
the results, expressed as IC50±SD (µM), are reported in Table 10 together with their corresponding 
selectivity indexes (S.I.).  
Table 10. In vitro data on antileishmanial activity against different species of Leishmania promastigotes and 
cytotoxicity on the human endothelial cell line (HMEC-1). 
 
Compound 
L.infantum 
IC50(μM)
a
 
S.I.
b L.tropica 
IC50(μM)
a S.I.
b
 
L.braziliensis 
IC50(μM)
a
 
S.I.
b
 
HMEC-1 
IC50(μM)
c
 
28 0.91±0.26 2.1 1.10±0.33 1.7 n.t. - 1.90±0.37 
29 0.30±0.03 3.3 0.54±0.30 1.8 n.t. - 0.98±0.10 
30 0.46±0.20 3.4 0.47±0.23 3.3 n.t. - 1.57±0.34 
31 0.37±0.11 3.3 0.22±0.08 6 0.17±0.08 7.2 1.23±0.03 
32 0.23±0.05 5 0.12±0.03 10 0.14±0.03 8.9 1.24±0.12 
33 0.48±0.26 4 0.84±0.53 2.3 n.t. - 1.96±0.25 
34 0.43±0.17 4 0.33±0.07 5.5 n.t. - 1.87±0.10 
35 0.35±0.08 4 0.24±0.07 5.5 n.t. - 1.35±0.17 
36 2.67±1.53 4 1.09±0.34 10 n.t. - 11.06±3.70 
37 6.02±2.70 0.6 2.01±0.51 1.9 n.t. - 3.89±0.73 
38 4.44±0.21 1.4 2.32±0.24 2.7 n.t. - 6.32±1.64 
39 0.34±0.07 7 0.34±0.11 7 n.t. - 2.33±1.03 
40 0.41±0.21 11 0.77±0.31 6 n.t. - 4.66±1.61 
Clofazimine 4.48±1.06 4.2 2.96±1.25 6.3 n.t. - 18.59
a
 
Amph B 0.08±0.02 321 0.09±0.04 286 0.09±0.02 286 25.70±1.90 
a
The results are expressed as IC50±SD of at least three different experiments each performed in duplicate or triplicate. 
b
Selectivity Index: IC50 HMEC/IC50 different species of Leishmania. 
c
The cytotoxic activity was assayed in vitro using the MTT assay.  
n.t.= not tested. 
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All the tested compounds inhibited the growth of different species of Leishmania promastigotes as 
well as CQ-S and CQ-R strains of P. falciparum. Most of them exhibited IC50 in the nanomolar 
range, with a clear improvement of potency compared to clofazimine, which was, generally, from 
one to two orders of magnitude less potent. These results confirm the importance of the introduction 
of a basic head on the imino nitrogen in position 3 on the phenazine. 
Concerning the antiplasmodial activity, the tested compounds exhibited similar activity against CQ-
S and CQ-R strains of  P. falciparum, with very low R.I. (0.4-2.4), thus demonstrating that this kind 
of compounds do not share the same resistance mechanisms of CQ. 
The most active compound on both P. falciparum strains was compound 32, which inhibited the 
D10 (CQ-S) and W2 (CQ-R) strains with IC50= 0.17 and 0.21 µM, respectively, thus showing a 
R.I.= 1.2.  
In the series of symmetrical quinolizidinylalkyl derivatives (31-39), the different length of the alkyl 
chain (4 or 6 CH2) didn’t influence the antiplasmodial activity. 
Interestingly, the quaternarization of the quinolizidine nitrogen with a methyl group (compound 36) 
increased significantly the selectivity index on Plasmodia, lowering the toxicity on the tested 
human cell line, while leaving unchanged the antiplasmodial activity. Thus the effect of the 
quaternarization of the basic head is surely worth of a more extensive investigation.  
The introduction on the phenyl rings of a substituent like Cl, F or CH3 didn’t affect significantly the 
antiplasmodial activity or toxicity on the human cell line.  
The replacement of the aniline moiety in position 2 with a differently substituted aminopyridine 
(compounds of series B) slightly increased the selectivity indexes on Plasmodia and the resistance 
indexes (R.I.=0.4-0.8). Indeed compounds of this series were always more active on W2 (CQ-R) 
strain of P. falciparum than on D10 (CQ-S) strain. 
Finally, the nature and the size of the basic head didn’t influence significantly the antiplasmodial 
activity. 
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Concerning the antileishmanial activity, all the tested compounds inhibited the growth of L. 
infantum and L. tropica promastigotes with IC50 in the range 0.12-6.02 µM and seven of them 
showed IC50≤0.5 µM. 
9-Quinolizidinyl derivatives (31-39) were the most active and in this group the different length of 
the chain spacer, as well as the substitution with alogen atoms on the phenyl rings, didn’t affect 
significantly the antileishmanial activity whereas, when the aniline moiety in position 2 was 
replaced by an aminopyridine (compounds of series B), the presence of a chlorine atom on the 
phenyl ring was clearly favourable (compare compound 37 with 39). 
Differently from antiplasmodial activity, the quaternarization of the quinolizidine ring with a 
methyl group was detrimental for the antileishmanial activity (compound 36 vs compound 31). 
The most potent compound 32 showed activity against different Leishmania promastigotes 
comparable with that of the reference drug Amphotericin B and activity against the W2 (CQ-R) 
strain of P. falciparum better than that of chloroquine and a selectivity index (S.I.) more favorable 
than that of clofazimine.  
In series B, the replacement of the bulky bicyclic basic head (quinolizidine) of compound 37 with 
the small dimethylamino group (compound 40) led to a compound with somewhat reduced activity 
against both the Leishmania promastigotes and the P. falciparum strains, but also with reduced 
toxicity on the endothelial cell line HMEC-1. 
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6.5 Aphidicolin derivatives 
The synthesized aphidicolin derivatives (41-44) and their parent compounds were tested in vitro 
against different species of Leishmania promastigotes and the results, expressed as IC50±SD (µM), 
are reported in Table 11, together with their cytotoxicity on the human endothelial cell line HMEC-
1.  
Table 11. In vitro data on antileishmanial activity against different species of Leishmania promastigotes and 
cytotoxicity on the human endothelial cell line (HMEC-1). 
 
Compound 
L.infantum 
IC50(μM)
a
 
L.tropica 
IC50(μM)
a 
L.braziliensis 
IC50(μM)
a
 
% of 
inhibition 
at 5 µg/ml 
(L.tropica)
b
 
HMEC-1 
IC50(μM)
c
 
41 24.39±12.91 25.06±10.04 n.t. - 2.21±0.47 
42 n.t. >16 >16 37.23 >79 
44 n.t. >21 17.51±6.75 33.34 29.27±6.85 
MF29 10.00±3.50 12.80±5.80 n.t. - 4.72±1.38 
Eflornithine n.t. >46 >46 - >229 
Aphidicolin 6.29±2.01 6.61±7.17 n.t. - 8.61±2.29 
Amph B 0.08±0.02 0.09±0.04 0.09±0.02 - 25.70±1.90 
a
The results are expressed as IC50±SD of at least three different experiments each performed in duplicate or triplicate. 
b
Inhibition (%) of L.tropica promastigotes at the higher tested concentration. 
c
The cytotoxic activity was assayed in vitro using the MTT assay.  
n.t.= not tested. 
n.c.= not calculable. 
 
Even though they exhibited the ability to inhibit the growth of Leishmania in the micromolar range, 
all synthesized hybrids didn’t increase the antileishmanial activity of their parent compounds. 
Compared to aphidicolin, hybrids exhibited a lower antileishmanial activity maybe due to their 
inappropriate solubility properties or because they could be partially hydrolyzed by some esterases 
present in the culture medium before entering into the promastigotes and, in this case, only the 
resulting free aphidicolin could pass the membranes and carry out its antileishmanial activity. 
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Alternatively, hybrids could enter into the promastigotes but they couldn’t be hydrolyzed and 
therefore the single parts could not exert their own activity. Actually, none synergistic effect was 
observed and other structural modifications should be done to obtain more potent compounds and to 
evaluate the real potentiality of these scaffolds as antileishmanial agents. It would be interesting to 
test the activity of these compounds against amastigotes, which are the replicative forms of the 
parasite and are much more susceptible to drugs than promastigotes. A limitation on the 
development of this kind of hybrids is that their activity was not specific and they were quite toxic 
on the human cells. In particular, compound 41 was more active against the human cells than 
against Leishmania promastigotes. The introduction of a more hydrophilic moiety, as in compound 
42, led to a decrease of the cytotoxicity; however further investigations should be carried out to 
improve this aspect.  
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6.6 Rosmaricine and derivative 
Rosmaricine and its derivative (46) were tested in vitro against D10 (CQ-S) and W2 (CQ-R) strains 
of P. falciparum and also against L. tropica promastigotes. Their antiprotozoal activities were 
expressed as IC50 (µM), and it is reported in Table 12. Resistance index (R.I.), cytotoxicity on the 
human endothelial cell line HMEC-1 and the selectivity index (S.I.) were also indicated (Table 12). 
 
Table 12. In vitro data on antimalarial activity against D10 and W2 strains of P. falciparum  and  antileishmanial 
activity against L. tropica promastigotes and cytotoxicity on the human endothelial cell line (HMEC-1). 
 
a
The results are expressed as IC50 ± SD of at least three different experiments each performed in duplicate or triplicate. 
b
Ratio between the IC50 values of each compound against the two strains of P. falciparum. 
c
The cytotoxic activity was assayed in vitro using the MTT assay.  
d
IC50 HMEC/IC50 W2 strain of P. falciparum.  
e
Results are expressed as IC50 and are preliminary. 
n.t. = not tested. 
 
Results suggested that both rosmaricine and compound 46 were able to inhibit the growth of the 
tested strains of P. falciparum, despite a quite poor antiplasmodial activity. On the other hand, they 
were clearly characterized by an insignificant antileishmanial activity (IC50 >57000 and >43000 
respectively). However, compound 46 was more active than rosmaricine on both the CQ-S and CQ-
R strains of P. falciparum. This aspect confirmed the hypothesis that the introduction of a side chain 
on the nitrogen of rosmaricine could increase the antiplasmodial activity. For this reason, further 
studies should be carried out and other rosmaricine derivatives, mainly with a basic side chain, as 
initially projected, should be prepared in order to assess this issue and to obtain more active 
compounds. 
Compound 
D10 (CQ-S) 
IC50 (nM)
a 
W2 (CQ-R) 
IC50 (nM)
a R.I.
b HMEC-1 
IC50 (nM)
c S.I.
d L. tropica 
IC50 (nM)
e
 
Rosmaricine >14000 11901±2658 <0.85 19502±1639 1.6 >57000 
46 5621±777 6541±1559 1.2 34999±9647 5.4 >43000 
CQ 31.3±4.1 712.5±105.8 23 >38000 53 - 
Amph B - - - n.t. 120±30 0.12±0.03 
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7. CONCLUSIONS 
 
In conclusion, different sets of novel antiprotozoal compounds were designed and synthesized and 
some of them exhibited very interesting antiplasmodial activities, in the nanomolar range. These 
molecules, in particular 4-aminoquinoline derivatives, indeno[2,1-c]quinolines and 
riminophenazines, could represent potential lead compounds to be optimized in order to discover 
more potent antiplasmodial and antileishmanial agents, following the encouraging strategies already 
used for the development of the presented compounds. They are new tiles in the complicated and 
alarming mosaic of the antiprotozoal drugs discovery, which is always threatens by the worldwide 
spread of drug resistant species of parasites.  
In this context, also compounds derived from natural products, such as aphidicolin and rosmaricine 
derivatives, that we have only started to explore, demonstrated to be an alternative that should be 
more investigated and improved to fight against protozoan diseases. 
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